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Worldwide, breast cancer (BC) is the most common type of cancer among women, 
accounting for 23% of the total number of cancer incidence [1]. In 2010 in the 
Netherlands, the ten-year prevalence of women with BC was 97266, with 13257 new 
cases of BC [2]. Due to advancements in treatment an increasing number of women live 
with the long-term effects of BC and its treatment [3]. BC treatment consists of primary 
loco-regional treatment (surgery), often in combination with adjuvant treatment. 
Adjuvant treatment is recommended depending on type of surgery, tumor size, degree of 
differentiation of the tumor, and the presence of axillary metastases. Chemotherapy, 
hormone therapy and radiotherapy can be recommended separately or in combination, 
based on national guidelines [4]. These days, 60% of the newly diagnosed BC patients 
younger than 65 years receive chemotherapy [5].  
 
 
Breast cancer treatment and cognitive functioning 
 
Although adjuvant chemotherapy significantly improves the clinical outcome of patients 
with early-stage BC, it is also known to have severe side-effects [3]. Apart from common 
complaints, such as fatigue, hair loss, and depression [6], cognitive impairment after 
chemotherapy, also known as ‘chemobrain’, is a reported concern of BC patients [7]. 
There is a growing body of research concerning the influence of adjuvant treatment on 
cognitive functioning in BC patients and survivors [7-41].  
When investigating cognitive functioning, a distinction must be made between 
objective cognitive functioning (OCF), measured with standardized neuropsychological 
tests, and subjective cognitive functioning (SCF), measured with self-report questionnaires 
[21]. SCF refers to the amount of cognitive problems a person experiences in daily life and 
the satisfaction with cognitive functioning [42]. Whether chemotherapy influences OCF or 
SCF is still inconclusive and prevalence rates vary strongly. These inconclusive results may 
be due to inconsistencies in study designs as well as methods of analysis. Some studies did 
not include a control group (e.g., [26, 43, 44]). However, in studies in which a control 
group was included, groups varied from healthy controls (e.g., [14, 27, 28]), cardiac 
patients [27], or BC patients treated with hormone therapy or radiotherapy (e.g., [20, 45, 
46]). Although all studies used neuropsychological tests to measure OCF, there is a large 
variation in the neuropsychological tests employed and in the definitions used to 
determine cognitive impairment. For instance, cognitive impairment was defined as one 
or two standard deviations below the mean of a specific test, and the number of impaired 
tests that is necessary to define the person as ‘cognitive impaired’ also varied between 
studies. Also, different reference data were used to classify patients as impaired or not. 
Furthermore, not all the longitudinal studies used a baseline measurement before 
chemotherapy was started (e.g., [44]), and timing of cognitive assessments varied 
between follow-up moments during chemotherapy (e.g., [26]) to measurements one year 
later (e.g., [9, 20, 28, 29, 43, 46] or even 20 years later [47]. Moreover, although most 
studies have controlled for a number of factors, there is also much variability in the 
assessed mediators and moderators of the relationship between chemotherapy and 
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cognitive functioning. The different age range of the included patients is another problem 
in the interpretation of the different existing studies. Maybe as a consequence of the wide 
variety in these aspects, no consistent findings have been reported with regard to the 
specific cognitive domain that is affected.  
Due to the aforementioned heterogeneity, there is a need for more research [48]. 
The International Cognition and Cancer Task Force provided research recommendations 
and guidelines to increase the homogeneity of studies [49]. They recommend longitudinal 
studies with a pre-treatment assessment. Furthermore, a control group should be 
included who undergo the same cognitive assessments in the same timeframe as the BC 
group. This approach makes it also possible to deal with practice effect i.e., change in 
neuropsychological performance over time due to familiarity with a test instead of a true 
improvement. Another recommendation is to assess at least the following cognitive 
domains: learning and memory, processing speed and executive functioning.   
 
 
Aim and clinical importance of the study 
 
Until now, the prospective studies examining the effect of chemotherapy on cognitive 
functioning in BC patients are limited and methodologically heterogeneous. Therefore, the 
aim of the current thesis was to examine the effects of chemotherapy on cognitive 
functioning (SCF and OCF) and quality of life (QoL) in BC patients in a prospective 
multicenter study. The evaluation of the potential effects of chemotherapy on cognitive 
functioning in BC patients is of great importance since it is a frequently reported complain 
of BC patients in clinical practice. Information about the existence, prevalence and course 
of problems with cognitive functioning can facilitate health care professionals to provide 
evidence-based information to their patients. Furthermore, knowledge about predictors 
of problems with SCF and OCF can underpin health care professionals in noticing patients 
with a higher risk to develop problems with cognitive functioning after their BC treatment 
in an earlier stage. This creates the opportunity to provide specific information and 
possibly an intervention to the patients in an earlier stage in order to limit the concerns 
about the complaints of cognitive functioning. The derived knowledge may also be used 
for the development of intervention techniques for BC patients who suffer from SCF 
and/or OCF. Besides the understanding of cognitive deficits following cancer treatment, 
the functional significance of these deficits also has to be considered. Focusing on the 
relationship between neuropsychological decline secondary to chemotherapy and QoL will 
enable a better understanding of the relative impact of cognitive functioning on the well-
being of BC patients. Relatively few studies have focused on the impact of problems in 
cognitive functioning due to chemotherapy on aspects of QoL. Thus, another aim of this 







Design of the study 
 
Women who were diagnosed with early stage BC (tumor smaller than five cm in diameter 
and there are no apparent metastases beyond the axilla) and were about to receive 
chemotherapy in St. Elisabeth hospital (Tilburg), TweeSteden hospital (Tilburg), Máxima 
Medical Centre (Eindhoven, Veldhoven), Catharina hospital (Eindhoven), St. Anna hospital 
(Geldrop), Amphia hospital (Breda), and Jeroen Bosch hospital (Den Bosch) were eligible 
for this study. In addition, women diagnosed with a benign breast disease (BBD) were also 
asked to participate. A cyst, mastopathy or a fibro-adenoma are the most common BBD 
diagnoses. Treatment of the BBD is not necessary for most women but some women are 
invited for a follow-up examination three or six months later. Furthermore, some women 
want their cyst or fibro-adenoma surgically removed. Women with proven BC recurrence 
or distant metastases were excluded. Other exclusion criteria were: a history of 
neuropsychological and/or psychiatric signs or symptoms that lead to deviant 
neuropsychological test results (e.g., dementia), the use of medication that may lead to 
deviant neuropsychological results, alcohol and/or drug addiction, and a poor expression 
in the Dutch language. BC patients were assessed prior to initiation of adjuvant 
chemotherapy (Time 1), three months (Time 2) and one year (Time 3) following the last 
cycle of chemotherapy. Patients with a BBD were assessed at comparable time points (see 
Figure 1). All participants provided written informed consent. At each time point 




Figure 1: Timeline of the study 
BC = Breast cancer; BBD = Benign breast disease  
 
Neuropsychological assessment 
A comprehensive test battery, which took approximately 1.5 hours to complete, was 
designed to assess a broad range of cognitive domains. The battery of 14 neuro-
psychological tests (comprising 24 test indexes) covered attention/processing speed, 
verbal and visual memory, visuospatial functioning, verbal fluency, executive functioning 
and motor functioning. In addition, the Dutch Adult Reading test provides information on 
verbal premorbid intelligence [50]. All tests are widely used in clinical neuropsychological 
practice and the psychometric properties are well described. Furthermore, the selection 
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of tests was based on previous neuropsychological studies with cancer patients, to make it 
possible to compare the results (e.g., [11, 51]). A recent review summarized the most 
frequently used neuropsychological tests in the assessment of post-chemotherapy 
cognitive changes in BC patients. Our selection shows overlap with the tests described in 
this review [51]. The assessments were conducted either at home or in the hospital. Tests 
were administered in a standardised identical order. The neuropsychological tests were 
scored independently by two persons. Possible discrepancies between both scores were 
solved by reaching consensus. The classification of the neuropsychological measures in 
each domain was based on clinical experience, the descriptives of Lezak, Howieson, Bigner 
and Tranel [52] and earlier research.  
Attention/processing speed: The Stroop test [53, 54] has two conditions for 
attention: color word reading (card A) and color ink naming (card B). The Trailmaking test 
condition A [55] is a condition in which a line need to be drawn to connect consecutively 
numbers. The D2 test [56] is a cancellation task that consists of rows of letters randomly 
interspersed with a designated target letter. The instruction is to cross out all target 
letters. The Digit span subtest of the Wechsler Adult Intelligence Scale [57] involves 
forward and backward repetitions of series of digits. The Digit symbol test of the Wechsler 
Adult Intelligence Scale [57] is a symbol substitution task. The Fepsy visual reaction test 
[58] presents stimuli (a white square on the screen at random time intervals measures 
basic perceptual-motor performance. The Fepsy visual searching test [58] consists of 
finding one grid pattern out of 24 that matches the one in the center of the screen.  
Verbal memory: The Rey auditory verbal learning test [59, 60] is a word list-learning 
task consisting of five verbal presentations with recall of a 15-word list.  
Visual memory: The Visual reproduction subtest of the Wechsler Memory Scale, 
revised [61] involves the reproduction from memory of geometric designs. The total score 
is reported. In the Complex figure test [62, 63] patients have to copy a complex figure.  
Visuospatial functioning: The copy score of the Complex figure test [62, 63] is used.  
Verbal fluency: In the Word fluency subtest [64] patients have to generate words 
from a specific semantic category (animals and professions) within a limited time.  
Executive functioning: In the zoo map test of the Behavioral Assessment of 
Dysexecutive Syndrome patients [65] have to figure out a route through the zoo following 
certain rules (map 1) and following a given order (map 2). In the Trailmaking test condition 
B [55] a line need to be drawn to connect numbers and letters by alternating between the 
two sequences (condition B). The Fepsy binary choice test [58] gives information about 
the decision-making process. The patient has to react differentially to stimuli on the 
screen. The Stroop test [53, 54] card C covers color ink naming of a word denoting a 
different color.  
Motor functioning: The Fepsy finger-tapping task [58] is a measure of motor speed. 
The speed of finger tapping is measured for both hands separately.  
 
Questionnaires 
QoL was measured with the World Health Organization Quality of Life assessment 
instrument-100 (WHOQOL-100), Dutch version [66]. The WHOQOL-100 is a cross-culturally 
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developed generic multidimensional QoL questionnaire. It consists of 100 items assessing 
24 facets of QoL and a general facet. These facets can be converted into four domains: 
Physical, Psychological, Social Relations, and Environment. The response scale is a 5-point 
scale. The time frame of reference is the previous two weeks. The instrument is reliable 
and valid [67] and the sensitivity of the instrument is also high [68]. Furthermore it is a 
reliable and valid instrument to measure QoL in women suspected of having BC [69]. 
The cognitive functioning facet (four items) of the WHOQOL-100, Dutch version [66], 
was used to assess the satisfaction with SCF, for example with the following question: 
‘how satisfied are you with your ability to learn new information?’ The rating scales range 
from 1 to 5. A high score on the cognitive functioning facet indicates satisfaction with SCF.  
The Cognitive Failures Questionnaire (CFQ) [70], Dutch version [71], was used to 
assess self-reported frequency of complaints about SCF. This self-report inventory consists 
of 25 items. The rating scales range from 0 to 4. A high score indicates more often 
experienced cognitive failure. Earlier research found several two, three and four factor 
solutions for the CFQ, but none of these factor structures has been validated in a sample 
of patients with breast problems (e.g., [72-74]).   
The Center for Epidemiological Studies-Depression Scale (CES-D) [75], Dutch version 
[76], was used to measure depressive symptoms. It is a well-established self-report scale 
designed to measure the presence and degree of depressive symptoms in broad-based 
survey research populations. It consists of 20 items, with rating scales range from 0 to 3. A 
higher score indicates more depressive symptoms. The CES-D is a valid and reliable 
measure of depressive symptoms in BC patients [77].  
The Fatigue Assessment Scale (FAS) [78] was used to measure fatigue. It is a 10-item 
questionnaire that taps fatigue and exhaustion. The response scale is a 5-point scale (1 to 
5). A higher score indicates more symptoms of fatigue. The psychometric properties have 
been studied in different patient populations, including BC patients, and the validity and 
reliability are reported to be good [79].  
The State-Trait Anxiety Inventory (STAI) state scale [80], Dutch version [81], was used 
to measure anxiety. The state scale asks persons how they feel at a particular moment in 
time, while the trait scale asks people to describe how they generally feel. In this study the 
validated shortened 6-item questionnaire for the STAI-state [82, 83] and the validated 10-
item version of the STAI-trait [84] were used. The rating scales range from 1 to 4, a higher 
score indicates more symptoms of anxiety.  
The Perceived Stress Scale-10 (PSS-10) [85] was used as a global measure of 
perceived stress during the last month. It is the shortened version of the PSS-14 and 
consists of 10 items, rated on a four-point Likert-scale from 0 to 4. A higher score indicates 
more perceived stress. The validity and reliability of the PSS are good [85]. 
 
 
Outline of the thesis 
 
This thesis is divided into three sections. The first two parts focus on SCF and OCF, 
respectively. The third part focuses on the impact of cognitive functioning on QoL.  
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Subjective cognitive functioning 
Chapter 2 gives an overview of the studies that have investigated SCF. The prevalence of 
problems with SCF, the differences between (treatment) groups in problems with SCF, the 
relationship between problems with SCF and psychological factors, and the relationship 
between SCF and OCF are examined. Furthermore, this review gives an overview of the 
used questionnaires to measure SCF. The CFQ is often used in studies concerning SCF in 
patients with BC. However, the factor structure of the CFQ is still unclear and the 
psychometric properties were not analyzed for patients with a breast disease before. This 
is assessed in Chapter 3. Chapter 4 reports SCF across time in BC patients in comparison 
with BBD patients. Because of heterogeneity in earlier research, both satisfaction and 
frequency of complaints about SCF are evaluated. Furthermore, predictors of SCF are 
examined. 
 
Objective cognitive functioning 
The timing of the baseline measurement in studies concerning OCF often is not 
standardized. Most longitudinal studies examining the effect of adjuvant chemotherapy 
on OCF perform the first measurement before chemotherapy, but after surgical treatment 
under general anesthesia. It should be recognized that general anesthesia can affect 
cognitive functioning, also known as post-operative cognitive dysfunction. In Chapter 5, 
the influence of post-operative cognitive dysfunctioning on OCF in BC patients is assessed. 
Therefore, a group of BC patients receiving neo-adjuvant chemotherapy, i.e., before 
surgery, was included in this study. In addition, the results concerning OCF before and 
three months after ending adjuvant chemotherapy in BC patients in comparison with 
patients with a BBD are described. Besides analyses on group level, changes at the 
individual level are examined. Furthermore, the relationship between OCF and SCF is 
explored in this chapter.  
Cognitive functioning is generally studied by means of prevalence rates or changes in 
mean scores over time. However, such an approach may mask subgroups of patients with 
different courses of cognitive functioning over time. Therefore, Chapter 6 focuses on 
identifying longitudinal development classes for OCF in BC patients treated with 
chemotherapy. Furthermore, the demographic, psychological, and clinical characteristics 
of these groups are described. 
 
Impact of cognitive functioning on quality of life 
Chapter 7 evaluates the course of QoL across time in BC patients treated with 
chemotherapy compared to patients with a BBD. In addition, the impact of OCF and SCF 
on QoL is examined. 
Chapter 8 contains a summary and discussion of the main findings. Furthermore, 
methodological considerations, implications for future research and clinical practice are 
described. Finally, an overview about OCF and SCF in BC patients in Dutch is included in 
the Appendix. This overview especially focuses on the implications for interventions for 
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Objective: Results from studies examining subjective cognitive dysfunctioning (SCD) in 
breast cancer (BC) patients are unclear. Therefore, this review examined (i) the prevalence 
of SCD, (ii) the differences between (treatment) groups in SCD, (iii) the course of SCD, (iv) 
the relationship of SCD with psychological factors, and (v) the relationship between SCD 
and objective cognitive dysfunctioning (OCD).   
 
Methods: Through a systematic literature-search, we identified 27 studies concerning SCD 
in BC patients. The methodological quality of these studies was examined according to 
predefined criteria. The methodological limitations and heterogeneity across studies were 
taken into account. 
 
Results: Eight studies were graded of high, 12 of moderate, and seven of low quality. 
Twenty-one to 90% of the patients reported SCD. The comparison between different 
(treatment) groups, at different time points of the cancer trajectory, rendered 
inconclusive evidence regarding the relation of SCD to the cancer itself, chemotherapy, 
and hormonal therapy. SCD and OCD were unrelated, but SCD was associated with 
psychological distress, fatigue, and health status.  
 
Conclusions: SCD does exist in BC patients, but it remains unclear if this is more commonly 
found in BC patients than in the general population. It is inconclusive if SCD is developed 
post-treatment, or already exists pre-treatment. Since there is a relationship between SCD 
and anxiety and depression, SCD may be more indicative of emotional distress instead of 
OCD. Attention toward SCD in future research is warranted in order to draw valid 
conclusions regarding SCD in BC patients.  
 
Key words: cancer, oncology, subjective cognitive dysfunction, self-report, systematic 
review 




Breast cancer (BC) is the most frequently diagnosed cancer in women in the world and 
comprises 18% of all female cancers [1]. Due to advancements in adjuvant treatment an 
increasing number of women live with the long-term effects of BC and its treatment [2]. 
Therefore, it is important to develop a better understanding of the post-treatment effects 
of adjuvant systemic therapy in BC patients, which involves chemotherapy and/or 
hormone therapy.  
Although adjuvant systemic chemotherapy significantly improves the clinical 
outcome of patients with early-stage BC, it is also known to have severe side-effects [3]. 
Apart from common complaints, such as fatigue, hair loss, and depression [4], cognitive 
impairment after chemotherapy is a reported concern of BC patients [5]. A large 
proportion of patients treated with chemotherapy will also receive hormonal therapy. 
There is a growing body of research concerning the influence of chemotherapy and 
hormonal therapy on neuropsychological functioning in BC patients and survivors (e.g., [5-
38]).  
Most studies examined objective cognitive dysfunction (OCD) of patients through 
neuropsychological testing, but the influence of adjuvant chemotherapy and hormone 
therapy on subjective cognitive dysfunction (SCD) has also been assessed by self-reports of 
patients. SCD refers to the amount of cognitive problems (memory, learning, language, 
concentration) that patients experience in their daily life and their satisfaction with their 
cognitive functioning. 
The results of the studies examining SCD in BC patients are unclear with regard to (i) 
the prevalence of SCD, (ii) differences between (treatment) groups in SCD, (iii) the course 
of SCD, (iv) the relationship of SCD with psychological factors, and (v) the relationship 






MEDLINE (1263 hits), and PsychINFO (200 hits) databases were searched to identify 
studies reporting on SCD in BC patients for the period 1960 to April 2009. The term ‘breast 
cancer’ was used in combination with other key terms: cognitive / memory /attention / 
neuropsychological in combination with problems / complaints / dysfunction / self-
assessment / self-report / patients’ perspective, subjective complaints / decline, and 
cognitive failure. The reference lists of all identified publications and reviews were 
checked to capture other relevant publications, which were not identified by the 
computerized search. Studies reporting an overlap in patient samples were analysed and 
only the highest quality study was included [20, 21]. When studies described the same 
patient sample and were of equal quality, only the most recent publication was included 
[6, 26]. After applying the selection criteria (see below) to the identified articles and their 
reference articles, 27 studies remained. 
26 Chapter 2 
 
Selection criteria 
Studies were included if they met the following criteria: (i) described aspects of SCD in BC 
patients, (ii) the studied population exclusively concerned BC, (iii) the full report of the 
article was published in English, German, or Dutch. The described inclusion criteria were 
applied to the initial 1464 hits. Seventy articles met the criteria based on titles of the 
articles. After inspection of the abstracts and hard copies, 22 articles met our selection 
criteria and were included in this review. Through hand search, five articles were found 



























Figure 1: Study selection progress 
 
Quality assessment 
The quality of the selected studies was independently assessed using a 17-item predefined 
checklist (Table 1) by two reviewers (MJJP and JDV). The checklist was based on an 
established criteria list for systematic reviews [39-42]. For each item in the checklist, 
studies could be assigned one point. A score of zero points indicated an insufficient or no 
description of the item. Disagreement about the quality of studies was solved through 
discussion in a consensus meeting. Studies scoring 70% or more of the maximum score 
 
Studies excluded following 
screening of title, duplicates  
N =1394 
Computerized search 
N = 1463 
Studies screened  
based on abstract  
N = 69 
Studies excluded  
based on abstract  
N = 25 
Studies screened  
based on full text  
N = 44 
Studies excluded based on full text 
N = 20 
Studies excluded based on overlap 
in patient sample N = 2 
Included studies based on 
computerized search N = 22 
Studies retrieved by hand search  
N = 5 
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(≥ 12 points) were considered to be of ‘high quality’. Studies scoring between 50% and 
70% were rated as ‘moderate quality’, and scores lower than 50% (≤ 8 points) were 
considered as ‘low quality’ studies [42]. Findings were considered consistent if ≥ 75% of 
the studies that investigated a particular factor showed the same direction of the 
association. We defined four levels of evidence (Table 2) [42], that we used to describe the 
results.  
 
Table 1: Criteria list for assessing the methodological quality of studies on subjective cognitive 




A. Patient signed an informed consent form before study participation. 
B. A description is present of at least two sociodemographic data (e.g., age, race, 
employment status, educational status etc.). 
C. Medical data is described (e.g., tumor stage at diagnosis, treatment etc.). 
D. Inclusion and/or exclusion criteria are formulated. 
E. Participation and response rates for patient groups have to be more than 75%. 
F.  Information is presented about patient/disease characteristics of non-responders.  
Study design 
G. Sample size is at least consisting of 50 patients (arbitrarily chosen). 
H. 
 
The data collection is described (e.g., neuropsychological assessments, self-report 
measurements, interview). 
I. Standardized or valid self-report measurements to assess SCD are used.  
J. Definition of SCD is described. 
K. A baseline measurement before treatment.  
L. There are multiple assessment points in time.  
M. Mean or median and range or standard deviation of time before/since diagnosis or 
treatment is given.  
N. The collection of data is prospectively gathered.   
O. Drop-out rate < 20%. 
P. 
 
The study controlled for at least two of the following factors in the results for SCD: 
depressive symptoms, fatigue, anxiety, stress, menopausal status, influence of hormonal 




The results of subjective SCD are compared between two groups or more (e.g., healthy 
population, different treatment groups, comparison with time and treatment etc.). 
R. Mean, median standard deviations or percentages are reported for the SCD.  
 
SCD = subjective cognitive dysfunctioning  
28 Chapter 2 
 







Consistent findings (≥ 75%) in at least two high quality studies or one high quality study 
and at least three moderate studies. 
Moderate Consistent findings (≥ 75%) in one high quality study and at least one low quality study 
or at least three moderate studies. 
Weak Findings of two moderate studies or consistent findings (≥ 75%) in at least three or 
more low quality studies. 







The main findings are summarized in Table 3. Considerable variation among the studies 
with regard to different study characteristics existed. The sample size was often small and 
ranged from 21 [22] to 1933 [43] patients (mean ± standard deviation = 201.4 ± 452.2). 
Nineteen studies used a cross-sectional design (four of these studies were longitudinal, 
but only reported cross-sectional results concerning SCD), seven used a longitudinal 
design, and one study used a randomised control trial. The timing of assessment in all the 
studies ranged between 18 days before surgery, to 15.8 years after diagnosis. Most 
assessments took place within two years after completion of treatment. From the seven 
studies which reported longitudinal outcomes concerning SCD, five studies included a 
baseline assessment of SCD before start of treatment (surgery or chemotherapy). Stages 
of BC, chemotherapeutic agents, doses, duration, and intensity of treatment were 
heterogeneous in and across the included studies. Heterogeneity also existed in the 
inclusion of controls and/or comparison groups. Nine studies did not include a comparison 
group at all. Different comparison groups were used, e.g., healthy controls, patients with 
another BC stage, or BC treatment other than chemotherapy.  
Only seven out of 27 studies included, described the definition of SCD [9, 11, 38, 44-
47]. Some reported a theoretical definition, whereas others reported cut-off points or 
percentiles that patients need to rate at least in order to consider them as having SCD. A 
total of 10 different self-report SCD questionnaires were used (Table 4 provides additional 
information on the SCD questionnaires utilized). Specific measures, as well as subscales 
from questionnaires that measure another construct, like health status (HS), were used. 
Nine authors used ‘self-made’ and non-validated questionnaires and/or semi-structured 
interviews to examine SCD [9, 11, 13, 22, 23, 25, 44, 48, 49]. A number of other self-report 
measurements were used to assess psychological factors, such as anxiety, depression, 
psychological distress, stress, fatigue and HS.  
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Methodological quality 
Eight studies were graded as high [9, 20, 24, 26-29, 44], 12 as moderate [11, 13, 19, 30-32, 
38, 43, 47-50], and seven as low methodological quality [22, 23, 25, 33, 45, 46, 51]. The 
quality scores ranged from six (low) to 14 (high) (mean ± standard deviation = 10 ± 2.2). 
Methodological shortcomings mainly concerned the following items: 25 studies did not 
control for at least two confounding factors in the results for SCD, 23 studies did not 
provide patient/disease characteristics of non-responders, 21 studies did not have a 
participation rate exceeding 75%, 20 studies did not describe a definition of SCD, 20 
studies did not have a baseline measurement before treatment, and 16 studies did not 
provide information of time since/before diagnosis or treatment.  
 
Prevalence of subjective cognitive dysfunctioning 
Eleven studies described percentages of prevalence of SCD ranging from 21% to 90%. The 
proportion of patients with SCD varied widely, reflecting differences in definitions, 
instruments utilized and cut-off points. SCD consisted of problems with memory (range 
between 14% and 95%) [9, 22, 23, 26, 29, 38, 44, 49], concentration (31% to 90%) [9, 22, 
23, 26, 49], language (78%) [22], and self-reported retardation in mental processes or 
lower effectiveness (25% to 47%) [30, 47].  
 
Subjective cognitive dysfunctioning in breast cancer patients versus healthy controls 
Evidence regarding differences in SCD between BC patients and healthy controls remains 
inconclusive. Five studies (one high, three moderate and one low methodological quality), 
found significantly more SCD in BC patients treated with chemotherapy, sometimes 
combined with hormone therapy and/or radiotherapy, compared with healthy controls at 
different time periods after treatment (six weeks, three and six months, and two and four 
years post-treatment) [13, 25, 31, 43, 44]. Two high quality studies did not find significant 
group differences in BC patients treated with chemotherapy, radiation therapy, and/or 
hormone therapy compared with healthy controls at one and two years after treatment 
[26, 44].  
 
Subjective cognitive dysfunctioning in different treatment types 
Evidence regarding differences between treatment types in SCD remains inconclusive. 
Four studies found evidence for group differences, but 10 studies did not find significant 
differences between treatment groups in SCD. Multiple differences were found in SCD 
between different treatment types. One study (moderate quality) found significant 
differences in SCD between patients treated with chemotherapy (sometimes with 
hormone therapy and/or radiotherapy) and patients treated without chemotherapy one 
year post-treatment [49]. Another study (moderate quality) found that women who 
received chemotherapy and hormonal therapy reported significantly more memory 
complaints one year after completing chemotherapy compared with women who received 
chemotherapy alone [27]. Furthermore, one moderate quality study found significantly 
more memory and concentration problems in BC patients treated with 
cyclophosphamide/methotrexate/5-fluorouracil (CMF) compared with lymph node-
 Subjective cognitive dysfunction: a systematic review 41 
 
negative BC patients (not treated with chemotherapy), four years after treatment [11]. 
One low quality study found more SCD in patients treated with radiotherapy in 
combination with hormone therapy compared to patients treated with only radiotherapy 
six weeks after ending radiotherapy [51]. 
Ten studies did not find significant differences between treatment groups in SCD [9, 
11, 13, 20, 27, 30, 44, 48, 49, 51]. Patients treated with high dose chemotherapy were 
compared with standard dose treated patients [13]. Other studies compared patients 
treated with chemotherapy and/or radiotherapy and/or hormonal therapy with patients 
treated with radiotherapy only [20, 27, 30, 48] or radiotherapy which was sometimes 
combined with hormone therapy [9]. No significant differences were found in a high and 
moderate quality study that compared different chemotherapies and hormonal therapies 
[11, 44]. 
 
The course of subjective cognitive dysfunctioning 
To examine if SCD exists due to systemic treatment or if it already exists pre-treatment 
after the patient is informed about the BC diagnosis, we looked at the pre-treatment 
results of SCD. Eight studies assessed the patients’ SCD prior to the start of systemic 
therapy. Most of these studies were longitudinal and of high or moderate quality [24, 26, 
28, 29, 31]. Three studies (low to moderate quality) focussed only on the pre-treatment 
assessment [46, 47, 50]. There was no major dissimilarity between the pre- and post-
treatment occurrence of SCD. Strong evidence is found for the increase of the severity of 
SCD directly after systemic treatment compared with baseline measurements [24, 26, 28, 
29, 31]. Fluctuating and inconclusive results were found for changes in severity and 
occurrence of SCD over time after treatment [24, 26, 31, 49].  
 
Relationship between subjective and objective cognitive dysfunctioning  
Strong evidence was found for the lack of a relationship between SCD and OCD. Fifteen 
studies evaluated the correlation between SCD and OCD, eleven of these studies did not 
find a significant correlation between the self-reports of the women and the outcome 
scores of the neuropsychological assessment [9, 13, 19, 24, 26-28, 30, 44, 49, 50]. Some 
studies (low to moderate quality) found a significant relationship between SCD and 
different domains of OCD: working memory [30], visuospatial ability [19], attention [25, 
45], visual learning, verbal memory and mental flexibility [45]. One moderate quality study 
found low correlations between SCD and OCD (.19 - .22) [11].  
 
Relationship between subjective cognitive dysfunctioning and psychological factors 
The lack of correlation between OCD and SCD suggests that the SCD may be more 
indicative of emotional distress than cognitive dysfunction. Studies which explored the 
effect of psychological factors on cognitive functioning, found moderate evidence for a 
relationship between SCD and anxiety between the end of chemotherapy and nine 
months later [13, 28, 32], and strong evidence was found two years after completion of 
systemic therapy [9, 44]. In addition, moderate evidence for the relationship between SCD 
and depression was found for six months [13, 24], weak evidence was found between nine 
42 Chapter 2 
 
and 12 months [27, 32], and strong evidence was found two years after completion of 
systemic therapy [9, 44]. Studies that focused on general psychological distress found 
moderate evidence for the relationship with SCD between 12 and 18 months post-
treatment [26, 49]. Moderate evidence was found for the relationship between fatigue 
and SCD between two and five years after completion of systemic therapy [19, 44]. 
Furthermore, one moderate quality study found significantly more SCD in severely 
fatigued patients compared with non-severely fatigued BC patients and controls [48]. For 
the relationship between SCD and HS, moderate evidence was found between 12 and 18 





This systematic review, examined the prevalence of SCD, the differences between 
(treatment) groups in SCD, the relationship of SCD with psychological factors, and the 
relationship between SCD and OCD. Strong evidence was found for the lack of a 
relationship between OCD and SCD. Methodological limitations and heterogeneity of the 
existing studies made it difficult to draw further definitive conclusions. The reported 
prevalence of SCD varied considerably, which is most likely the result of the variety in 
definitions, questionnaires, and cut-off scores. SCD does exist in the BC population, but 
inconclusive evidence was found for the comparisons with other populations, so it is 
unclear if SCD is more commonly found among BC patients than in the general population. 
Due to the heterogeneity in systemic treatments, no specific results could be reported 
concerning the effects of individual treatment modalities on SCD (e.g., the exact effect of 
chemotherapy or hormonal therapy alone).  
This review did not find evidence for differences in the prevalence of SCD between 
post- and pre-treatment assessments, which implies that there is no effect of systemic 
treatment on the occurrence of SCD. Evidence was found for short time increased severity 
of SCD directly after systemic treatment, compared to the baseline assessment, but 
inconclusive evidence was found for the course of SCD after treatment. The evidence for 
the differences in the occurrence of SCD between pre- and post-treatment assessments 
and the course of SCD after treatment was probably lacking because most longitudinal 
studies focused on OCD and therefore did not provide the results of SCD over time. At this 
moment it is still unknown whether SCD already exists before the BC diagnosis, so it 
remains unclear whether the pre-treatment SCD is due to stress, related to the diagnosis, 
or if it is just a symptom that exists in the general population and is not specifically related 
to BC.   
While there is an increasing number of studies focusing on OCD in BC patients, more 
attention needs to be paid to SCD as well. As stressed by Castellon et al., both OCD and 
SCD should be examined [19]. This review supports this statement because we found 
strong evidence for a lack of a relationship between OCD and SCD, but both are relevant 
topics in order to investigate cognitive functioning in BC patients. There are a number of 
possible explanations for this lacking relationship. First, the neuropsychological tests may 
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be insufficiently sensitive to detect mild OCD in patients treated for cancer, because these 
tests are routinely used with groups of patients with degenerative decline or other brain 
injuries [52, 53]. A second explanation could be that, except for the longitudinal designs of 
some included studies, objective tests evaluate performance at a point in time, whereas 
self-report encompasses assessment of performance over a broader period (e.g., patients 
need to rate how often they had suffered from memory problems the last month) [54]. 
Third, increased knowledge about the relationship between chemotherapy and cognitive 
dysfunction could influence the expression of SCD. Schagen et al. examined the influence 
of knowledge about the ‘chemo-brain schema’, which is described as the cognitive 
representation of past experience, knowledge, and expectancies (explicitly informed or 
due to pre-existing knowledge) [53]. They found an increase in SCD in patients with pre-
existing knowledge about chemotherapy-associated cognitive problems compared with 
patients without this knowledge [53]. Fourth, subjective measures and neuropsychological 
tests do not measure the same construct. Objective performance on tests may not 
accurately reflect the SCD that many women experience after treatment of BC. 
Alternatively, reported SCD may indicate emotional distress instead of real cognitive 
problems [52], and is a way in which a patient copes with stressful events [53].  
This review found evidence for the association of SCD with anxiety, depression, 
psychological distress, fatigue, and lower HS. It is unknown if the existing cognitive 
problems lead to psychological distress or if psychological distress leads to the persistence 
of cognitive problems. Cognitive problems may indicate psychological distress: diminished 
ability to think and concentrate is one of the possible symptoms of a depressive episode, 
and concentration problems could be a symptom of an anxiety disorder [55]. Literature 
has shown a negative influence of chemotherapy and hormonal therapy on fatigue and 
OCD [14, 56] and fatigue is found as the most important predictor of SCD [57]. Thus, this 
overlap between the symptoms of SCD and anxiety, depression and fatigue is a valuable 
explanation for the association of SCD with these constructs. It is likely that SCD is more a 
reflection of psychological symptoms instead of OCD.    
There are several shortcomings in the available studies. The cross-sectional nature of 
many included studies limits conclusions of causality and the development of SCD over 
time. The lack of baseline measurements made it difficult to make inferences regarding a 
real increase of SCD after systemic treatment. The small patient populations, lack of 
control groups, and lack of controlling for confounding variables were other shortcomings. 
Prospective longitudinal follow-up research with a baseline measurement, more patients, 
and a control group is needed in order to draw valid conclusions regarding SCD in BC 
patients. In order to accomplish this, studies should use a validated instrument and cut-off 
points to measure SCD. Anxiety, depressive symptoms, fatigue, and quality of life should 
be topics in future research elucidating the persistence of these post-treatment SCD in BC 
patients. 
Self-report measures are important to understand the BC patients’ perspective of the 
experienced problems. Despite the inconsistent results concerning the persistence and 
prevalence of SCD in BC patients and the relation with psychological distress, it should be 
assessed and intervened upon in clinical practice. This is necessary because patients do 
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express their concerns regarding SCD and this review found evidence for the presence of 
SCD in BC patients.   
In conclusion, SCD does exist in BC patients, but it remains unclear if this is due to 
systemic treatment or to the stress related to the diagnosis of BC. Since there is no 
relationship between SCD and OCD and there is evidence for relationships between SCD 
and anxiety, depression, and HS, SCD may be more indicative of emotional distress. 
Attention toward SCD in future high quality research is needed in order to draw definitive 
conclusions. 
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Purpose: To gather useful information about subjective cognitive functioning among 
patients with a breast disease, the cognitive failures questionnaire (CFQ) have been 
frequently used, although its factor structure is still unclear. This study examines the 
factorial representation and psychometric properties of the CFQ in this population.  
 
Methods: The CFQ was completed by 180 women with a breast disease. Furthermore, all 
participants completed measures of state anxiety, depression, fatigue, and the satisfaction 
with cognitive functioning. For each of the existing factor structures a confirmatory factor 
analysis was conducted to examine the fit of the factor structures of the CFQ. 
Furthermore, an exploratory factor analysis was done. 
 
Results: None of the existing models met the criteria for an acceptable fit in the sample of 
patients with a breast disease. The three-factor model (Forgetfulness, Absentmindedness, 
and Social recklessness) derived from the exploratory technique showed good reliability 
and validity.  
 
Conclusions: The CFQ with the three-factor model is an adequate instrument for 
measuring the frequency of everyday cognitive lapses in women with a breast disease. 
 
Keywords: Cognitive failures questionnaire, cognitive functioning, factor structure, breast 








Breast cancer (BC) is the most frequently diagnosed cancer in women in the developed 
countries. In the Netherlands, one in nine women will develop BC during her life [1]. 
Women who feel an abnormality in their breast or women whose screening 
mammography is abnormal are referred for further examination. This will result in the 
diagnosis BC or a benign breast disease (BBD). In addition to surgery, BC patients are often 
treated with adjuvant therapies, such as chemotherapy. During and after this adjuvant 
treatment, complaints of cognitive functioning are frequent among BC patients (see Wefel 
and Schagen for a recent overview [2]). While most studies focus on objective cognitive 
functioning (OCF) in BC patients, some investigators are also interested in subjective 
cognitive functioning (SCF) (e.g., [3-5]). SCF refers to the cognitive problems that persons 
experience in their daily life and their satisfaction with their cognitive functioning. When 
examining cognitive functioning in patients with a breast disease, it is important to assess 
both OCF and SCF, as strong evidence is found for the lack of a relationship between OCF 
and SCF [6]. However, there is some literature that supports the ability that individuals 
have to subjectively detect changes in cognitive function before they are documented 
with objective neuropsychological tests [7]. Thus, there might be a relationship between 
SCF and subsequent cognitive decline in particular populations. Therefore, the assessment 
of SCF in patients with breast disease can be of great importance as predictor for 
longitudinal cognitive outcomes of patients.  
Earlier research regarding SCF in BC patients did not find differences between BC 
patients and healthy controls. One of our suggestions is that problems with SCF may be 
more indicative of emotional distress than problems with OCF [6]. However, another 
hypothesis is that differences between patients with a breast disease and the healthy 
population are not found because problems with SCF should be measured with a validated 
factor structure for patients with a breast disease. 
Various measures have been used in assessing SCF in patients with a breast disease 
(both BC and BBD). There are specific measures and subscales from questionnaires that 
measure another construct, such as quality of life. Furthermore, investigators use ad hoc, 
non-validated questionnaires and/or semi-structured interviews to examine SCF (see 
Pullens, De Vries, and Roukema for an overview [6]). One of the specific measures that is 
available in many languages, such as Dutch, is the Cognitive Failures Questionnaire (CFQ) 
[8]. It is a 25-item scale that assesses the self-perceived frequency of cognitive 
dysfunctions in daily life by reporting the frequency of incidents on a 5-point scale.  
To gather useful information about SCF among patients with a breast disease, it is 
important to use assessment tools that are reliable and validated. Although the CFQ have 
been used several times to assess SCF in patients with a breast disease [3, 9-11], its factor 
structure is still unclear. A number of factor analyses have been conducted in different 
samples to capture the structure of the CFQ. Although Broadbent, Cooper, FitzGerald and 
Parkes [8] assumed that a general factor adequately described the CFQ, others found 
more than one factor [12-19]. The findings of these different factor analyses are 
contrasting.  
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 Furthermore, no information is available about the factor structure for patients with 
a breast disease. This information could be helpful in the investigation of problems with 
SCF in patients with a breast disease. Therefore, the first aim of the present study was to 
find a factorial representation of the CFQ in a population of women with a breast disease 
(both malignant and benign problems) by examining known factor structures and using an 
exploratory technique. Furthermore, the psychometric properties of the factor structure 





Participants and procedure 
Women who were diagnosed with BC and received chemotherapy between January 2009 
and January 2011 in St. Elisabeth hospital (Tilburg), TweeSteden hospital (Tilburg), Maxima 
Medical Centre (Eindhoven, Veldhoven), Catharina hospital (Eindhoven), St. Anna hospital 
(Geldrop), Amphia hospital (Breda), and Jeroen Bosch hospital (Den Bosch) were eligible 
for this study. In addition, women diagnosed with a BBD were also asked to participate. A 
cyst, mastopathy or a fibro-adenoma are the most common BBD diagnoses. Treatment of 
the BBD is not necessary for most women but some women are invited for a follow-up 
examination several months later. Furthermore, some women want their cyst or fibro-
adenoma to be surgically removed.  
Women with proven BC recurrence or distant metastases were excluded. Other 
exclusion criteria were related to the assessment of OCF with neuropsychological tests 
(these results will be described elsewhere): a history of neuropsychological and/or 
psychiatric signs or symptoms that lead to deviant neuropsychological test results (e.g., 
dementia), the use of medication that may lead to deviant neuropsychological results, 
alcohol and/or drug addiction, and a poor expression in the Dutch language. 
When women were invited to participate in the study, the diagnosis was known, but 
no adjuvant treatments were started yet. All participants provided written informed 
consent and this study was approved by a central medical ethic committee. 
 
Materials 
All patients were asked to report a number of sociodemographic aspects (age, living with 
partner, having children, educational level, having salaried work/retirement) and 
completed the following questionnaires after diagnosis is known.  
The Cognitive Failures Questionnaire (CFQ) [8], Dutch version [20] was used to assess 
cognitive failure on everyday tasks (e.g. memory, perception, and motor control). This 
self-report inventory consists of 25-items assessing the frequency of cognitive slips during 
the last six months. The rating scale is a 5-point Likert-scale. High scores indicate high 
levels of cognitive failure.  
The cognitive functioning facet of the World Health Organization Quality of Life 
assessment instrument-100 (WHOQOL-100) [21], Dutch version [22], was used to assess 
satisfaction with SCF. The WHOQOL-100 consists of 100 items assessing 24 facets of QoL, 
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four questions each, that combined compile QoL. QoL refers to the evaluation of function, 
e.g., satisfaction with aspects of life. The cognitive functioning facet measures satisfaction 
with SCF, for example with the following question: ‘how satisfied are you with your ability 
to learn new information?’ The rating scales range from 1 to 5. A high score on the 
cognitive functioning facet indicates satisfaction with SCF. The instrument is reliable and 
valid [23] and the sensitivity of the instrument is high as well [24]. 
The Center for Epidemiological Studies-Depression Scale (CES-D) [25], Dutch version 
[26], was used to measure the presence and degree of depressive symptoms. It consists of 
20 items. The rating scales range from 0 to 3. A higher score indicates more depressive 
symptoms. An indication of a depression was defined as a score above 16 [27]. The CES-D 
has been established as a valid and reliable measure of depressive symptoms in BC 
patients [28].   
The Fatigue Assessment Scale (FAS) [29] was used to measure fatigue. It is a 10-item 
questionnaire that taps fatigue and exhaustion. The response scale is a 5-point scale (1 to 
5). A higher score indicates more symptoms of fatigue. High fatigue was defined by a score 
above 21 [29]. The psychometric properties have been studied for different patient 
populations including BC patients and are reported to be good [30].  
The State-Trait Anxiety Inventory-state (STAI) [31], Dutch version [32] was used to 
measure anxiety. The state scale asks persons how they feel at a particular moment in 
time, while the trait scale asks people to describe how they generally feel. In this study the 
validated shortened 6-item questionnaire for the STAI-state and the 10-item version of the 
STAI-trait was used. The response scale is a 4-point scale (1 to 4). A higher score indicates 
more symptoms of anxiety. High state anxiety was defined as a score above 14, high trait 
anxiety was defined as a score above 22 [33-35].  
 
Statistical analyses 
Calculation of frequencies was used to present the demographic and psychological data of 
the total group. Independent sample t-tests (continuous data) and χ
2
-tests (nominal data) 
were used to examine potential differences between the BC patients and the BBD 
patients.   
Confirmatory factor analyses (CFA) were conducted to test the structures found in 
earlier research. Goodness of fit was verified by the following fit indices: the Comparative 
Fit Index (CFI) and the Root Mean Square Error of Approximation (RMSEA). The models 
have a satisfactory to good fit when CFI > 0.90 and RMSEA < 0.06 [36].  
An exploratory factor analysis (EFA) (principal axis factoring), followed by varimax 
rotation, was conducted to find an adequate and interpretable dimensional 
representation of the CFQ in our sample of patients with a breast disease. Frequencies 
were employed for calculating the skewness and kurtosis of the CFQ questions. Items 
were excluded from this EFA when the converted z-scores of both the skewness as the 
kurtosis were greater than 1.96. The interpretation of the scores on these items showed 
that there is almost no variation in the score between the participants on these items. A 
combination of the scree test and interpretability was used to choose the number of 
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factors. Items with cross-loadings were excluded when the difference between the factor 
loadings was smaller than .15.  
The internal consistency for each factor was estimated using Cronbach’s alpha 
coefficients. Depending on the number of items in a scale, values should be at least 0.70 
[37]. In order to provide information on construct validity, Pearson’s correlation 
coefficients were calculated between the CFQ and the CES-D and STAI-state to examine 
the divergent validity. To examine the convergent validity, Pearson’s correlation 
coefficients between CFQ and the cognitive functioning facet of the WHOQOL-100 and the 
FAS were calculated. Fatigue was chosen because an association is found between fatigue 
and cognitive complaints (e.g., [38]). We did not use a neuropsychological test to examine 
convergent validity, because the literature is consistent about the lack of a relationship 
between OCF and SCF [6]. Moderate (r = 0.30 - 0.49) and high (r = > 0.49) correlations are 
indicative for convergent validity, whereas small correlations (r = 0.10 - 0.29) are indicative 
for divergent validity [37]. The data were processed by means of the Statistical Package for 






In total, 180 patients with a breast disease completed the questionnaires; 91 BC patients 
and 89 BBD patients. The baseline psychological factors showed a significantly lower score 
on fatigue in BC patients. The percentages of fatigued patients also differed significantly 
between BC and BBD patients. In addition, a higher score on state anxiety in patients with 
BC was found, however, the percentages of patients scoring high on state anxiety did not 
significantly differ between BC and BBD patients. Furthermore, significant differences in 
educational level were found between BC and BBD patients. BC patients and BBD patients 
did not significantly differ on the original CFQ-25 item version. No additional significant 
differences were found concerning sociodemographic factors and the remaining 
psychological factors and classifications in ‘high trait anxiety’ and ‘indication of a 
depression’ (see Table 1). 
 
Confirmatory factor analyses 
Ten studies in which the factor structure of the CFQ was identified were found in the 
literature [8, 12, 14-20]. For each of these factor structures a CFA was conducted to 
examine the fit of the factor structures of the CFQ. None of the models met the criteria for 
an acceptable fit. Table 2 gives an overview of the tested factor structures.  
 
Exploratory factor analysis 
Five questions were excluded before the EFA because the z-scores of both skewness and 
kurtosis were higher than 1.96: item 4 (confuse right and left), 5 (bump into people), 18 
(throw away something you want to keep), 19 (daydream), and 24 (drop things). The scree 
plot of the EFA revealed three factors. Based on the factor loadings, items 13 (feel to see a 
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product in supermarket), 15 (trouble making up your mind), 12 (forget which way to turn 
on a road), and 21 (start doing one thing and get distracted into doing something else) 
were excluded because the difference between the cross-loadings of these items with 
other factors was smaller than .150. The three-component solution explained 37.2% of the 
variance, with factor one (Forgetfulness) contributing 16.0%, factor two (Absent-
mindedness) contributing 11.3%, and factor three (Social recklessness) contributing 9.9%. 
The EFA results are presented in Table 3. 
 
Table 1: Patient characteristics  
 
Characteristics Total group 
(N = 180) 
BC group 
(N = 91) 
BBD group 
(N = 89) 
P-value 
Sociodemographics  
Age 49.3 ± 10.4 50.7 ± 10.2 47.8 ± 10.6 .067 
Living with partner (%) 145 (85.3) 73 (86.9) 72 (83.7) .563 
Children (%) 141 (82.5) 65 (74.7) 76 (87.4) .053 























  .020* 
Salaried work/retirement 136 (81.0) 64 (79.0) 72 (82.8) .674 
Psychological characteristics     
Frequency of complaints about SCF 30.2 ± 10.9 28.7 ± 10.8 31.8 ± 10.9 .060 
Fatigue 19.6 ± 5.9 18.4 ± 5.7 20.8 ± 5.8   .007* 
High fatigue 54 (30.5) 20 (22.2) 34 (39.1)   .023* 
Depressive symptoms 10.2 ± 9.1 11.1 ± 9.1 9.4 ± 9.0 .222 
Indication of depression 40 (23.5) 20 (23.8) 20 (23.3) .932 
State anxiety 11.2 ± 3.7 12.2 ± 3.4 10.2 ± 3.7 < .001* 
High state anxiety 30 (17.2) 20 (23.0) 10 (11.5) .071 
Trait anxiety 17.4 ± 5.4 17.6 ± 5.4 17.2 ± 5.5 .635 
High trait anxiety 30 (17.3) 16 (18.4) 14 (16.3) .868 
Satisfaction with SCF 14.7 ± 2.3 14.8 ± 2.3 14.6 ± 2.4 .637 
BBD = Benign breast disease; BC = Breast cancer; SCF = Subjective cognitive functioning 
Mean ± standard deviation are presented for age and psychological factors, percentages are between 
brackets; for the calculation of the percentage missings are not included 
a
 L = low education (primary school, lower vocational education); M = middle education (lower general 
secondary education, intermediate vocational education); H = high education (higher general secondary 
education, pre-university education, higher vocational education, university) 
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 CFI NNFI RMSEA 
Wallace et al. [12]/ Wallace [20] 1.839 < .001 247 454.28 .838 .689 .066 
Ponds et al. [18] 2.031 < .001 115 233.60 .835 .726 .076 
Broadbent et al. [8]  1.967 < .001 275 540.87 .789 .654 .073 
Larson et al. [14]/ Matthews et 
al. [15] 
1.817 < .001 251 456.02 .828 .689 .076 
Rast et al. [19]  2.0 < .001 183 366.09 .823 .706 .075 
Pollina et al. [17]  1.677 < .001 268 449.331 .856 .712 .061 
Meiran  et al. [16] 1.914 < .001 271 518.617 .804 .668 .071 
Wagle et al. [39] Functional 
sample 
2.286 < .001 61 97.5 .823 .731 .085 
Wagle et al. [39] Organic 
sample
a 
1.970 < .001 115 226.5 .854 .748 .073 
CFI = Comparative Fit Index; CMIN/DF = minimum discrepancy/degrees of freedom; df = degree of 
freedom; χ
2
 = chi square; NNFI = Non-Normed Fit Index; RMSEA = Root Mean Square Error of 
Approximation 
a
 Item 17 was used in two factors in the original factor structure (factor Cognition/concentration and 
factor Cognition/memory). In this confirmatory factor analysis this item is only used in the factor 
Cognition/concentration because the factor loading of this item was higher in this factor. 
 












22. on the tip of your tongue .59   
1. read something without thinking .58   
2. forget why you went from one part of the house 
to the other 
.58   
25. think of anything to say .57   
14. wonder if you’ve used a word correctly .53   
23. forget buy items at shop .50   
20. forget people’s names .43   
7. fail to listen to people’s names .42   
6. forget turning out light/fire .39   
17. forget where you put something .31 .78  
16. forget appointments  .58  
11. leave letters unanswered   .58 .42 
3. fail notice signposts  .39  
8. say something insulting   .63 
9. fail to hear people speaking when doing 
something else 
.32  .55 
10. lose temper   .45 
CFQ = Cognitive Failures Questionnaire  
Factor loadings of items belonging to each of the three factors are in bold  
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Reliability model based on the exploratory factor analysis 
Cronbach’s alpha coefficients were calculated for the model based on the EFA. The 
internal consistency of the domains varied: total score CFQ (16 items) (α = .85), 
Forgetfulness (nine items) (α = .80), Absentmindedness (four items) (α = .74), Social 
recklessness (three items) (α = .60).  
 
Validity 
To measure divergent validity, the scores of the CES-D, and STAI-state were correlated 
with the total score CFQ (16 items) and the three factors. Pearson’s correlations ranged 
between .08 and .26, indicating small correlations. To measure convergent validity, 
Pearson’s correlations between the total scores and the domains of the CFQ and the FAS 
and the facet ‘cognitive functioning’ from the WHOQOL-100 were calculated. These 
correlations ranged between .30 and -.52 indicating moderate to large correlations. See 
Table 4 for details.  
 
Table 4: Construct validity of the EFA: Pearson’s Correlation Coefficients 
 
 CES-D STAI-state FAS WHOQOL-100 cognitive 
functioning facet 
Total CFQ (16 items) .26 .24 .46 -.52 
Forgetfulness .25 .24 .40 -.49 
Absentmindedness .20 .19 .35 -.41 
Social recklessness .10 .08 .30 -.31 
CES-D = Center for Epidemiological Studies-Depression Scale; CFQ = Cognitive Failures Questionnaire; FAS 
= Fatigue Assessment Scale STAI-state = State-Trait Anxiety Inventory-State scale; WHOQOL-100 = World 
Health Organization Quality of Life instrument – 100 items  





The aim of this study was to find the best suitable subscales of the CFQ in a population of 
patients with a breast disease and to examine the psychometric properties. None of the 
existing models provided an acceptable fit of the factor structure of the CFQ for patients 
with a breast disease. Therefore, an EFA was done to find the best factorial representation 
of the CFQ in a population of patients with a breast disease. A three factor solution was 
found with good psychometric properties. In addition, a total score (16 items) can be 
calculated which is also reliable and valid. The three factors were Forgetfulness (nine 
items), Absentmindedness (four items), and Social recklessness (three items). This factor 
solution accounted for 37% of the variance. This is comparable to most of the other 
suggested factor solutions by other researchers ranging between 30-36% (e.g., [8, 16, 18]). 
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However, some exceptions are reported. For instance, Ponds, Boxtel, and Jolles [17] found 
an explained variance of 49.8%.  
The reliability of our three-factor solution was good, although, the internal 
consistency from one factor fell below the threshold. This could be due to the small 
number of items within this factor (three items), whereas at least four items are 
recommended to obtain a Cronbach’s alpha level of at least .70 [37].  
Our three-factor solution is different from the existing CFQ models. Some similarities 
exist though. The factor Forgetfulness e.g., is also suggested as a factor by Rast, Zimprich, 
Van Boxtel, and Jolles [18], but the items in this factor are not completely the same as in 
our factor. Also, our factor Social recklessness is comparable to the factor 
Absentmindedness in social situations of Ponds et al. [17], which included only one extra 
item. Furthermore, our Social recklessness factor (three items) is fully incorporated in the 
factor Blunders (seven items) from Wallace, Kass, and Stanny [12], and Wallace [19]. 
Broadbent et al. [8] have stated that self-perceived cognitive failure is a unitary system. 
Like Rast et al. [18], we have to conclude that it is a composition of different dimensions.  
Concerning divergent validity, the factors of the CFQ correlated low with the CES-D 
and STAI-state. These results are comparable to other studies that examined the 
correlations between the CFQ (total score of 25 items) and anxiety and depressive 
symptoms in a population of patients with a breast disease (e.g., Schilder et al. [38]). 
Convergent validity was shown by moderate to high correlations with the facet Cognitive 
functioning of the WHOQOL-100. The correlations between the CFQ and the FAS were 
moderate, suggesting at least an overlap between self-reported problems with SCF and 
fatigue. This is not surprising since fatigue is one of the predictors of self-reported 
cognitive functioning [40].  
It is important to keep in mind that the CFQ measures the frequency of cognitive 
lapses and not per se the experience of having complaints about SCF. As earlier research 
showed, the results of the CFQ are not comparable to answers in response to interview 
questions concerning memory or attention [38]. So, it could be the case that when 
patients rate their frequency of everyday cognitive failures, they do in fact not experience 
this as a problem and thus do not complain about it. It could also be the case that the 
everyday cognitive failures, measured with the CFQ, are not recognized/experienced as 
cognitive problems. For example, the item ‘leave letters unanswered’ could be interpreted 
as ‘a normal problem’ that exist one’s entire life instead of ‘cognitive problems’.  
A limitation of the present study is the relatively small sample size which made it 
impossible to run separate factor analyses for the BC patients and the patients with a BBD. 
This leads to heterogeneity in the study population. However, patients did not score 
significantly different on the original CFQ (25 items version). In addition, while emotional 
distress is experienced by BC patients [41], patients with a BBD may also have heightened 
levels of distress during and after the diagnosis [42, 43]. Our results concerning 
differences between BC and BBD patients on psychological characteristics are in line with 
these findings. Concerning depressive symptoms and trait anxiety, no significant 
differences were found when group means or the percentage of patients scoring high on 
this variable were compared. Concerning state anxiety, a significant difference in the 
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group mean was found between BC and BBD patients, but the percentages of patients 
scoring high on state anxiety did not differ significantly. Furthermore, the aim of future 
studies is to compare BC patients with BBD patients. Thus, for comparison reasons it is 
useful to create one factor structure for both groups instead of different structures. 
Future studies should examine our three-factor solution in separate larger groups of 
women with BC and BBD to observe if our factor-structure is as stable for both groups as 
we expect.  
Self-report measures are important to understand the patient’s perspective on the 
experienced problems. It is necessary to assess SCF and intervene upon it in clinical 
practice, because previous research showed that patients do express their concerns 
regarding these complaints [4, 5]. Until now, the clinical practice is making use of different 
measures (both validated and non-validated) to examine SCF. The results of the present 
study show that our three-factor model of the CFQ is the most suitable factorial 
representation in a population of women with a breast disease, with good reliability and 
validity. Therefore, it seems an adequate instrument for measuring the frequency of 
everyday cognitive lapses in women with a breast disease. 
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Background: Results of existing studies are inconclusive concerning the relationship 
between chemotherapy and subjective cognitive functioning (SCF). The aim of this study 
was to evaluate SCF of breast cancer (BC) patients and to find predictors of impaired SCF. 
Both satisfaction and frequency of complaints about SCF were measured.   
 
Methods: BC patients who were about to receive chemotherapy (N = 74) and patients 
with a benign breast disease (BBD) (N = 63) participated. Before chemotherapy started 
(Time 1) and three months after ending chemotherapy (and at comparable moments for 
the BBD group) (Time 2) women completed validated questionnaires concerning the 
frequency of complaints and satisfaction with SCF, fatigue, perceived stress, anxiety, and 
depressive symptoms.  
 
Results: No differences were found between the BBD and BC patients concerning the 
frequency of complaints about SCF across time. Satisfaction with SCF decreased across 
time in BC patients, but remained stable across time in BBD patients (p < .001; p = .003 
after controlling for state anxiety and perceived stress). Correlations coefficients between 
the satisfaction and the frequency of complaints about SCF ranged between -.26 to -.49. 
Depressive symptoms and satisfaction with SCF (Time 1) predicted the frequency of 
complaints about SCF (Time 2). Diagnosis, frequency of complaints about SCF and state 
anxiety (Time 1) predicted satisfaction with SCF (Time 2).  
 
Conclusions: BC patients do not differ in the frequency of complaints about SCF compared 
with BBD patients, but their satisfaction with SCF decreased after treatment. Psychological 
factors predicted the frequency of complaints about SCF. Psychological factors and 
diagnosis predicted satisfaction with SCF.  
 
Keywords: cancer, oncology, breast cancer, chemotherapy, subjective cognitive 
functioning, cognitive complaints 
  
  




Breast cancer (BC) is the most frequently diagnosed cancer in women in the developed 
countries. Because of early detection and the advancements in treatment, the prevalence 
of BC survivors has increased [1]. Although systemic treatment, such as chemotherapy, 
improves the clinical outcome of patients with BC, it is also known to have severe side-
effects such as complaints about cognitive functioning.  
When investigating cognitive functioning, we must make a distinction between 
objective cognitive functioning (OCF), as measured with standardized neuropsychological 
tests, and subjective cognitive functioning (SCF), as measured with self-report 
questionnaires. Problems with SCF refer to the amount of cognitive problems a person 
experiences in daily life and satisfaction with cognitive functioning [2]. Strong evidence is 
found for a lack of correlation between OCF and SCF in BC patients [2, 3]. Conflicting 
results were found regarding the differences in SCF between BC patients and healthy 
controls [e.g., 4-6] or BC patients with other treatment modalities (e.g., without 
chemotherapy) [e.g., 6-9]. Furthermore, different periods post-chemotherapy were used 
(i.e. ranging from six weeks until two years). Also, various measures have been used in 
assessing SCF in patients with breast problems. Because research regarding the influence 
of chemotherapy on SCF is scarce and methodologically heterogeneous, it is hard to draw 
conclusions [2].  
In order to identify patients at risk for the development of problems with SCF, it is 
crucial to examine the existence of sociodemographic, clinical, and psychosocial predictors 
of SCF. Some studies found that anxiety, depression, psychological distress, trait negative 
affectivity and fatigue predicted SCF [5, 10, 11]. With a better knowledge about the 
changes in SCF due to chemotherapy and about the predictors of SCF, we may be able to 
identify a subgroup of patients who are at risk of experiencing problems with SCF during 
clinical practice and, as a consequence, are at risk of a reduced quality of life (QoL) [12]. 
The first aim of this study was to evaluate SCF of BC patients both before and three 
months after ending chemotherapy in comparison with patients with a benign breast 
disease (BBD). Because of the heterogeneity in earlier research, both satisfaction and the 
frequency of complaints about SCF were evaluated. The second aim was to examine the 
relationship between the frequency of complaints with SCF and the satisfaction with SCF. 





Participants and procedure 
Women who were diagnosed with early stage BC and were about to receive 
chemotherapy between January 2009 and June 2011 in St. Elisabeth hospital (Tilburg), 
TweeSteden hospital (Tilburg), Maxima Medical Centre (Eindhoven, Veldhoven), Catharina 
hospital (Eindhoven), St. Anna hospital (Geldrop), Amphia hospital (Breda), and Jeroen 
Bosch hospital (Den Bosch) were eligible for this study. Women diagnosed with a BBD 
66 Chapter 4 
 
were also asked to participate. A cyst, mastopathy or a fibro-adenoma are the most 
common BBD diagnoses. Treatment of the BBD is not necessary for most women but 
some women are invited for a follow-up examination several months later. Furthermore, 
some women want their cyst or fibro-adenoma to be surgically removed.  
Women with proven BC recurrence or distant metastases were excluded. Other 
exclusion criteria were related to the assessment of OCF with neuropsychological tests 
(these results will be described elsewhere): a history of neuropsychological and/or 
psychiatric signs or symptoms that lead to deviant neuropsychological test results (e.g., 
dementia), the use of medication that may lead to deviant neuropsychological results, 
alcohol and/or drug addiction, and a poor expression in the Dutch language.  
BC patients were assessed after surgery, but prior to the start of the first cycle of 
chemotherapy (Time 1), and three months after ending chemotherapy (Time 2). BBD 
patients were assessed at equivalent time points. This study was approved by a central 
medical ethic committee and all local medical ethic committees. All participants provided 
written informed consent. 
 
Measures 
Clinical data were obtained from medical records. Sociodemographic data were obtained 
from a self-report questionnaire. Furthermore, the following questionnaires were 
completed, which took approximately 30 minutes:  
The Cognitive Failures Questionnaire (CFQ) [13], Dutch version [14] was used to 
assess self-reported frequency of complaints about SCF. This self-report inventory consists 
of 25-items. The rating scales range from 0 to 4. A high score indicates more often 
experienced cognitive failure. A reduced 16-item version of the CFQ was found to assess 
three factors in women with breast problems: Forgetfulness (e.g., forget why you went 
from one part of the house to the other, forget to buy items at shop), Absentmindedness 
(e.g., forget appointments, fail notice signposts), and Social recklessness (e.g., say 
something insulting, lose temper). The internal consistency, reliability, and validity are 
reported to be good [Pullens, De Vries, Bogaarts and Roukema, submitted for publication]. 
To make comparisons with other studies possible, we reported our results with both the 
original general factor (CFQ 25-items) and the newly developed 16-item version (CFQ-16 
items). The Cronbach’s alpha coefficients in the current sample are as follows: CFQ-25 
item = .88; CFQ-16 item = .83; Forgetfulness = .77; Absentmindedness = .74; Social 
recklessness = .55. 
The cognitive functioning facet of the World Health Organization Quality of Life 
assessment instrument-100 (WHOQOL-100), Dutch version [15], was used to assess the 
satisfaction with SCF. The WHOQOL-100 covers 24 facets, assessed by 96 questions, and 
one General Health and Overall QoL facet. QoL refers to the evaluation of function, e.g., 
satisfaction with aspects of life. The cognitive functioning facet measures satisfaction with 
SCF, for example with the following question: ‘how satisfied are you with your ability to 
learn new information?’ The rating scales range from 1 to 5. A high score on the cognitive 
functioning facet indicates satisfaction with SCF. The instrument is reliable and valid [16] 
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and the sensitivity of the instrument is high [17]. The Cronbach’s alpha in the present 
sample is 0.71 
The Center for Epidemiological Studies-Depression Scale (CES-D) [18], Dutch version 
[19], was used to measure the presence and degree of depressive symptoms. It consists of 
20 items. The rating scales range from 0 to 3. A higher score indicates more depressive 
symptoms. The CES-D is a valid and reliable measure of depressive symptoms in BC 
patients [20]. The Cronbach’s alpha in the present sample is .88. 
The Fatigue Assessment Scale (FAS) [21] was used to measure fatigue. It is a 10-item 
questionnaire that taps fatigue and exhaustion. The response scale is a 5-point scale (1-5). 
A higher score indicates more symptoms of fatigue. The psychometric properties have 
been studied in different patient populations, including BC patients, and the validity and 
reliability are reported to be good [22]. The Cronbach’s alpha in the present sample is .85. 
The State-Trait Anxiety-state Inventory (STAI) [23], Dutch version [24], was used to 
measure anxiety. The state scale asks persons how they feel at a particular moment in 
time, while the trait scale asks people to describe how they generally feel. In this study the 
shortened 6-item questionnaire for the STAI-state and the 10-item version of the STAI-
trait was used. The rating scales range from 1 to 4, a higher score indicates more 
symptoms of anxiety. The validity and reliability are well established and considered good 
[24-27]. The Cronbach’s alpha in the present sample is .90. 
The Perceived Stress Scale-10 (PSS-10) [28] was used as a global measure of 
perceived stress during the last month. It is the shortened version of the PSS-14 and 
consists of 10 items, rated on a four-point Likert-scale from 0 to 4. A higher score indicates 
more perceived stress. The validity and reliability of the PSS are good [30]. The Cronbach’s 
alpha in the present sample is .87. 
 
Statistical procedure 
Independent sample t-tests (continuous data) and χ
2
-tests (nominal data) were used to 
examine potential differences between the BC patients and the BBD patients.  
General linear model analyses for repeated measures were used to examine the 
frequency of complaints about SCF (total score, Forgetfulness, Absentmindedness, and 
Social recklessness) and the satisfaction with SCF across time. Subsequently, these 
analyses were repeated with variables on which patient groups were different from each 
other at baseline as covariates. Because of multiple testing, these analyses were corrected 
with the Bonferroni method (significant at p < .004).  
Normative samples were used to provide information on when complaints about the 
satisfaction of and the frequency of complaints about SCF are classified as impaired or not. 
From a large sample only women were selected and quota sampling was applied to ensure 
that different age groups were equally represented in the normative samples and the BC 
group. We defined SCF as impaired if the mean score of the BC group was 1 standard 
deviation below (satisfaction with SCF) or above (frequency of complaints about SCF) the 
mean score of the age and gender matched norm group.  
Pearson’s correlation coefficients between CFQ-25 items, CFQ-16 items, the CFQ 
subscales and the cognitive functioning facet of the WHOQOL-100 were calculated to 
68 Chapter 4 
 
examine the relationship between frequency of complaints about SCF and satisfaction 
with SCF. 
To determine predictors of SCF at Time 2, multivariate regression analyses were 
conducted. Before the final multivariate regression analyses were run, univariate linear 
regression analyses with sociodemographic, clinical, and psychological factors at Time 1 as 
independent variables were performed, aiming at minimizing the number of independent 
variables in the final multivariate regression analysis. The variables with a p < .10 were 
entered in the final multivariate regression analyses (method: backward). We have chosen 
for a p < .10 instead of p < .05 to reduce the risk of excluding a potentially relevant 
variable [29]. The variable diagnosis was forced in every multivariate regression analysis. 
Furthermore, because BC patients and BBD patients differed significantly on state anxiety 
and perceived stress at baseline, effect modifications and confounders were examined for 
these variables on each dependent variable. A confounder refers to the variable, which 
influences the found relationship. This can statistically be examined by comparing the beta 
from the linear regression analysis with and without the variable as a covariate. A 
difference in the beta value of 10% or more indicates a confounding effect of the 
variable/covariate [29]. An effect modification is present when different effects are found 
for different values of a variable, for instance, the found effect is different for patients 
with or without BC. This can be examined by including the interaction effect in the 
regression analysis and assessing this p-value [29]. All analyses were performed with the 






Of the 213 patients who consented to participate after a phone conversation with the 
researcher, 23 of them eventually refused to participate because of ‘lack of interest’ 
(N = 5), ‘lack of time’ (N = 4), ‘experiencing the study as too burdensome’ (N = 3), ‘not 
showing up during appointment’ (N = 5), ‘experiencing the study subject as too 
confronting’(N = 3), ‘sickness (personal/a family member)’ (N = 2), or ‘a personal 
relationship with the researcher’ (N = 1). At baseline, 190 women completed the 
assessments. At the moment of analysis, 137 women completed Time 1 and Time 2; 74 
patients with BC and 63 patients with a BBD. 
The baseline psychological factors showed a significantly higher score on state 
anxiety for the BC group (p < .001) and perceived stress (p = .049). No additional 
significant differences were found concerning sociodemographic factors and the 
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Table 1: Sociodemographic, clinical, and psychological characteristics  
 
Characteristics BC group 
(N = 74) 
BBD group 
(N = 63) 
p-value 
Sociodemographics    
Age 51.1 ± 9.9 47.8 ± 10.3 .056 
Living with partner  59 (79.7) 52 (82.5) .642 
Children  54 (73.0) 54 (85.7) .206 



















Salaried work/retirement  53 (71.3) 53 (84.1) .609 
Psychologist/psychiatric counseling in past 18 (24.3) 14 (22.2) .638 
Clinical characteristics    
Comorbidity
b 
28 (37.8) 28 (44.4) .325 
Type of surgery  






Chemotherapy 74 (100)   
Radiotherapy 40 (54.8)   
Hormone therapy 50 (67.6)   
Tumor size    
 <1 cm 
 1-3 cm 

















Axillary lymph node dissection 41 (55.4)   
Psychological characteristics (baseline)    
Trait anxiety 17.7 ± 5.5 16.7 ± 4.7  .269 
State anxiety 12.1 ± 3.5 9.7 ± 3.5 < .001* 
Depressive symptoms 10.4 ± 8.3 8.4 ± 8.0  .149 
Fatigue 18.8 ± 5.7 20.0 ± 5.2  .208 
Perceived stress 21.3 ± 5.5 19.6 ± 4.6 .049* 
Mean ± standard deviation are presented for age and psychological factors, percentages are between 
brackets; for the calculation of the percentage missings are not included  
BBD = Benign breast disease; BC = Breast cancer 
a 
L = low education (primary school, lower vocational education); M = middle education (lower general 
secondary education, intermediate vocational education); H = high education (higher general secondary 
education, pre-university education, higher vocational education, university) 
b 
Comorbidity consists of heart disease and/or lung disease and/or diabetics and/or neuromuscular 
disease and/or orthopedic disease 
c 
Tumor grade following the Bloom and Richardson grading system for breast cancer 
* p < .05 
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Frequency of complaints about subjective cognitive functioning 
An effect for time was found on the CFQ-25 items, CFQ-16 items, Forgetfulness and 
Absentmindedness subscale, indicating that the frequency of complaints about SCF 
increased across time. After controlling for state anxiety and perceived stress, these 
effects for time did not remain significant. With regard to the subscale Social recklessness, 
no significant effects were found. After controlling for state anxiety and perceived stress 
at Time 1, the results remained the same (Table 2). The mean scores of the BC group on 
the measures of the frequency of complaints were not more than 1 standard deviation 
above the mean scores of the norm group, thus the patients were not classified with an 
impairment on the frequency of complaints about SCF.  
 
Satisfaction with subjective cognitive functioning 
An interaction effect was found, indicating that BC patients were less satisfied with their 
SCF after treatment compared to their satisfaction before the start of the chemotherapy 
(Table 2 and Figure 1). Satisfaction with SCF in BBD patients did not change across time. 
After controlling for state anxiety and perceived stress at Time 1, we found that the 
interaction effect remained significant (Table 2). The mean scores of the BC group were 
not classified as ‘impaired satisfaction with SCF’. 
 
Relationship between frequency of complaints about subjective cognitive functioning 
and satisfaction with subjective cognitive functioning  
Pearson’s correlation coefficients between satisfaction with SCF and frequency of 
complaints about SCF were calculated: satisfaction with SCF correlated significantly with 
the frequency of complaints about SCF (CFQ 25-items: r = -.49; CFQ 16-items: r = -.47), 
Forgetfulness (r = -.45), Absentmindedness (r = -.38) and Social recklessness (r = -.26). 
 
Predictors of subjective cognitive functioning 
Univariate linear regression analyses revealed that all psychological factors at Time 1 (trait 
and state anxiety, depressive symptoms, fatigue and perceived stress) predicted the 
frequency of complaints and satisfaction with SCF. Frequency of complaints about SCF was 
predicted by satisfaction with SCF and vice versa. These factors, combined with different 
sociodemographic and clinical variables were included in all final multivariate regression 
analyses.  
Frequency of complaints about SCF (CFQ-25 items, CFQ-16 items) and the subscales 
Forgetfulness and Absentmindedness were predicted by satisfaction with SCF at Time 1 
and depressive symptoms at Time 1, explaining 15.9 to 19.8% of the variance. The CFQ 
subscale Social recklessness was predicted by satisfaction with SCF at Time 1, depressive 
symptoms at Time 1 and age, explaining 16.9% of the variance (Table 3).  
With regard to satisfaction with SCF, three multivariate linear regression analyses 
were carried out, one with the CFQ-25 items included as possible predictor, one with the 
CFQ-16 items included as possible predictor and one with the CFQ subscales included as 
possible predictors. See Table 3 for significant predictors and beta weights. 
 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Effect of chemotherapy on satisfaction with subjective cognitive functioning (SCF).  
Graph shows the significant interaction effect of time-by-treatment for breast cancer (BC) group. 





The aim of this prospective study was to assess the effect of chemotherapy on frequency 
and satisfaction with SCF in BC patients compared with women with a BBD and to identify 
predictors of SCF. This distinction between the two aspects of the definition of SCF 
(frequency and satisfaction) delivered the interesting finding that even when BC patients 
and BBD patients report the same frequency of complaints about SCF, satisfaction with 
SCF decreased across time in BC patients and not in patients with a BBD. This decrease in 
the satisfaction with SCF in BC patients is also clinically significant: Den Oudsten, Zijlsta 
and De Vries [submitted for publication] estimated the minimal clinical important 
difference for BC patients on the WHOQOL-100 to be 1. The mean decrease in satisfaction 
with SCF was 1.4 for the BC patients in our sample. However, we did find that the mean 
scores on the satisfaction with SCF stay between the normal range of scores on 
satisfaction with SCF (on the basis of the norm group).  
The discrepancy between the magnitude of the problem (frequency of SCF) and the 
satisfaction is also seen in other constructs. Concerning social relations, for example, it is 
known that the size of a person’s social network does not represent the satisfaction of 
that person with his/her social network [30]. A possible explanation of our finding of a 
decreased satisfaction with SCF in BC patients is that when BC patients for example 
experience problems with focusing on a text, they can feel extremely bothered by this 
disability due to the psychological distress they experience during and after the BC 
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treatment. Another explanation is the growing public awareness of the relationship 
between cancer treatment and cognition [31]. 
Schilder et al. also found different patterns for SCF measured with an interview and 
with the CFQ-25 items in BC patients, but a limitation of this study is that the used 
interview was non-validated and that the response-scale of this interview was 
dichotomous (e.g., Do you have complaints with regard to memory? (yes/no)) [32]. This 
made it impossible to observe a change in gradation of these complaints over time. In the 
current study satisfaction with SCF is measured with a validated questionnaire and, 
because of the Likert-scale that has been used, is able to observe change over time within 
a patient. 
Moderate correlations were found between the satisfaction with SCF and the 
frequency of complaints about SCF and the subscales Forgetfulness and 
Absentmindedness. This indicates that some overlap not only exists between the two 
constructs, but also confirms that our approach to SCF (measuring different aspects) is 
valid. 
An association between depressive symptoms and cognitive complaints has often 
been reported in cancer patients [5, 8, 33]. We found that the frequency of complaints 
about SCF and its subscales at Time 2 were predicted by satisfaction with SCF and 
depressive symptoms at Time 1. Social recklessness was also predicted by age. Satisfaction 
with SCF was predicted by diagnosis, frequency of complaints about SCF (and the subscale 
Absentmindedness) and state anxiety at Time 1. In one of the regression analyses 
psychologist/psychiatrist counseling in the past also was a significant predictor of 
satisfaction with SCF. To our knowledge, this is the first study that examined this 
relationship. Hermelink et al. found depressive symptoms, together with trait negative 
affectivity, and chemotherapy as consistent predictors of global problems with SCF as well 
as specified attention problems experienced in daily life [3]. Other studies found state or 
trait anxiety as predictors of SCF [33]. Breckenridge et al. found that depressive 
symptoms, anxiety and fatigue were positively associated with greater perceived cognitive 
dysfunction [34]. Furthermore, they support our finding that variables concerning 
demographics and medical/treatment history were not statistically significant for the 
frequency of SCF. Thus, psychological factors appear to be determinants of SCF. In 
addition, diagnosis is an important determinant for the satisfaction with SCF, which is 
reasonable because we found that BC patients, but not the patients with a BBD, decreased 
in their satisfaction with SCF over time.  
The strength of this study is that the frequency of complaints about SCF as well as 
the satisfaction with SCF is measured with validated questionnaires in patients with breast 
problems. Our results prove that it is important to make this distinction between the two 
aspects. Also, contrary to the earlier research [4, 5, 32, 35-37], the version of the CFQ used 
in the current study is validated in a sample of patients with breast problems. Other 
strengths are the inclusion of the control group and the longitudinal design with a baseline 
measurement before the start of chemotherapy. A limitation of this study is the problem 
with the power to run separate regression analyses for BC patients and BBD patients to 
identify predictors of SCF. However, by forcing diagnosis in the multivariate regression 
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analyses, we examined the predictive value of the diagnosis. A significant effect of 
diagnosis was found concerning only satisfaction with SCF.  
In conclusion, BC patients do not differ in the frequency of complaints about SCF 
compared with BBD patients, but their satisfaction with SCF decreased after 
chemotherapy. Psychological factors predicted frequency of complaints about SCF. 
Psychological factors and diagnosis predicted satisfaction with SCF. These findings stress 
the importance for health care professionals to pay attention to the psychological aspects 
of the patient. The findings of this study can facilitate health care professionals to identify 
and support women with breast problems who are at risk for developing a lower 
satisfaction with SCF.   
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Background: Results of existing studies are inconclusive about objective cognitive 
functioning (OCF) in breast cancer (BC) patients who are treated with adjuvant 
chemotherapy. The aims of this study were (i) to evaluate OCF in BC patients, (ii) to 
examine the effect of anesthesia on OCF, and (iii) to examine the relationship between 
OCF and subjective cognitive functioning (SCF).  
 
Methods: BC patients who were scheduled to receive adjuvant chemotherapy (N = 58) 
and a control group of women with a benign breast disease (BBD) (N = 63) participated in 
the study. Before chemotherapy started and three months after ending chemotherapy 
(and at comparable moments for the BBD group) women completed validated 
questionnaires and a neuropsychological test battery. BC patients with neo-adjuvant 
chemotherapy (N = 13) participated only before the start of chemotherapy.  
 
Results: BC patients showed an impaired course in the domains of verbal memory 
(p = .015) and executive functioning (p = .042), compared to BBD patients. With exception 
from the verbal fluency in professions (p = .049), no differences between the BC patients 
and BBD patients in the percentage of patients who experienced a decrease or an 
improvement on any neuropsychological measure were found. No specific effect of 
anesthesia on cognitive functioning was found. Some small to moderate correlations were 
found between OCF and specific domains of SCF.   
 
Conclusions: Chemotherapy negatively influenced verbal memory and executive 
functioning in patients with BC. A baseline assessment after surgery seems accurate given 
that no effect of anesthesia on cognitive functioning was found.   
 
Keywords: cancer, oncology, breast cancer, chemotherapy, objective cognitive 








The relationship between systemic cancer treatment and objective cognitive functioning 
(OCF) has gained increasing interest and was initially studied by cross sectional designs. 
Since 2004, a number of longitudinal studies were conducted to further unravel this 
relationship [1]. Whether chemotherapy influences OCF is still inconclusive and prevalence 
rates vary strongly. These inconclusive results may be due to inconsistencies in study 
designs as well as methods of analysis. Some studies did not include a control group (e.g., 
[2-4]). However, in studies in which a control group was included, groups varied from 
healthy controls (e.g., [5, 6]), to cardiac patients [6], or BC patients treated with hormone 
therapy or radiotherapy (e.g., [7-9]). Although all studies used neuropsychological tests to 
measure OCF, there is a large variation in the neuropsychological tests employed and in 
the definitions used to determine cognitive impairment. Furthermore, timing of cognitive 
assessments varied between follow-up moments during chemotherapy (e.g., [4]) to 
measurements one or two years later (e.g., [2, 8, 9, 10, 11]).  
In sum, there is a need for longitudinal studies with baseline measurements and 
appropriate control groups. The timing of the baseline measurement often is not 
standardized in studies designed to analyze OCF in BC patients treated with additional 
chemotherapy. The first measurement moment of most longitudinal studies in which the 
effect of adjuvant chemotherapy on OCF is examined takes place before chemotherapy, 
but after surgical treatment under general anesthesia. It should be recognized that 
general anesthesia can affect cognitive functioning, also known as postoperative cognitive 
dysfunction (POCD) [12]. 
The aims of the study were (i) to examine OCF before and three months after 
adjuvant chemotherapy in comparison with patients with a benign breast disease (BBD). 
Besides analyses on group level, changes at the individual level were examined too; (ii) to 
preliminary assess the influence of POCD on OCF in BC patients (for that purpose a group 
of BC patients receiving neo-adjuvant chemotherapy, i.e., before surgery, was included in 
this study); (iii) to explore the relationship between OCF (measured with 
neuropsychological tests) and subjective cognitive functioning (SCF) (measured with self-





Participants and procedure 
Women who were diagnosed with BC and received chemotherapy between January 2009 
and August 2011 were eligible for this prospective study. The control group consisted of 
women diagnosed with a BBD. A cyst, mastopathy or a fibro-adenoma are the most 
common BBD diagnoses. To examine the effect of POCD on OCF, a group of patients with 
BC receiving neo-adjuvant chemotherapy was included. Exclusion criteria were defined as: 
proven loco regional recurrence, distant metastases, a history of neuropsychological 
and/or psychiatric signs or symptoms that lead to deviant neuropsychological test results 
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(e.g., dementia), use of medication that may influence neuropsychological results, alcohol 
and/or drug addiction, and a poor expression in the Dutch language. Patients were 
recruited by their physician (assistant).   
BC patients were assessed prior to initiation of adjuvant chemotherapy (Time 1) and 
three months following the last cycle of chemotherapy (Time 2). Patients with a BBD were 
assessed at comparable time points (see Figure 1). BC patients receiving neo-adjuvant 
chemotherapy were only assessed at Time 1. All participants provided written, informed 
consent. This study was approved by the central medical ethic committee of the St. 











Figure 1: Timeline of the study 
BC = Breast cancer; BBD = Benign breast disease 
 
Measurements 
Clinical data were obtained from medical records and sociodemographic data were 
obtained from a self-report questionnaire. 
 
Assessment of neuropsychological performance  
A comprehensive test battery, which took approximately 1.5 hours to complete, was 
designed to assess a broad range of cognitive domains. All tests are widely used in clinical 
neuropsychological practice and the psychometric properties are well described. 
Furthermore, the selection of tests was based on previous neuropsychological studies with 
cancer patients, to enable comparisons of results (e.g., [13, 14]). In addition, the Dutch 
Adult Reading test provides information on verbal premorbid intelligence [15]. The 
assessments were conducted either at home or in the hospital. 
Attention/processing speed: The Stroop test (card A and B) [16, 17], the Trailmaking 
test (TMT) A [18], the D2 test [19], the Digit span (forward and backward) and Digit symbol 
subtest of the Wechsler Adult Intelligence Scale (WAIS) [20], the Fepsy visual reaction test 
(dominant and non-dominant) and visual searching test [21] were used.   
Verbal memory: The Rey auditory verbal learning test (RAVLT) (total recall, delayed 
recall and recognition) [22, 23] was used.  
Visual memory: The visual reproduction subtest of the Wechsler Memory Scale, 
revised [24] and the Complex figure test (CFT) [25, 26] were used.  
Visuospatial functioning: The copy score of the CFT [25, 26] was performed.  
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Verbal fluency: The Word fluency test (animals and professions) [27] was performed.   
Executive functioning: The zoo map test of the Behavioral Assessment of 
Dysexecutive Syndrome (BADS) (map 1 and map 2) [28], the TMT B [18], the Fepsy binary 
choice test [21], the Stroop test (card C) [16, 17] were used.  
Motor functioning: The Fepsy finger-tapping task (dominant and non-dominant) [21] 
was used.  
 
Questionnaires 
Frequency of complaints about subjective cognitive functioning (SCF) was measured with a 
reduced 16-item version of the Cognitive Failures Questionnaire (CFQ) [29]. Three factors 
were assessed: Forgetfulness, Absentmindedness, and Social Recklessness (Pullens, De 
Vries, Bogaarts and Roukema, submitted for publication). Satisfaction with SCF was 
measured with the cognitive functioning facet of the World Health Organization Quality of 
Life assessment instrument-100 (WHOQOL-100) [30]. The Center for Epidemiological 
Studies-Depression Scale (CES-D) [31] was used to measure depressive symptoms. Fatigue 
was measured with the Fatigue Assessment Scale (FAS) [32]. The State-Trait Anxiety 
Inventory (STAI) [33] was used to measure anxiety. In this study the validated shortened 6-
item questionnaire for the STAI-state and the 10-item version for the STAI-trait was used 
[34, 35]. Perceived stress was measured with the Perceived Stress Scale-10 (PSS-10) [36]. 
 
Statistical analyses 
Independent sample t-tests (continuous data) and χ
2
-tests (nominal data) were used to 
examine potential differences between the BC patients and the BBD patients at Time 1. 
Furthermore, Mann-Whitney U tests and Fisher exact tests were used to examine 
differences between (1) participants at Time 1 and Time 2 and participants who dropped 
out of the study, and (2) BC patients receiving adjuvant chemotherapy and neo-adjuvant 
chemotherapy at Time 1. Fisher exact tests were used to examine differences between 
patients who decrease and increase on neuropsychological measures. 
For analyses on group level, general linear model analyses for repeated measures 
with age, educational level, perceived stress, state anxiety and fatigue as covariates were 
used to investigate the course of OCF (with computed cognitive domain scores) across the 
two assessment points and the differences between the BC and the BBD patients. The 
cognitive domain scores were computed by first transforming the raw neuropsychological 
measures to standardized scores (using the BBD patients as reference group) and then 
computing a mean standardized score for each domain by summing up the standardized 
scores from the neuropsychological measures, which represent the cognitive domain, and 
divide this by the number of measures for each cognitive domain. If a significant effect 
was found for the cognitive domain, subsequently multivariate general linear model 
analyses for repeated measures were done with the raw neuropsychological measures 
which represent this cognitive domain. 
To identify individuals who have shown a significant change in performance across 
time, a modified version of the Reliable Change Index (RCI) [37] with correction for 
practice effects was used. The RCI method was defined as ((X2−X1) − (Mbbd2 –
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Mbbd1))/SDDbbd, where X1 was the observed score at Time 1, X2 was the observed score 
at Time 2, SDDbbd was the standard deviation of test–retest difference of BBD patients, 
Mbbd1 was the mean score at Time 1 of BBD patients, and M2 was the mean score at 
Time 2 of BBD patients (based on [38]). This approach was applied to each 
neuropsychological test. Reliable improvement occurred when values exceeded 1.96 and 
reliable decrease when values fell below −1.96. Scores were recoded so that a lower score 
at Time 2 indicated a decrease (e.g., the Stroop test indicated a decrease instead of an 
increase when scores are higher at Time 2). Performance across variables was summed 
and patients were classified according to the number of tests on which they significantly 
decreased (no decrease, decrease on one test, two tests, ≥ three tests). 
Pearson correlation coefficients were calculated between the neuropsychological 
assessments and the measures of SCF (satisfaction and frequency). All analyses were 
performed with the Statistical Package for Social Sciences (SPSS version 18). For all tests, a 






Of the 213 patients who initially consented to participate by a telephone call from the 
researcher (MP), 23 of them eventually did not participate because of ‘lack of interest’ 
(N = 5), ‘lack of time’ (N = 4), ‘study to burdensome’ (N = 3), ‘did not show up during 
appointment’ (N = 5), ‘study subject to confronting’ (N = 3), ‘sickness (personal/a family 
member)’ (N = 2), or ‘personal relationship with the researcher’ (N = 1). At baseline 
(Time 1), 190 women completed the assessments. At Time 2, seven patients refused to 
participate because they had lost interest in the study. Furthermore, two patients were 
excluded because of disease recurrence within three months after the last cycle of 
chemotherapy (Time 2). Due to the fact that the study was very burdensome and because 
the main focus of this project is a longer follow-up, we decided not to examine all the 
patients at Time 2 in order to reduce the number of patients who drop out of the study. 
The omission of the neuropsychological assessment at Time 2 happened chronologically. A 
total of 121 women completed both first and second neuropsychological assessment; 58 
patients with BC and 63 patients with a BBD. 
Concerning the sociodemographic factors, the BC patients were significantly older 
compared to the BBD patients (see Table 1). The baseline psychological factors showed a 
significantly higher score on state anxiety and perceived stress for the BC group. 
Furthermore, patients with a BBD scored higher on fatigue. No additional significant 
differences were found concerning the remaining psychological factors (see Table 1). 
Out of the seven patients who dropped out the study, six had a BBD diagnosis. The 
drop outs had a significantly lower educational level compared with women who 
remained in the study (p = .002). There were no significant differences concerning other 
sociodemographic factors, psychological factors or neuropsychological measures. 
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Table 1: Sociodemographic, clinical, and psychological characteristics of the participants  
 
Characteristics BC group 
(N = 58) 
BBD group 
(N = 63) 
P-value 
Sociodemographics  
Age 51.7 ± 9.9 47.6 ± 10.0   .024* 
Living with partner (%) 44 (84.6) 51 (81.0) .788 
Children (%) 39 (73.6) 55 (87.3) .101 

















Verbal intelligent quotient 80.3 ± 12.6 16 (25.4) .104 
Paid work/retirement 38 (77.6) 21 (33.3) .675 
Psychologist/psychiatric counseling in past 12 (23.1) 76.0 ± 15.7 .926 
Clinical characteristics  
Comorbidity
b
 18 (32.1) 22 (36.1) .801 
Type of surgery  






Chemotherapy 58 (100)   
Radiotherapy 26 (50.0)   
Tumor size    
 1 cm 
 1-3 cm 
















Axillary lymph node dissection 38 (31.4)   
Psychological characteristics    
CFQ-16 items 19.6 ± 6.2 20.9 ± 6.5 .283 
CFQ Forgetfulness 12.5 ± 4.3 13.2 ± 4.5 .443 
CFQ Absentmindedness 3.5 ± 2.0 3.9 ± 2.4 .402 
CFQ Social recklessness 3.6 ± 1.6 3.9 ± 1.5 .297 
Satisfaction with SCF 14.7 ± 2.1 14.6 ± 2.3 .897 
Depressive symptoms 10.2 ± 8.3 8.7 ± 8.2 .350 
Fatigue 18.3 ± 5.3 20.3 ± 5.6   .047* 
Trait anxiety 18.3 ± 5.5 16.7 ± 5.0 .091 
State anxiety 12.2 ± 3.3 9.8 ± 3.5 < .001* 
Stress 21.8 ± 5.5 20.0 ± 4.7   .050* 
BBD = Benign breast disease; BC = Breast cancer; CFQ = Cognitive Failures Questionnaire; SCF = Subjective 
cognitive functioning 
Mean ± standard deviation are presented for age and psychological factors, percentages are between 
brackets; for the calculation of the percentage missings are not included 
a
 L = low education (primary school, lower vocational education); M = middle education (lower general 
secondary education, intermediate vocational education); H = high education (higher general secondary 
education, pre-university education, higher vocational education, university) 
b
 Comorbidity consists of heart disease and/or lung disease and/or diabetics and/or neuromuscular 
disease and/or orthopedic disease 
c
 Tumor grade following the Bloom and Richardson grading system for breast cancer 
* p < .05 
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Group analyses 
Neuropsychological test scores (means and standard deviations) at Time 1 and Time 2 are 
shown in Table 2. After controlling for age, educational level, perceived stress, state 
anxiety and fatigue at Time 1, three significant effects were found concerning the 
neuropsychological domains. Both BC patients and BBD patients significantly decreased on 
the visuospatial functioning (p = .037). Furthermore, significant interaction effects in 
verbal memory (p = .015) and in executive functioning (p = .042) were found. In both 
domains BC patients showed a decrease over time while the BBD patients showed a small 
increase over time. 
Evaluating the neuropsychological tests of these significant cognitive domains 
separately revealed significant interaction effects on the RAVLT recall and recognition 
measure (p = .041 and p = .038, respectively). Both BC patients and BBD patients increased 
in the RAVLT recall measure over time, but the BBD patients showed a higher increase 
compared to the BC patients. On the RAVLT recognition measure, BC patients showed a 
small decrease over time, in contrast to the BBD patients, who showed a small increase on 
the RAVLT recognition measure over time. No significant effects were found on the 
neuropsychological tests which were combined for the cognitive domain of executive 
functioning.  
 
Individual change analyses 
Changes on the individual level are shown in proportions of patients with reliable change 
(decrease or increase) on every neuropsychological measure in Table 3. With the 
exception of verbal fluency in professions (p = .049), analyses revealed no differences 
between the BC patients and BBD patients in the percentage of patients who experienced 
a decrease or an improvement on any neuropsychological measure. Figure 2 shows the 
percentage of patients who experienced a decrease or an improvement on one, two, or 
three or more neuropsychological measures stratified by BC patients and BBD patients. 
There were no significant differences in sociodemographic and psychological factors 
between patients who showed a decrease on three or more neuropsychological measures 
and patients with no decrease, or a decrease on one or two neuropsychological measures. 
 
Influence of POCD 
Comparisons between BC patients with adjuvant chemotherapy (after surgery) and neo-
adjuvant chemotherapy (N = 13) at Time 1 (baseline) revealed no significant differences 
concerning sociodemographic factors, psychological factors and neuropsychological 
measures.  
 
Correlations between OCF and SCF 
Baseline mean and standard deviation of the subjective measures of cognitive functioning 
are shown in Table 1. Pearson correlations between these subjective measures and all the 
neuropsychological measures in BC patients at Time 1 revealed six small to moderate 
significant correlations. The Rey recall (r = .27), Stroop card C (r = -.33), TMT B (r = -.30), D2 
test (r = .42) and Fepsy tapping dominant (r = .30) correlated with the factor Social 
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Recklessness from the CFQ. The professions subtest of the verbal fluency test correlated 
with the satisfaction with SCF (r = .35). 
 








 Time 1 Time 2 Time 1 Time 2 
Attention/processing speed  
Stroop card A
a
 43.4 ± 7.9 45.1 ± 9.2 43.1 ± 7.7 44.3 ± 8.4 
Stroop card B
a
 54.7 ± 8.7 56.1 ± 9.4 55.2 ± 11.6 54.5 ± 10.4 
TMT A
a
 36.6 ± 12.2 35.9 ± 13.0 34.9 ± 14.1 35.6 ± 17.3 
D2 408.8 ± 82.0 414.5 ± 80.7 411.3 ± 110.5 430.4 ± 90.4 
WAIS digit span 15.6 ± 3.7 16.1 ± 3.8 15.1 ± 3.8 15.4 ± 3.8 
WAIS symbol search 74.3 ± 13.3 74.2 ± 16.0 74.2 ± 18.6 75.0 ± 20.3 
Fepsy visual reaction dominant hand
a
 308.2 ± 53.0 306.8 ± 52.3 292.1 ± 39.0 299.3 ± 36.3 




308.2 ± 53.0 314.5 ± 80.4 302.0 ± 45.1 312.8 ± 44.8 
Fepsy visual searching
a
 11.6 ± 3.4 11.8 ± 3.6 11.1 ± 3.3 11.2 ± 3.4 
Verbal memory  
RAVLT total recall 48.6 ± 9.4 50.7 ± 8.3 45.7 ± 8.8 50.4 ± 9.4 
RAVLT delayed recall 10.2 ± 2.8 10.5 ± 2.5 9.6 ± 2.6 10.8 ± 2.6 
RAVLT recognition 29.2 ± 1.2 29.1 ± 1.01 28.9 ± 1.5 29.3 ± 1.2 
Visual memory  
WMS 83.7 ± 12.8 83.4 ± 11.5 83.4 ± 13.7 87.2 ± 11.2 
CFT delayed recall 17.9 ± 6.0 20.4 ± 5.9 17.1 ± 5.9 19.2 ± 6.6 
Visuospatial functioning  
CFT copy 31.7 ± 4.8 31.5 ± 3.4 32.0 ± 2.3 31.4 ± 2.7 
Verbal fluency  
Verbal Fluency animals 26.3 ± 5.6 26.7 ± 5.7 26.9 ± 6.2 25.8 ± 6.4 
Verbal Fluency professions 19.4 ± 4.9 18.8 ± 4.8 17.9 ± 5.4 18.9 ± 5.7 
Executive functioning  
BADS zoo map 1 5.0 ± 3.1 4.6 ± 3.7 3.8 ± 3.6 4.2 ± 3.5 
BADS zoo map 2 7.8 ± 0.7 7.3 ± 2.5 7.7 ± 0.9 7.9 ± 0.3 
TMT B
a
 77.8 ± 28.8 74.6 ± 34.5 77.6 ± 35.5 70.8 ± 36.4 
Fepsy binairy choice
a
 433.1 ± 63.9 445.2 ± 68.9 422.4 ± 62.4 424.2 ± 60.3 
Stroop card C
a
 89.1 ± 19.0 86.4 ± 19.8 85.2 ± 22.9 81.3 ± 20.0 
Motor functioning  
Fepsy finger tapping dominant hand 62.1 ± 7.5 61.6 ± 8.2 62.9 ± 8.4 61.5 ± 9.2 
Fepsy finger tapping non-dominant 
hand 
56.8 ± 7.4 56.1 ± 8.2 58.9 ± 7.8 57.6 ± 8.7 
BADS = Behavioral Assessment of Dysexecutive Syndrome; CFT = Complex Figure Test; RAVLT = Rey 
Auditory Verbal Learning Test; TMT = Trailmaking Test; WAIS = Wechsler Adult Intelligence Scale; WMS = 
Wechsler Memory Scale 
a
 A higher score on this test indicates a poorer performance at this test 
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 Decrease Increase Stable Decrease Increase Stable 
Attention/processing speed       
Stroop card A 5.2 1.7 93.1 4.8 1.6 93.7 
Stroop card B 5.2 0.0 94.8 3.2 0.0 96.8 
TMT A 0.0 0.0 100.0 1.6 0.0 98.4 
D2 1.7 0.0 98.3 1.6 3.2 95.2 
WAIS digit span 1.7 8.6 89.7 3.2 4.8 92.1 
WAIS symbol search 3.4 0.0 96.6 1.6 1.6 96.8 




3.4 12.1 84.5 4.8 1.6 93.7 
Fepsy visual reaction non-
dominant hand 
5.2 3.4 91.4 6.3 3.2 90.5 
Fepsy visual searching 5.2 5.2 89.7 3.2 1.6 95.2 
Verbal memory       
RAVLT total recall 3.4 5.2 91.4 0.0 4.8 95.2 
RAVLT delayed recall 3.4 0.0 96.6 3.2 7.9 88.0 
RAVLT recognition 1.7 3.4 94.8 1.6 3.2 95.2 
Visual memory       
WMS 0.0 1.9 98.3 3.2 4.8 92.1 
CFT delayed recall 1.7 3.4 94.8 1.6 1.6 96.8 
Visuospatial functioning       
CFT copy 1.7 5.2 93.1 4.8 0.0 95.2 
Verbal fluency       
Verbal Fluency animals 3.4 6.9 89.7 1.6 1.6 96.8 
Verbal Fluency professions 5.2 0.0 94.8 0.0 4.8 95.2 
Executive functioning       
BADS zoo map 1 1.7 0.0 98.3 1.6 1.6 96.8 
BADS zoo map 2 6.9 1.7 91.4 1.6 7.9 90.5 
TMT B 3.4 1.7 94.8 1.6 3.2 95.2 
Fepsy binairy choice 6.9 1.7 91.4 4.8 1.6 93.7 
Stroop card C 1.7 3.4 94.8 3.2 4.8 92.1 
Motor functioning       
Fepsy finger tapping dominant 
hand 
1.7 5.2 93.1 3.2 1.6 95.2 
Fepsy finger tapping non-
dominant hand 
5.2 3.4 91.4 1.6 3.2 95.2 
BADS = Behavioral Assessment of Dysexecutive Syndrome; CFT = Complex Figure Test; RAVLT = Rey 
Auditory Verbal Learning Test; TMT = Trailmaking Test; WAIS = Wechsler Adult Intelligence Scale; WMS = 
Wechsler Memory Scale  
 
 





















Figure 2: Plot of results Reliable Change Index 





The first aim of this prospective study was to examine the effect of chemotherapy on OCF 
in BC patients compared to patients with a BBD. BC patients showed an impaired verbal 
memory across time. Quesnel, Savard and Ivers also found a specific negative effect of 
chemotherapy on verbal memory in BC patients three months after chemotherapy, 
compared to BC patients who received radiotherapy [39]. In addition, Bender et al. found 
verbal (working) memory as an affected domain [10]. However, another study did not find 
effects of treatment on word fluency and memory [40]. We found mixed results 
concerning executive functioning: separate neuropsychological measures revealed no 
significant differences, but the created domain score of executive functioning showed a 
significant interaction effect. Results from the study by Jansen et al. are contrasting with 
our results concerning executive functioning [4]. They found an improvement in executive 
functioning over time. Besides the affected domains found in our study, earlier studies 
reported other affected domains as well, such as working memory [8], visual memory [8], 
visuospatial functioning [4], processing speed [11, 41], and attention [11]. Studies 
reporting normal cognitive functioning also exist (e.g., [6, 7, 42, 43]). 
Cross-sectional and longitudinal studies have found evidence for cognitive changes 
due to chemotherapy in a subgroup of BC patients (e.g., [3, 9]). We only found a 
difference on the test verbal fluency in professions between the BC patients and BBD 
patients in the percentage of patients who experienced a decrease or an improvement on 
any neuropsychological measure. The difference in verbal fluency is found in some earlier 
research as well [39, 41, 44] and is in accordance with the clinical practice in which BC 
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patients often complain of having problems with finding the correct words after they 
received chemotherapy. Furthermore, we did not find differences in descriptive 
characteristics between increasers and decreasers on neuropsychological measures.  
Earlier prospective studies found cognitive impairments in BC patients at the baseline 
measurement (after diagnosis before the start of the adjuvant treatment) (e.g., [11, 45]). 
Therefore it would be interesting to have a baseline measurement before the diagnosis of 
BC is known. However, this is logistically impossible in clinical practice. Therefore, a 
baseline measurement after the diagnosis is known is unavoidable. However, nowadays 
the baseline measurement often takes place after surgery for BC. This study showed no 
specific effect of anesthesia on cognitive functioning. BC patients with neo-adjuvant 
chemotherapy did not significantly differ on the neuropsychological measures from the BC 
patients with adjuvant chemotherapy at Time 1. It is important to notice that our results 
are preliminary and should be further examined in larger samples of BC patients.  
We did not find correlations between OCF and the global measure of the frequency 
of problems with SCF (measured with the CFQ), but we did find some small to moderate 
correlations between OCF and the specific domain Social recklessness from the CFQ. 
Furthermore, a moderate relationship between the satisfaction with SCF and the verbal 
fluency in professions was found. Independent from the frequency of this complaint, it 
can disturb patients during daily life if they have word finding problems. Results from 
earlier research suggest a lack of a relationship between OCF and SCF, but SCF was mostly 
measured with the global measure in previous studies. The lack of high correlations 
between OCF and SCF raises the question if the neuropsychological measures are 
ecologically valid [10, 13, 46]. Because participation is burdensome, it is of great 
importance to get a better idea of which neuropsychological test actually measure the 
clinically important changes in OCF in BC patients. Future research should focus on specific 
domains of SCF when examining the relationship with OCF.  
In the current study patients were tested in the hospital or at home to improve the 
inclusion rate and to lower the number of drop outs. Although this study approach 
corresponds with most other studies in this field, it could be argued that this interferes 
with the homogeneity in gathering the data. However, we did not find significant 
differences in neuropsychological functioning between patients being tested at home or in 
the hospital (data not shown).   
A strength of this study is that an intensive neuropsychological test battery was used 
instead of short screening instruments. In addition, analyses were done on cognitive 
domains as well as on each neuropsychological test from the significant cognitive 
domains, and analyses were done both on group level and on an individual level. 
Furthermore, group analyses were corrected for confounders and the RCI was corrected 
for practice effects. Other strengths are the longitudinal design with a baseline 
assessment, the inclusion of a control group, and the relatively low drop-out rate. Collins 
and MacKenzie [47] stated that it would be useful to have an agreement on a standardized 
protocol for cancer and cognition studies. This would allow us to establish a large 
normative database that would provide accurate estimates of reliability and practice 
effects for a battery of relevant tests. 
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The longitudinal design and especially the timing of the second measurement three 
months after the last cycle of chemotherapy are of great value. At this point in life 
patients pick up their normal daily activities and even sometimes try to recommence 
work. It is of great interest to have information concerning OCF at this moment, because 
exactly in this period patients can be confronted with possible disabilities. What would be 
even more interesting is to examine the course of cognitive functioning not only at this 
moment in life but over a longer period. 
The patients in the control group of this study were BBD patients rather than a 
healthy control group. We have chosen for BBD patients because they also experienced 
the emotional and cognitive toll of waiting for the diagnosis that they may have cancer 
and a subgroup of the BBD’s experience stress over and over again because of the follow-
up measurements for monitoring the abnormality in the breast. Despite these similarities, 
BC patients experienced more stress and anxiety at baseline in comparison with BBD 
patients and patients with a BBD scored higher on fatigue. The analyses on the group level 
were corrected for these baseline differences. 
The number of analyses which were done on the neuropsychological tests increases 
the chance of a Type 1 error. However, we have chosen for this approach because it was 
recommended by the International Cognition and Cancer Task Force. With this approach 
no important information gets lost by only using the created sum scores for the cognitive 
domains.   
In conclusion, the present findings suggest that chemotherapy negatively influenced 
verbal memory and executive functioning in patients with BC. Furthermore, no differences 
were found between BC patients and BBD patients in percentages of decreasers on 
neuropsychological tests (except for verbal fluency). We did not find indications of the 
existence of POCD. This finding confirms the accuracy of the baseline measurement of OCF 
after surgery and before the start of chemotherapy. This is of great importance for future 
longitudinal studies. 
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Introduction: Results of existing studies suggest the existence of subgroups within 
patients with breast cancer (BC) who are treated with chemotherapy with regard to 
problems with cognitive functioning. Therefore, the aims of this study were to (i) examine 
cognitive functioning across time in BC patients compared to patients with a benign breast 
disease (BBD) by evaluating the group means across time, (ii) identify longitudinal 
development classes for cognitive functioning in BC patients treated with chemotherapy, 
(iii) describe the sociodemographic and clinical characteristics of the resulting groups, and 
to compare the groups on their psychological functioning across time.  
 
Methods: BC patients who were scheduled to receive adjuvant chemotherapy (N = 86) 
and a control group of women with a benign breast disease (BBD) (N = 95) participated in 
the study. BC patients completed validated questionnaires and a neuropsychological test 
battery before chemotherapy started, three months and one year after ending 
chemotherapy (and at comparable moments for the BBD group). 
 
Results: Concerning verbal memory BBD patients stayed stable across time, while it 
declined in BC patients three months after ending chemotherapy but increased at one 
year after ending chemotherapy (though they remained below their baseline verbal 
memory functioning) (p = .033). Three longitudinal developmental classes were identified: 
‘consistently high/average/low cognitive functioning’. This last group had a higher age, 
lower educational level, and less often salaried work/retirement compared to the other 
subgroups. Furthermore, they scored worse on state anxiety and depressive symptoms 
three months after ending chemotherapy compared to the other subgroups. 
 
Conclusion: Verbal memory is affected in BC patients treated with chemotherapy. Three 
subgroups can be defined within the BC patients: ‘consistently high/average/low cognitive 
functioning’. Further research with a larger sample size is warranted to examine the 
vulnerability of this last subgroup to develop problems with cognitive functioning after BC 
treatment.   
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The number of long-term breast cancer (BC) survivors is steadily increasing. Therefore, the 
short-term and long-term side-effects of BC treatment are becoming more important. 
Over the last decades a growing number of studies have been published that go into the 
impact of chemotherapy on objective cognitive functioning. Initially, cross-sectional 
studies showed evidence of cognitive deficits. Recently, longitudinal studies provide 
further insights into cognitive changes following chemotherapy. The most common 
affected domains include learning and memory, processing speed and executive function 
[1]. Most researchers did not find cognitive deficits in all BC patients, but in a smaller 
proportion of patients, with reports generally ranging between 15 and 50% (e.g., [2-5]).  
Cognitive functioning is generally studied by means of prevalence rates or changes in 
mean scores over time. However, such an approach may mask subgroups of patients with 
different courses of cognitive functioning over time. Looking into trajectories across time 
may provide insight in the chronicity of the cognitive problems and may provide more 
information about the possible subgroups of BC patients with problems concerning 
cognitive functioning. Knowledge about sociodemographic, clinical and psychological 
characteristics of the subgroups with different trajectories of cognitive functioning can be 
helpful in future research concerning the predictors of cognitive deficits after 
chemotherapy, since this is a topic of ongoing research [6].  
Therefore, the first aim of this study was to examine cognitive functioning across 
time for BC patients compared to patients with a benign breast disease (BBD) by 
evaluating the group means across time. The second aim was to identify longitudinal 
development classes for cognitive functioning in BC patients treated with chemotherapy. 
Thirdly, we aimed to describe the sociodemographic and clinical characteristics of the 






Participants and procedure 
Women who were diagnosed with BC and received chemotherapy between January 2009 
and August 2011 were eligible for this prospective study. In addition, women diagnosed 
with a BBD during the same period were also asked to participate in the control group. A 
cyst, mastopathy or a fibro-adenoma are the most common BBD diagnoses. Women with 
proven BC recurrence or distant metastases were excluded. Other exclusion criteria were: 
a history of neuropsychological and/or psychiatric signs or symptoms that lead to deviant 
neuropsychological test results (e.g., dementia), the use of medication that may influence 
neuropsychological results, alcohol and/or drug addiction, and a poor expression in the 
Dutch language. To assess these exclusion criteria, the medical records of all patients were 
checked. 
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BC patients were assessed prior to initiation of chemotherapy (Time 1), three months 
(Time 2) and one year following completion of chemotherapy (Time 3). Patients with a 
BBD were assessed at equivalent time points. See Figure 1 for the study design. Due to the 
fact that the study was very burdensome for the participants and because the main focus 
of this project is at Time 3, we decided not to examine the neuropsychological 
performance of all patients at Time 2 in order to reduce the number of patients who drop 
out of the study. The omission of the neuropsychological assessment at Time 2 happened 
chronologically. All patients did receive the questionnaires at Time 2. All participants 
provided written, informed consent. This study was approved by the central medical ethic 










Figure 1: Timeline of the study 




Clinical data were obtained from medical records and sociodemographic data were 
obtained from a self-report questionnaire. 
 
Assessment of neuropsychological performance  
A comprehensive test battery, which took approximately 1.5 hours to complete, was 
designed to assess a broad range of cognitive domains. The battery of 14 
neuropsychological tests (comprising 24 test indexes) covered attention, verbal/visual 
memory, visuospatial functioning, verbal fluency, executive functioning and motor 
functioning. All tests are widely used in clinical neuropsychological practice and the 
psychometric properties are well described. Furthermore, the selection of tests was based 
on previous neuropsychological studies with cancer patients, to enable comparisons of 
results (e.g., [7, 8]). The assessments were conducted either in the patients’ home or in 
the hospital. Tests were administrated in a fixed order. The neuropsychological tests were 
scored independently by two persons, after which discrepancies were undone by 
consensus. 
Attention/processing speed: The Stroop test (card A and B) [9, 10], the Trailmaking 
test (TMT) A [11], the D2 test [12], the Digit span (forward and backward) and Digit symbol 
subtest of the Wechsler Adult Intelligence Scale (WAIS) [13], the Fepsy visual reaction test 
(dominant and non-dominant) and visual searching test [14] were used.   
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Verbal memory: The Rey auditory verbal learning test (RAVLT) (total recall, delayed 
recall and recognition) [15, 16] was used.  
Visual memory: The visual reproduction subtest of the Wechsler Memory Scale, 
revised [17] and the Complex figure test (CFT) [18, 19] were used.  
Visuospatial functioning: The copy score of the CFT [18, 19] was performed.  
Verbal fluency: The Word fluency test (animals and professions) [20] was performed.   
Executive functioning: The zoo map test of the Behavioral Assessment of 
Dysexecutive Syndrome (BADS) (map 1 and map 2) [21], the TMT B [11], the Fepsy binary 
choice test [14], the Stroop test (card C) [9, 10] were used.  
Motor functioning: The Fepsy finger-tapping task (dominant and non-dominant) [14] 
was used.  
 
Questionnaires 
Frequency of complaints about subjective cognitive functioning (SCF) was measured with a 
reduced 16-item version of the Cognitive Failures Questionnaire (CFQ) [22]. Three factors 
were assessed: Forgetfulness, Absentmindedness, and Social Recklessness (Pullens, De 
Vries, Bogaarts and Roukema, submitted for publication). Satisfaction with SCF was 
measured with the cognitive functioning facet of the World Health Organization Quality of 
Life assessment instrument-100 (WHOQOL-100) [23]. The Center for Epidemiological 
Studies-Depression Scale (CES-D) [24] was used to measure depressive symptoms. Fatigue 
was measured with the Fatigue Assessment Scale (FAS) [25]. The State-Trait Anxiety 
Inventory (STAI) [26] was used to measure anxiety. In this study the validated shortened 6-
item questionnaire for the STAI-state and the 10-item version for the STAI-trait were used 
[27, 28]. Perceived stress was measured with the Perceived Stress Scale-10 (PSS-10) [29]. 
 
Statistical analyses 
Independent sample t-tests (continuous data) and χ
2
-tests (nominal data) were used to 
examine potential differences between the BC patients and the BBD patients at Time 1. 
Furthermore, Mann-Whitney U tests and Fisher exact tests were used to examine 
differences between participants and patients who dropped out of the study at Time 2 
and/or Time 3. 
The cognitive domain scores were computed by first transforming the raw 
neuropsychological measures to standardized scores (using the BBD patients as reference 
group) and then computing a mean standardized score for each domain by summing up 
the standardized scores from the neuropsychological measures, which represent the 
cognitive domain, and divide this by the number of measures for each cognitive domain.  
In order to examine cognitive functioning across time for BC and BBD patients, 
repeated measures analysis of variance using general linear mixed modeling analyses 
were performed, using an unstructured covariance structure. Age, educational level and 
the variables on which patient groups differed at baseline were used as covariates. In 
contrast to traditional repeated measures analysis of variance, this method does not 
automatically exclude every patient from the analysis who has a missing data on a 
particular moment which preserves the statistical power. Furthermore, this technique is 
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suitable for analysis of repeated measurements, as it takes into account the possibility of 
correlated data. 
Latent class linear regression analysis, with educational level as covariate, was used 
to determine the number of latent classes (trajectories) in the course of cognitive 
functioning (three data waves). The dependent variable was the mean of the scores on the 
seven separate cognitive domains. Because we were interested in the change over time, 
time was used as a predictor in the regression model, yielding what is sometimes referred 
to as a latent class growth model. Models with one to five classes were estimated, using 
the Bayesian Information Criterion (BIC) for model selection. BIC provides a quantitative 
index for fit (correspondence between the observed and model predicted responses) 
taking into account parsimony (number of parameters not being larger than necessary). 
Based on the results of the selected latent class regression model, each respondent was 
assigned to the most likely class.  
For comparison of sociodemographic, clinical and psychological characteristics 
between the encountered latent classes, independent sample Mann Whitney U tests and 
Fisher-exact tests were used. Furthermore, repeated measures analysis of variance using 
general linear mixed modeling analyses were performed to examine the course of 
emotional distress (state anxiety, depression, perceived stress, fatigue, SCF (satisfaction 
and frequency of complaints)) across time for the latent classes. All analyses were 
performed with the Statistical Package for Social Sciences (SPSS version 19), except for the 






Of the 213 patients who initially consented to participate after receiving a telephone call 
from the researcher, 23 of them eventually did not participate because of ‘lack of interest’ 
(N = 5), ‘lack of time’ (N = 4), ‘study too burdensome’ (N = 3), ‘did not show up during 
appointment’ (N = 5), ‘study topic too confronting’ (N = 3), ‘sickness (personal/a family 
member)’ (N = 2), or ‘personal relationship with the researcher’ (N = 1). At baseline 
(Time 1), 190 women completed the assessments. Seven patients refused to participate at 
Time 2 (one BC patient and six BBD patients) and seven patients dropped out of the study 
at Time 3 (two BC patients and five BBD patients) because they had lost interest in the 
study. Furthermore, nine patients were excluded because of disease recurrence or 
metastases during the study. At the moment of the analyses, eight patients still needed to 
participate at Time 3. The drop outs had a significantly lower educational level compared 
to women who remained in the study (p = .039). Furthermore, the drop outs scored 
significantly lower on the visual memory domain at Time 1 (p = .035). There were no 
significant differences concerning other sociodemographic factors, psychological factors or 
neuropsychological measures.   
Concerning the sociodemographic factors, the BC patients more often had no 
children and they had a higher educational level compared to the BBD patients (see 
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Table 1). The baseline psychological factors showed that BC patients had a significantly 
higher score on state anxiety, while the BBD patients scored higher on fatigue. No 
additional significant differences were found between the two groups (see Table 1). 
The drop outs had a significantly lower educational level compared to women who 
remained in the study (p = .039). Furthermore, the drop outs scored significantly lower on 
the visual memory domain at Time 1 (p = .035). There were no significant differences 
concerning other sociodemographical factors, psychological factors or neuropsychological 
measures. 
 
Course of cognitive functioning across time 
Concerning visual memory, visuospatial functioning, verbal fluency, attention, executive 
functioning, and motor functioning no significant effects of time or group were found. 
Concerning verbal memory, a significant effect of time (p = .007) and a significant 
interaction effect (p = .033) were found. BBD patients remained stable across time, while 
verbal memory declined in BC patients three months after ending chemotherapy but 
increased at one year after ending chemotherapy (though they remained below their 
baseline verbal memory functioning). In all analyses, diagnosis was not significant. See 
Figure 2 for the course of the cognitive domain verbal memory across time for BC and BBD 
patients.  
 
Figure 2: Verbal memory domain across time for BC and BBD patients 
BBD = Benign breast disease; BC = Breast cancer 
 
 
Trajectories of cognitive functioning across time in patients with BC   
Based on the BIC we selected the model with thee trajectories for the total score of 
cognitive functioning for BC patients over the first year after completing chemotherapy. 
The overall R2 equals 0.76, indicating that the three latent classes describe a large part of 
the individual differences in the level and change cognitive functioning. The trajectories 
are visualized in Figure 3 and reflect ‘consistently high cognitive functioning’, ‘consistently 
average cognitive functioning’, and ‘consistently low cognitive functioning’. The 















































































estimated proportion of misclassification when assigning individuals to the three classes 
for further analysis was less that 10%. The most important difference between the three 
trajectory classes was in the overall level of cognitive functioning (i.e., the intercept) (Wald 
statistic = 228.84, p < .001). The time effect did not significantly differ across classes (Wald 
statistic = 6.2302, p = .40). Although not statistically significant, Figure 3 illustrates that BC 
patients with the lowest baseline scores show a further decline in their cognitive 















Figure 3: Longitudinal development classes in BC patients 
BC = Breast cancer 
 
 
Characteristics of the three subgroups 
A number of significant differences were found in sociodemographic, clinical and 
psychological characteristics between the three subgroups of BC patients at baseline. The 
most significant results were found in the subgroup ‘consistently low cognitive 
functioning’: their age was significantly higher compared to the other two subgroups, 
significantly fewer patients had paid work/retirement compared to the other two 
subgroups, they had the lowest educational level compared to the other two subgroups, 
and they scored significantly lower on the subscale Social recklessness compared to BC 
patients with an ‘consistently average cognitive functioning’ (see Table 1). 
Furthermore, the interaction effects of the mixed linear modeling analyses with the 
different psychological variables as outcome measures were examined to test if these 
variables significantly differed across time for the three trajectories. The analyses revealed 
a significant interaction effect for state anxiety (p = .033) and depressive symptoms 
(p = .047) at Time 2. BC patients in the group ‘consistently low cognitive functioning‘ 
increased in their symptoms of state anxiety and depressive symptoms at Time 2 while the 
other two groups decreased (state anxiety) or increased less (depressive symptoms) at 
Time 2 compared to Time 1. 
 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This study examined (i) the course of cognitive functioning up to one year after ending 
chemotherapy in BC patients compared to BBD patients, and (ii) the existence of different 
trajectories across time within this sample of BC patients. Evaluations of the group means 
revealed that verbal memory was affected in BC patients three months after ending 
chemotherapy and partly recovered one year after ending chemotherapy, while BBD 
patients remained stables across time. Earlier research also found verbal memory as an 
affected domain after BC treatment (e.g., [32, 33]). While other domains remained stable 
across time in our study, previous studies also found changes across time in processing 
speed and executive function in BC patients [1].  
As far as we know this is the first study that looked into different trajectories over 
time in cognitive functioning for BC patients treated with chemotherapy. Three 
longitudinal development classes were found: ‘consistently high cognitive functioning’, 
‘consistently average cognitive functioning’, and ‘consistently low cognitive functioning’. 
The overall level of cognitive functioning significantly differed between the three groups. 
Earlier studies also found pre-treatment cognitive deficits (e.g., [3, 4, 34]). It is unclear 
whether this pre-treatment cognitive deficit is due to adverse effects of the cancer itself 
or to other, undefined, factors [35]. It is hypothesized that the adverse effects of cancer(-
treatment) manifest themselves in vulnerable individuals. These individuals are most likely 
to show cognitive changes associated with cancer treatments [35]. The effects of time for 
the different trajectories on cognitive functioning were not significant in this study. Thus, 
the development across time concerning cognitive functioning is not significantly different 
for the three subgroups in this sample. More research, with a larger sample size, is needed 
to examine if the temporary affected cognitive functioning for the patients in the 
trajectory ‘consistently low cognitive functioning’ (which can be observed in Figure 3) is 
statistically significant and clinically relevant. The characteristics of these potentially 
vulnerable individuals were found with baseline comparisons between the identified 
classes. This revealed the interesting finding that the BC patients in the group of 
‘consistently low cognitive functioning’ were significantly older, less educated and had less 
often salaried work/retirement. The possible vulnerability of older patients with less 
cognitive reserve is shown in earlier research [36, 37]. 
Furthermore, concerning psychological factors, this group with ‘consistently low 
cognitive functioning’ scored lower on Social recklessness. What’s more, changes in state 
anxiety and depressive symptoms were found. Vearncombe et al. found increased anxiety 
as a predictor of impairment on two or more cognitive tests in women with BC [38]. 
Additionally, this study found a significant association between depression at baseline and 
executive functioning and attention. In contrast, other studies did not find relationships 
between psychological variables and chemotherapy-induced problems with OCF [39] 
which demands more research into the relationship between OCF and psychological 
variables.  
Strengths of this study are the prospective design with a baseline assessment and the 
inclusion of a control group. The patients in the control group of this study were BBD 
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patients rather than a healthy control group. We have chosen for BBD patients because 
they also experienced the emotional and cognitive toll of waiting for the possible 
diagnosis of BC, and a subgroup of the BBD’s experienced stress over and over again 
because of the follow-up measurements for monitoring the abnormality in the breast [40]. 
Despite these similarities, BC patients experienced more state anxiety at baseline in 
comparison with BBD patients, while patients with a BBD scored higher on fatigue. The 
analyses concerning the course of the cognitive domains across time are corrected for 
these differences. Another strength of this study is the relatively low drop-out rate (3.7% 
at Time 2; 3.8% at Time 3). We did, however, notice that more patients with a BBD 
diagnosis dropped out during the study. A possible explanation is that participating in the 
study is of less importance for these patients because they do not share the worries about 
the side effects of treatment. Furthermore, patients who dropped out during this study 
scored significantly lower on visual memory at baseline and had a lower educational level. 
An additional strength of this study is the relatively large sample size for the analyses 
across time for all patients with BC treated with chemotherapy, compared to other studies 
in this field. Jim et al. also used a relatively large sample size [41], but sample sizes of 
other studies were smaller (e.g., [3, 33, 42-47]).   
A limitation of this study is the relatively small subgroup of patients with a 
‘consistently low cognitive functioning’, which may have destabilized the latent classes. 
The three classes found in this study are a good description of this sample size, however, 
before we can generalize these findings, these three latent classes need to be replicated in 
a larger sample. Despite this limitation, the characteristics of these latent classes are 
useful in clinical practice to signalize patients who can be at risk for developing a decline in 
their cognitive functioning after treatment with chemotherapy. Another limitation of this 
study is that not all patients completed the neuropsychological assessment at Time 2. 
However, for the analyses across time we have used the repeated measures analysis of 
variance using general linear mixed modeling analyses instead of the traditional repeated 
measures analysis of variance, so that patients still were included in the analyses when 
they have a missing data on a particular moment. This preserves the statistical power. 
In conclusion, the cognitive domain verbal memory is affected in BC patients treated 
with chemotherapy. Three subgroups can be defined within the BC patients: ‘consistently 
high, average, and low cognitive functioning’. This last group had a higher age, lower 
educational level, and less often had salaried work/retirement compared to the other 
subgroups. More attention is required in clinical practice for a patient with these patient 
characteristics. More research with a larger sample size is warranted to examine the 
vulnerability of this subgroup of BC patients to develop problems with cognitive 
functioning after BC treatment. 
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Purpose: The course of quality of life (QoL) in women with breast cancer (BC) and the 
impact of objective cognitive functioning (OCF) and subjective cognitive functioning (SCF) 
on QoL were examined. 
 
Methods: BC patients who were about to receive chemotherapy (N = 86) and patients 
with a benign breast disease (BBD) (N = 95) participated. Before chemotherapy started 
(Time 1), three months (Time 2) and one year after ending chemotherapy (and at 
comparable moments for BBD patients) (Time 3) women completed validated 
questionnaires and a neuropsychological test battery. General linear mixed modeling 
analyses and hierarchical regression analyses were used.  
 
Results: BC patients scored significantly lower on Overall QoL and General Health, Physical 
Health, Psychological Health and Social Relationships at Time 3, compared to BBD 
patients. SCF and OCF do not add significant variance to the predictive model of QoL. 
There are indications that the domain of visual memory has a predictive value for Social 
Relationships. 
 
Conclusion: Overall QoL and General Health, and the Physical Health domain are affected 
in BC patients one year after ending chemotherapy. Overall, SCF and OCF did not add 
significant variance to the predictive model for QoL. Further examination of the impact of 
OCF and SCF on QoL is warranted. 
 
Keywords: breast cancer, quality of life, chemotherapy, objective cognitive functioning, 
subjective cognitive functioning, cognitive complaints 




An increasing number of women survive breast cancer (BC). Despite lower mortality rates, 
BC treatment can also have severe side-effects. Cognitive impairment as a side effect of 
chemotherapy is a frequently reported concern of BC patients, popularly referred to as 
‘chemobrain’. An increasing amount of research is focusing on this ‘chemobrain’. 
Problems with cognitive functioning can be measured objectively with neuropsychological 
tests and subjectively using self-report questionnaires on cognitive complaints. The effects 
of chemotherapy on cognitive functioning are still inconclusive and prevalence rates vary 
strongly (e.g., [1-7]).  
Because more and more women receive BC treatment such as chemotherapy, the 
quality of life (QoL) of BC patients has been identified as an end point of great importance 
in research and clinical practice [8]. Relatively few studies have focused on the impact of 
problems in cognitive functioning due to chemotherapy on aspects of QoL.  
Qualitative studies have found that women can experience cognitive difficulties that 
affect their functioning at home or their job performance [9-11]. These results underscore 
the serious ways in which problems with cognitive functioning can affect the life 
experiences of cancer survivors. Quantitative studies also focused on the association 
between cognitive functioning and QoL [11-17] or on the predictive value of QoL on 
cognitive functioning [18]. These studies revealed different results and an association is 
not always found (e.g., [17, 19]). Besides these studies it is interesting to analyze the 
clinical significance of cognitive changes in cancer survivors. Reid-Arndt et al. studied 
neuropsychological functioning and QoL the first year after completing chemotherapy for 
BC, but they highlighted the preliminary nature of their findings that cognitive difficulties 
among cancer survivors may be associated with poorer functional outcomes [20]. Further 
research is needed to validate the potential relationships.   
The aims of this prospective follow-up study were (i) to evaluate the course of QoL in 
BC patients until one year after ending chemotherapy and (ii) to examine the impact of 
objective cognitive functioning (OCF) and subjective cognitive functioning (SCF) on QoL at 
one year after ending chemotherapy. Patients with a benign breast disease (BBD) are the 
control group. Cognitive functioning is associated with emotional distress (e.g., [14, 21-
23]), therefore we will not only focus on cognitive functioning, but also take psychological 





Participants and procedure 
Women who were diagnosed with BC and received chemotherapy between January 2009 
and August 2011 were eligible for this prospective longitudinal study. In addition, women 
diagnosed with a BBP during the same period were also asked to participate in the control 
group. A cyst, mastopathy or a fibro-adenoma are the most common BBD diagnoses. 
Women with proven BC recurrence or distant metastases were excluded. Other exclusion 
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criteria were: a history of neuropsychological and/or psychiatric signs or symptoms that 
lead to deviant neuropsychological test results (e.g., dementia), the use of medication that 
may influence neuropsychological results, alcohol and/or drug addiction, and a poor 
expression in the Dutch language. To assess these exclusion criteria, the medical records 
of all patients were checked. 
BC patients were assessed prior to initiation of chemotherapy (Time 1), three months 
(Time 2) and one year following completion of chemotherapy (Time 3). Patients with a 
BBD were assessed at equivalent time points. See Figure 1 for the study design. All 
participants provided written, informed consent. This study was approved by the central 
medical ethic committee of the St. Elisabeth hospital (Tilburg) and the local ethic 
committees of TweeSteden hospital (Tilburg), Maxima Medical Centre (Eindhoven, 
Veldhoven), Catharina hospital (Eindhoven), St. Anna hospital (Geldrop), Amphia hospital 
(Breda), and Jeroen Bosch hospital (Den Bosch). 
 
 
Figure 1: Timeline of the study 




Clinical data were obtained from medical records and sociodemographic data were 
obtained from a self-report questionnaire. 
 
Assessment of neuropsychological performance  
A comprehensive test battery, which took approximately 1.5 hours to complete, was 
designed to assess a broad range of cognitive domains. The battery of 14 neuro-
psychological tests (comprising 24 test indexes), covered attention, verbal-visual memory, 
visuospatial functioning, verbal fluency, executive functioning, and motor functioning. All 
tests are widely used in clinical neuropsychological practice and the psychometric 
properties are well described. Furthermore, the selection of tests was based on previous 
neuropsychological studies with cancer patients, to make it possible to compare the 
results (e.g., [24, 25]). A recent review summarized the mostly used neuropsychological 
tests in the assessment of post-chemotherapy cognitive changes in BC patients. Our 
selection shows overlap with the tests described in this review [25]. The assessments were 
conducted either in the patients’ home or in the hospital. Tests were administrated in a 
fixed order. The neuropsychological tests were scored independently by two persons 
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because of the subjective nature of their scoring. Eventually discrepancies between both 
scores were solved by reaching consensus. Results from the neuropsychological measures 
were reported separately and domain scores were calculated.  
Attention/processing speed: The Stroop test (card A and B) [26, 27], the Trailmaking 
test (TMT) A [28], the D2 test [29], the Digit span (forward and backward) and Digit symbol 
subtest of the Wechsler Adult Intelligence Scale (WAIS) [30], the Fepsy visual reaction test 
(dominant and non-dominant) and visual searching test [31] were used.   
Verbal memory: The Rey auditory verbal learning test (RAVLT) (total recall, delayed 
recall and recognition) [32, 33] was used.  
Visual memory: The visual reproduction subtest of the Wechsler Memory Scale 
(WMS), revised [34] and the Complex figure test (CFT) [35, 36] were used.  
Visuospatial functioning: The copy score of the CFT [35, 36] was performed.  
Verbal fluency: The Word fluency test (animals and professions) [37] was performed.   
Executive functioning: The zoo map test of the Behavioral Assessment of 
Dysexecutive Syndrome (BADS) (map 1 and map 2) [38], the TMT B [28], the Fepsy binary 
choice test [31], the Stroop test (card C) [26, 27] were used.  




QoL was measured with the World Health Organization Quality of Life assessment 
instrument-100 (WHOQOL-100), Dutch version [39]. The WHOQOL-100 is a cross-culturally 
developed generic multidimensional quality of life questionnaire. It consists of 100 items 
assessing 24 facets of quality of life and a general facet. These facets can be converted 
into four domains: Physical, Psychological, Social Relations, and Environment. The 
response scale is a 5-point scale. The time frame of reference is the previous two weeks. 
The instrument is reliable and valid [40] and the sensitivity of the instrument is also high 
[41]. Furthermore it is a reliable and valid instrument to measure QoL in women 
suspected of having BC [42]. 
The Cognitive Failures Questionnaire (CFQ) [43], Dutch version [44], was used to 
assess self-reported frequency of complaints about SCF. This self-report inventory consists 
of 25-items. The rating scales range from 0 to 4. A high score indicates more often 
experienced cognitive failure. A reduced 16-item version of the CFQ was found with good 
psychometric properties [Pullens, De Vries, Bogaarts and Roukema, submitted for 
publication]. In order to make comparisons with other studies possible, we reported our 
results with both the original general factor (CFQ 25-items) and the new developed 16-
item version (CFQ-16 items).  
The cognitive functioning facet of the World Health Organization Quality of Life 
assessment instrument-100 (WHOQOL-100), Dutch version [39], was used to assess the 
satisfaction with SCF. A high score on the cognitive functioning facet indicates satisfaction 
with SCF.  
The Center for Epidemiological Studies-Depression Scale (CES-D) [45], Dutch version 
[46], was used to measure the presence and degree of depressive symptoms. It consists of 
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20 items, with rating scales range from 0 to 3. A higher score indicates more depressive 
symptoms. The CES-D is a valid and reliable measure of depressive symptoms in BC 
patients [47]. 
The Fatigue Assessment Scale (FAS) [48] was used to measure fatigue. It is a 10-item 
questionnaire that taps fatigue and exhaustion. The response scale is a 5-point scale (1 to 
5). A higher score indicates more symptoms of fatigue. The psychometric properties have 
been studied in different patient populations, including BC patients, and the validity and 
reliability are reported to be good [49]. 
The State-Trait Anxiety Inventory (STAI) [50], Dutch version [51], was used to 
measure anxiety. The state scale asks persons how they feel at a particular moment in 
time, while the trait scale asks people to describe how they generally feel. In this study the 
shortened 6-item questionnaire for the STAI-state [52] and the shortened 10-item version 
for the STAI-trait [53]. The rating scales range from 1 to 4, a higher score indicates more 
symptoms of anxiety. The validity and reliability are well established and considered good 
[51-54]. 
The Perceived Stress Scale-10 (PSS-10) [55] was used as a global measure of 
perceived stress during the last month. It is the shortened version of the PSS-14 and 
consists of ten items, rated on a 4-point Likert-scale from 0 to 4. A higher score indicates 
more perceived stress. The validity and reliability of the PSS are good [55]. 
 
Statistical analyses 
Independent sample t-tests (continuous data) and χ
2
-tests (nominal data) were used to 
examine potential differences between the BC patients and the BBD patients at Time 1. 
Furthermore, Mann-Whitney U tests and Fisher exact tests were used to examine 
differences between participants and patients who dropped out of the study at Time 2 
and/or Time 3. 
In order to examine whether BC patients report poorer QoL compared to patients 
with a BBD, repeated measures analysis of covariance using general linear mixed modeling 
analyses were performed, using an unstructured covariance structure. Variables on which 
patient groups were different from each other at baseline were used as covariates. In 
contrast to traditional repeated measures analysis of variance, this method does not 
automatically exclude every patient from the analysis who has a missing data on a 
particular moment. This preserves the statistical power. Furthermore, this technique is 
suitable for analysis of repeated measurements, as it takes into account the possibility of 
correlated data.  
To determine the predictive value of SCF (Time 1) and OCF (Time 1) on QoL at Time 3 
(after controlling for the possible effects of sociodemographic, clinical and psychological 
variables) hierarchical multiple regression analyses were conducted. For the calculation of 
the QoL domain Psychological Health the facet ‘satisfaction with SCF’ was excluded, 
because this facet was used as a possible predictor in the model. The cognitive domain 
scores were computed by first transforming the raw neuropsychological measures to 
standardized scores (using the BBD patients as reference group) and then computing a 
mean standardized score for each domain by summing up the standardized scores from 
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the neuropsychological measures, which represent the cognitive domain, and divide this 
by the number of measures for each cognitive domain. Aiming at minimizing the number 
of independent control variables in the final hierarchical regression analysis, separate 
preliminary regression analyses (method: stepwise) were performed with socio-
demographic, clinical and psychological variables as independent variables. The variables 
with a p < .10 were entered in the final hierarchical multiple regression analyses (method: 
Enter). We have chosen for a p < .10 instead of p < .05 to reduce the risk of excluding a 
potentially relevant variable. From the clinical variables, only the variable diagnosis was 
forced in every multivariate regression analysis. Furthermore, because BC patients and 
BBD patients differed significantly on state anxiety and fatigue at baseline, effect 
modifications and confounders were examined for these variables on each dependent 
variable in univariate regression analyses. If a confounding effect was found, the variable 
was included in the final multivariate regression analysis. Adjusting for these preliminary 
selected covariates, we composed a five-step model. In step 1, sociodemographic 
variables were included. Step 2 represented the clinical block with the variable ‘diagnosis’. 
Step 3 included psychological variables. In order to assess the unique association between 
SCF and QoL, frequency of complaints about SCF (analyses were done separately for CFQ-
16 and CFQ-25 items), and satisfaction with SCF were included in step 4. Finally, in order 
to assess the unique contribution of OCF, step 5 contained the seven OCF domains 
(attention, verbal memory, visual memory, verbal fluency, visuospatial, executive 
functioning, and motor functioning). All analyses were performed with the Statistical 






Of the 213 patients who initially consented to participate by a telephone call from the 
researcher, 23 of them eventually refused to participate because of ‘lack of interest’ 
(N = 5), ‘lack of time’ (N = 4), ‘study too burdensome’ (N = 3), ‘did not show up during 
appointment’ (N = 5), ‘study subject too confronting’ (N = 3), ‘sickness (personal/a family 
member)’ (N = 2), or ‘personal relationship with the researcher’ (N = 1). At baseline 
(Time 1), 190 women completed the assessments at Time 1. Seven patients refused to 
participate at Time 2 (1 BC patient and 6 BBD patients) and seven patients dropped out 
the study at Time 3 (2 BC patients and 5 BBD patients) because they had lost interest in 
the study. Furthermore, nine patients were excluded because of disease recurrence or 
metastases during the study. At the moment of the analyses eight patients still needed to 
participate at Time 3. 
Concerning the sociodemographic factors, the BC patients had significantly more 
often no children and they had a higher educational level compared to the BBD patients 
(see Table 1). The baseline psychological factors showed that BC patients had a 
significantly higher score on state anxiety. Furthermore, patients with a BBD scored higher 
on fatigue. No additional significant differences were found (see Table 1). 
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Table 1: Sociodemographic, clinical, and psychological characteristics of the participants  
 
Characteristics BC group 
(N = 86) 
BBD group 
(N = 95) 
P-value 
Sociodemographics  
Age 50.2 ± 9.9 47.8 ± 10.5 .112 
Living with partner 69 (85.2) 80 (87.0) .737 
Children 60 (73.2) 80 (87.9)   .014* 




















Paid work/retirement 61 (81.3) 75 (81.5) .975 
Psychologist/psychiatric counseling in past 12 (23.1) 76.0 ± 15.7 .926 
Clinical characteristics  
Comorbidity
b
 23 (27.7) 30 (33.3) .423 
Type of surgery  






Chemotherapy 86 (100)   
Radiotherapy 46 (53.5)   
Tumor grade









Axillary lymph node dissection 47 (56.0)   
Psychological characteristics (baseline)    
Trait anxiety 17.5 ± 5.2 17.2 ± 5.4  .708 
State anxiety 12.1 ± 3.3 10.0 ± 3.7 < .001* 
Depressive symptoms 10.5 ± 8.4 9.3 ± 8.7  .359 
Fatigue 17.9 ± 5.2 20.6 ± 5.8    .002* 
Perceived stress 20.9 ± 5.1 20.0 ± 4.7  .212 
Satisfaction with SCF 14.8 ± 2.3 14.6 ± 2.4  .471 
Frequency of complaints about SCF (CFQ-25 items) 29.4 ± 10.3 31.6 ± 10.8  .171 
Frequency of complaints about SCF (CFQ-16 items) 20.1 ± 6.7 21.6 ± 7.3  .156 
Forgetfulness 12.5 ± 4.3 13.4 ± 4.7  .206 
Absentmindedness 3.9 ± 2.2 4.2 ± 2.5  .466 
Social recklessness 3.6 ± 1.7 4.0 ± 1.7  .067 
Mean ± standard deviation are presented for age and psychological factors, percentages are between 
brackets; for the calculation of the percentage missings are not included  
BBD = Benign breast disease; BC = Breast cancer; CFQ = Cognitive Failures Questionnaire; SCF = 
Subjective cognitive functioning 
a
 L = low education (primary school, lower vocational education); M = middle education (lower general 
secondary education, intermediate vocational education); H = high education (higher general secondary 
education, pre-university education, higher vocational education, university) 
b
 Comorbidity consists of heart disease and/or lung disease and/or diabetics and/or neuromuscular 
disease and/or orthopedic disease 
c
 Tumor grade following the Bloom and Richardson grading system for breast cancer 
* p < .05 
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The drop outs had a significantly lower educational level compared to women who 
remained in the study (p = .039). Furthermore, the drop outs scored significantly lower on 
the visual memory domain at Time 1 (p = .035). There were no significant differences 
concerning other sociodemographic factors, psychological factors or neuropsychological 
measures.   
 
Course of quality of life across time 
After controlling for fatigue and state anxiety several significant effects were found. A 
description is given below, but all information is summarized in Table 2 and Figure 2. BBD 
patients significantly score higher on Overall QoL and General Health, Physical Health, 
Psychological Health and Social Relationships at Time 3 compared to BC patients. 
Furthermore, Physical Health is significantly lower for BC patients compared to BBD 
patients at Time 1. In addition, BC patients score higher on Social Relationships compared 
to BBD patients at Time 1, but the significant interaction effects reflect a decrease in Social 
Relationships for BC patients and an increase for BBD patients across time.  
 
Cognitive functioning as predictor of quality of life 
The results of these final hierarchical multiple regressions are shown in Table 3. Although 
beta coefficients, total R Square, R square change, F-values and p-values differed slightly, 
the same significant results were found for the CFQ-16 and CFQ-25 item version. The R 
square change of the SCF blocks (Time 1) and the OCF blocks (Time 1) were not statistically 
significant for the Overall QoL and General Health (Time 3) and for the domains of QoL 
(Time 3). Thus, the SCF and OCF blocks did not add significant variance to the model. 
When we look at the beta’s of the specific SCF (Time 1) and OCF (Time 1) variables, only 
visual memory was a significant predictor for Social Relationships (Time 3). See Table 3 for 
the beta coefficients of the included covariates in the final models. 
 
















 -.204   -.780* 279 1.345* .016 
Time 2
b
   .377 -.330 .101   .789* .125 
Diagnosis
c
    .929*     .841*    .539* 1.189* .112 
Interaction Time X diagnosis F = 1.270; 
p = .284 
F = 2.559;  
p = .080 
F = 1.764;  
p = .175 
F = 10.540;  
p < .001 
F = 4.888;  
p = .009 
Time 1 X diagnosis  -.044    .692*  -.533  -1.768*  -.473 
Time 2 X diagnosis   -.445  .513  -.274  -1.486*    -.764* 
QoL = Quality of Life 
Overall main effects are not given due to the inclusion of interaction effects in the model
  
a
 Adjusted for fatigue and state anxiety  
b
 Time 3 as reference value for BC patients 
c
 BC patients as reference value at Time 3 
* p ≤ .05 











Figure 2: Mean QoL scores on the three measurement moments for Overall QoL and General Health 
and each domain stratified by diagnosis 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    




In this study the relationship between cognitive functioning (SCF and OCF) and QoL was 
examined. First, QoL was evaluated across time to examine if QoL was affected in this 
sample of BC patients. Our specific interest was in patients’ QoL one year after ending 
chemotherapy (Time 3), because the second aim of this study was to examine the 
predictive value of cognitive functioning (SCF and OCF) on QoL at this measurement. We 
found that BC patients treated with chemotherapy scored significantly lower on Overall 
QoL and General Health (Time 3), Physical Health (Time 1 and Time 3), Psychological 
Health (Time 3) and Social Relationships (Time 3) compared to BBD patients. These results 
are in line with earlier studies in which patients with chemotherapy scored worse on QoL 
compared to BC patients treated with local therapy [56], radiotherapy [15] or patients 
treated without chemotherapy [24].  
To better understand the relative impact of cognitive functioning on survivors’ well-
being, another aim of this study was to assess the unique contribution of cognitive 
functioning (SCF and OCF) to patients’ QoL. We found that SCF and OCF (measured at 
Time 1) did not add significant variance to the predictive model of QoL at Time 3 (when 
sociodemographic, clinical, and psychological factors were taken into account). When we 
looked at the beta coefficients of the various domains of OCF in the final predictive 
models for QoL we found that visual memory was a significant predictor for Social 
Relationships at Time 3. This indicates that from the cognitive functioning variables, visual 
memory may be of importance in the prediction of Social Relationships. However, because 
the omnibus effect of cognitive functioning did not reach a statistically significant value, 
this effect of visual memory may only be a sample specific effect which should be verified 
in other samples.    
Our results, in combination with results from earlier research, are inconclusive with 
regard to the impact of cognitive functioning on QoL [20, 57]. However, evidence exists 
about the role of neuropsychological measures on specific aspects of daily living such as 
affected productivity at home and at work, problems with returning to work, and affected 
community integration (e.g., [9, 10, 57-60]). In addition, in clinical practice BC patients 
continue to report to be bothered by cognitive changes during and after their BC 
treatment. Thus, the inconsistent findings about the contribution of cognitive functioning 
(SCF and OCF) to QoL may be explained by the possible weak ecological validity of the SCF 
and OCF measures [61].  
Strengths of this study are the longitudinal design with a baseline assessment, and 
the relatively low drop-out rate (3.7% at Time 2; 3.8% at Time 3). We did, however, notice 
that more patients with a BBD diagnosis dropped out during the study. It seems that 
participating in the study is of less importance to patients who do not have BC. This may 
be explained by the fact that these patients do not have the worries about side effects of 
treatment. Furthermore, patients who dropped out during this study scored significantly 
lower on visual memory at baseline. We cannot explain this finding and we need to take 
into account that this could be a type 1 error. Another strength of this study is the 
inclusion of a control group. The patients in the control group of this study were BBD 
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patients, rather than a healthy control group. We have chosen for BBD patients because 
they also experienced the emotional and cognitive toll of waiting for the possible 
diagnosis of BC, and a subgroup of the BBD’s experience stress over and over again 
because of the follow-up measurements for monitoring the abnormality in the breast [62]. 
Despite these similarities, BC patients experienced more state anxiety at baseline in 
comparison with BBD patients, and patients with a BBD scored higher on fatigue. The 
analyses concerning patients’ QoL are corrected for these differences. In addition, another 
strength of this study is that, compared to earlier research concerning the relationship 
between cognitive functioning and QoL, our sample size is relatively large (e.g., [9, 17, 
20]).  
A limitation of the study is that the patient population was too small to run separate 
regression analyses for the BC and BBD patients. Diagnosis turned out to be a significant 
predictor for Overall QoL and General Health, Physical Health and Social Relationships. 
However, the aim of these regression analyses was to find the predictive value of OCF and 
SCF on QoL. Therefore we think that this could be examined in a good way in patients with 
a breast disease (benign and malignant) to preserve power of the analyses. In this way we 
were able to include more variables in the predictive model to examine the impact of 
cognitive functioning (OCF and SCF) on QoL, taking into account the effects of emotional 
distress, sociodemographic and clinical variables. More research, with larger sample sizes 
are needed to test the predictive value of cognitive functioning (OCF and SCF) on QoL and 
to test if our found effect of visual memory on Social Relationships was a sample specific 
effect or can be generalized. 
In conclusion, compared to BBD patients, Overall QoL and General Health and the 
Physical Health domain are affected in BC patients one year after ending chemotherapy. 
Overall, SCF and OCF (measured at Time 1) did not add significant variance to the 
predictive model for QoL (measured at Time 3). There are indications that the specific OCF 
domain visual memory has a predictive value for Social Relationships. Further examination 
of the impact of this domain on QoL is warranted. Indentifying risk factors is of great 
importance because this can lead to interventions that could reduce the impact of cancer 
and its treatment on cognitive functioning and QoL.   
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Cognitive functioning (subjective cognitive functioning (SCF) and objective cognitive 
functioning (OCF)) in patients with breast cancer (BC) who were treated with 
chemotherapy was examined in this thesis. Furthermore, the relationship between 
cognitive functioning (SCF and OCF) and quality of life (QoL) was examined. This chapter 
consists of a summary and interpretation of the main findings of the studies that have 
been presented. Subsequently, methodological considerations, suggestions for future 
research, and clinical implications that follow from these studies will be given.  
 
 
Summary and interpretation of main findings 
 
Subjective cognitive functioning 
When this study started, at the end of 2008, the literature about the effects of 
chemotherapy on cognitive functioning was emerging. However, most research focused 
on the effects of chemotherapy on OCF. At that moment, several meta-analyses were 
written (e.g., [1-4]) and an international working group (The International Cognition and 
Cancer Task Force (ICCTF)) met each other several times [5-7]. However, the effects of 
chemotherapy on SCF were not examined thoroughly and there were no articles available 
which provided an overview of this topic. Therefore, we performed a systematic review of 
the literature to investigate the effects of adjuvant treatment for BC on SCF (Chapter 2). 
The reported prevalence of problems with SCF appeared to vary considerably, which is 
most likely the result of the variety in definitions, questionnaires, and cut-off scores. 
Problems with SCF do exist in the BC population, but it is unclear if these problems are 
more commonly found among patients with BC than in the general population. No 
differences were found in the prevalence of problems with SCF between pre- and post-
treatment assessments, which implies that there is no effect of systemic treatment on the 
occurrence of problems with SCF. However, evidence was found for short time increased 
severity of problems with SCF directly after systemic treatment, compared to the baseline 
assessment. Fluctuating results were found for the changes in severity and occurrence of 
problems with SCF across time after treatment.  
Another finding was the inconsistent way in which SCF was measured across studies. 
Different ad-hoc semi-structured interviews and a number of self-report questionnaires 
were used to determine SCF. One of the used questionnaires was the Cognitive Failures 
Questionnaire (CFQ) (25 items) [8]. Because the CFQ shows a different factor structure in 
different diseases, the factor structure and psychometric properties of the questionnaire 
have been examined in Chapter 3. None of the existing models met the criteria for an 
acceptable fit in the confirmatory factor analyses. Therefore, an exploratory factor 
analysis was done to find the best factorial representation of the CFQ in a population of 
patients with a breast disease. A three factor solution with good psychometric properties 
was found. The three factors were Forgetfulness (nine items), Absentmindedness (four 
items), and Social recklessness (three items). This factor solution accounted for 37% of the 
variance. Concerning divergent validity, the factors of the CFQ correlated low with 
depressive symptoms and state anxiety. The new three-factor model showed good 
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reliability and validity. Convergent validity was shown by moderate to high correlations 
with satisfaction with SCF. The correlations between the CFQ and fatigue were moderate, 
suggesting at least an overlap between self-reported problems with SCF and fatigue. The 
results of the present study show that our three-factor model of the CFQ is the most 
suitable factorial representation in a population of women with a breast disease, with 
good reliability and validity. Therefore, it seems an adequate instrument for measuring 
the frequency of everyday cognitive lapses in women with a breast disease.  
Chapter 2 also described several shortcomings in the available studies concerning 
SCF: The cross-sectional nature of many existing studies limits conclusions about causality 
and the development of SCF over time. Furthermore, the lack of baseline measurements 
problematized inferences regarding a real increase of problems with SCF after systemic 
treatment. Other shortcomings were the small patient populations, lack of control groups, 
and lack of controlling for confounding variables. In order to overcome these issues 
Chapter 4 described the results of a prospective study, with a control group and a baseline 
assessment, concerning SCF in BC patients who are treated with chemotherapy. Both 
satisfaction (with a facet from the WHOQOL-100) and frequency of complaints (with the 
CFQ-16 items) about SCF were measured before the start of chemotherapy and three 
months after ending chemotherapy. Patients with BC did not differ in the frequency of 
complaints about SCF compared to patients with a benign breast disease (BBD), but their 
satisfaction with SCF was decreased three months after ending chemotherapy. This 
decrease in the satisfaction with SCF in patients with BC was also clinically relevant. 
Furthermore, the mean scores of satisfaction with SCF stayed within the normal range of 
scores at both times of measurement (based on data from a large norm population). 
Psychological factors (especially depressive symptoms and state anxiety) predicted the 
frequency of complaints about SCF. Psychological factors, diagnosis (benign/malign), as 
well as prior counselling by a psychologist or psychiatrist predicted satisfaction with SCF. 
As far as we know, this was the first study that examined the role of prior counseling in 
emotional distress on SCF and it turned out that earlier emotional distress was an 
important predictor of SCF.   
Thus, the review showed that the severity of problems with SCF shortly increased 
directly after treatment. Our own study found that the satisfaction with SCF decreased 
three months after ending chemotherapy in BC patients. Despite the finding that the 
problems stay within the normal range, the statistically and clinically relevant decrease in 
satisfaction with SCF across time needs to be taken seriously.  
 
Objective cognitive functioning 
Chapter 5 examined the effect of chemotherapy on OCF (i.e., different cognitive domains 
and the separate neuropsychological tests) in BC patients compared to patients with a 
BBD before and three months after ending chemotherapy (and at comparable moments 
for the patients with a BBD). BC patients showed an impaired verbal memory across time 
compared to BBD patients. We found mixed results concerning executive functioning: the 
separate neuropsychological measures revealed no significant differences concerning time 
or group, but the created domain score of executive functioning showed a significant 
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interaction effect between BC and BBD patients. Earlier studies reported other affected 
domains as well, such as working memory [9], visual memory [9], visuospatial functioning 
[10], processing speed [11, 12], and attention [12]. There are also studies reporting normal 
cognitive functioning (e.g., [13-16]), or even improvements in cognitive functioning [10]. 
Furthermore, we only found a difference on the test verbal fluency in professions 
between the BC patients and BBD patients in the percentage of patients who experienced 
a decrease or an improvement on any neuropsychological measure. The difference in 
verbal fluency is found in some earlier research as well [11, 17, 18], and is in accordance 
with clinical practice in which BC patients who received chemotherapy often complain of 
having problems with finding the correct words. In addition, a Reliable Change Index with 
a correction for practice effects [19] was used to identify individuals with a significant 
change over time in patient with BC or a BBD. We did not find differences socio-
demographical and psychological factors between patients who showed a decrease on 
three or more neuropsychological measures and patients with no decrease, or a decrease 
on one or two neuropsychological measures.  
The aim of Chapter 6 was to examine the course of OCF up to one year after ending 
chemotherapy in BC patients compared to BBD patients as well as to examine the 
existence of different longitudinal trajectories within this sample of BC patients. Verbal 
memory was decreased in BC patients one year after treatment while it stayed stable in 
patients with a BBD. Three longitudinal development classes were found within the 
patients with BC: ‘consistently high cognitive functioning’, ‘consistently average cognitive 
functioning’, and ‘consistently low cognitive functioning’. BC patients in this last group 
were significantly older, less educated, and less often had paid work (or had paid work in 
the past and are with retirement at this moment). The possible vulnerability of older 
patients with less cognitive reserve is shown in earlier research [11, 20]. 
Thus, concerning OCF we can conclude that verbal memory was affected three 
months and one year after ending chemotherapy in patients with BC compared to patients 
with a BBD. Executive functioning (at the domain level) was affected three months after 
ending chemotherapy in BC patients while patients with a BBD showed a small increase 
across time. Furthermore, we can distinguish three longitudinal developmental classes 
within the patient with BC. It needs to be further examined if the patients in the 
‘consistently low cognitive functioning’ group are the individuals who are vulnerable for 
the adverse effects of cancer treatment.   
 
Relationship between subjective and objective cognitive functioning 
In Chapter 2 and Chapter 5 of this thesis, the relationship between SCF and OCF was 
examined. Strong evidence was found in Chapter 2 (systematic review) for a lack of a 
relationship. There are a number of possible explanations for the absence of this 
relationship. First, the neuropsychological tests may be insufficiently sensitive to detect 
mild problems with OCF in patients treated for cancer, because these tests are routinely 
used in groups of patients with degenerative decline in cognitive functioning (e.g., 
Alzheimer) or other brain injuries [5, 21]. In addition, the goal of neuropsychological 
assessments is to obtain participants’ best performance, thus environmental factors which 
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are known to reduce cognitive functioning are minimized during the assessment [22]. It is 
questionable if this specific test-situation provides relevant information about the 
performance in everyday life and is able to detect subtle cognitive impairments [5, 23, 24]. 
The discrepancy in the time frame could be a second explanation: objective tests evaluate 
performance at a point in time, whereas self-report encompasses assessment of 
performance over a broader period (e.g., ‘the last two weeks’) [5]. Third, increased 
knowledge about the relationship between chemotherapy and cognitive dysfunction could 
influence the expression of problems with SCF [25]. Fourth, subjective measures and 
neuropsychological tests do not measure the same construct. Objective performance on 
tests may not accurately reflect the problems with SCF that many women experience after 
treatment of BC. Alternatively, reported problems with SCF may indicate emotional 
distress instead of real cognitive problems and is a reaction of a patient to stressful events 
[26]. This correlation between SCF and emotional distress has also been observed in other 
populations (e.g. epilepsy patients or patients with multiple sclerosis [27, 28]. Fifth, OCF 
and SCF possibly are not measured specific enough: in the studies included in Chapter 2 
SCF was measured with a global scale [26, 29]. In line with the previous studies, no 
correlations were found in Chapter 5 between OCF and the global measure of the 
frequency of problems with SCF (measured with the CFQ). However, we did find some 
small to moderate correlations between specific neuropsychological tests (Rey recall [30], 
Stroop [31], Trail Making Test B [32], D2-test [33], Fepsy tapping dominant [34]) and 
specific domains of SCF (Social recklessness). It seemed that there might be a small to 
moderate relationship between OCF and SCF, when SCF is measured with more specific 
outcome measures. The assessment of specific problems with SCF seems to be fruitful in 
other patient populations as well (e.g., in predicting preclinical Alzheimer’s disease [35]). 
 
Impact of cognitive functioning on quality of life 
To better understand the relative impact of cognitive functioning on survivors’ well-being, 
the aim of Chapter 7 was to assess the unique contribution of cognitive functioning (SCF 
and OCF) to patients’ QoL. Compared to BBD patients, Overall QoL and General Health, 
and the Physical Health domain are affected in BC patients one year after ending 
chemotherapy. Overall, cognitive functioning (SCF and OCF) did not add significant 
variance to the predictive model for QoL (when sociodemographical, medical, and 
psychological variables were taken into account). Our results, in combination with results 
from earlier research, are inconsistent with regard to the impact of cognitive functioning 
on QoL [36, 37]. However, evidence exists about the role of neuropsychological measures 
on aspects related to QoL, i.e. aspects of daily living, such as affected productivity at home 
and at work, problems with returning to work, and affected community integration (e.g., 
[36, 38-42]. In addition, in clinical practice BC patients continue to report to be bothered 









Considerations with regard to the study design 
Cognitive functioning and patient-reported outcomes 
An important strength of this thesis is that it provides insight in the chemobrain in patients 
with BC by examining both SCF and OCF. An additional strength of this thesis is that both 
the frequency of complaints about SCF and satisfaction with SCF were measured. This is 
unique and delivered interesting findings.  
Furthermore, this thesis used a broad neuropsychological assessment as opposed to 
quick screening tests (such as the Mini-Mental State Examination [43]). The test selection 
of this thesis was based on the psychometric properties of the tests and on earlier 
research (e.g., [44, 45]) which enabled the comparison of results. The division of these 
tests in the cognitive domains was based on recommendations [46], experience in clinical 
practice, and earlier research. However, we need to stress that the selected 
neuropsychological tests and the division of these tests into different domains are 
heterogeneous in the available literature. Another division of the neuropsychological tests 
may deliver some other results. In 2011, the ICCTF published their recommendations 
concerning the selection of neuropsychological tests and cognitive domains [7]. They 
recommend using neuropsychological measures that assess cognitive functioning from the 
following cognitive domains which are related to a frontal sub-cortical profile: learning 
and memory, processing speed and executive functioning. The broad neuropsychological 
assessment in this thesis covers these aspects and included other domains as well.  
This thesis did not only focus on measures of cognitive functioning (SCF and OCF); 
other patient-reported outcomes were also taken into account. Besides the 
demographical and clinical characteristics, these patient-reported outcomes provide a 
more complete picture of the patient. In addition, because of the associations between 
anxiety, depression, fatigue and stress with cognitive functioning (SCF and OCF) [24], these 
psychological variables are important confounders for the effects of chemotherapy on 
cognitive functioning. Moreover, especially depressive symptoms and state anxiety are 
predictors of problems with SCF.  
  
Prospective design and inclusion of a control group 
The prospective design of this study included a baseline measurement of cognitive 
functioning, which made it possible to evaluate cognitive functioning of BC patients after 
surgery, but prior to the start of chemotherapy. However, baseline scores may be 
confounded by symptoms of emotional distress (such as anxiety/depressive symptoms) 
due to the diagnosis of BC [29].  
Because of the inclusion of a control group in this study, we were able to examine 
the role of psychological distress on cognitive functioning at baseline in both groups. 
Psychological variables on which the groups differed significantly at baseline were used as 
covariates in the analyses. The patients in the control group of this study were BBD 
patients, rather than a healthy control group. We have chosen for BBD patients because 
they also experienced the emotional and cognitive toll of waiting for the diagnosis that 
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may have been cancer. In addition, a subgroup of the BBD’s experience stress over and 
over again because of the follow-up measurements for monitoring the abnormality in the 
breast [47]. Furthermore, besides the possible effect of psychological distress on cognitive 
functioning, it is hypothesized that cognitive functioning measured at baseline also can be 
affected by the anesthesia which was necessary for the surgery, also known as post-
operative cognitive dysfunctioning (POCD) [48]. This possible effect of POCD was 
examined in Chapter 5 by comparing BC patients scheduled for adjuvant chemotherapy 
(after the surgery) with BC patients scheduled for neo-adjuvant chemotherapy (before the 
surgery). We did not find significant differences on the neuropsychological measures at 
baseline.  
In sum, the timing of the baseline measurement seemed not to be of influence on 
OCF and because of the comparisons with the control group at baseline, we were able to 
control for the influence of psychological variables on cognitive functioning. 
 
Considerations concerning study procedure 
Participants 
Because this study was very burdensome for the patient as well as the physician or the 
nurse practitioner who provided the first information about this study to the patient, 
there was a potential loss of eligible patients. We do not know if these samples of BC and 
BBD patients are representative for the whole BC and BBD populations. A possibility is that 
more patients who actually do experience complaints about SCF and/or OCF are more 
interested in participating in this study. This can lead to an overestimation of the results. 
On the other hand, some reasons for not participating in the study (10.8% refused to 
participate after they initially consented to participate) were that the study was too 
burdensome or that the study subject was too confronting, which can lead to an 
underestimation of the problems observed in the current studies.  
Patients included in this study knew that the objective of this study was to examine 
problems with cognitive functioning after chemotherapy. As a researcher I always 
emphasized that we do not know if there are effects and that this is the reason for this 
study. Despite this effort, participants may have been predisposed to pre-existing 
knowledge about chemobrain [49]. This may result in an overestimation of the problems 
observed in the current studies.  
The studies in this thesis had a relatively low drop-out rate (3.7% at Time 2; 3.8% at 
Time 3). We did, however, notice that the loss to follow-up was not completely random, 
as more patients with a BBD than a BC diagnosis dropped out during the study. This may 
be explained by the fact that these patients do not have to worry about the side effects of 
any treatment. Furthermore, patients who dropped out at Time 3 scored significantly 
lower on visual memory at baseline and had a lower educational level. 
 
Procedure of neuropsychological assessment 
In the current study patients were tested at home or in the participating hospitals. 
Secondary analyses showed no differences in the performance on neuropsychological 
tests between patients tested at home and patients tested in the hospital. Thus, it seemed 
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that the location of the neuropsychological assessments did not influence the 
performance on these tasks. 
Due to the burdensome of the study for the patients and due to insufficient 
resources to examine the neuropsychological functions of all participating patients and 
because the main interest of this study was cognitive functioning and QoL after one year, 
not all participants were invited for a neuropsychological assessment at Time 2. However, 
all patients received the questionnaires concerning the psychological variables and QoL at 
Time 2. The omission of the neuropsychological assessment at Time 2 happened 
chronologically, so it is unlikely that there is a bias concerning the patients who 
participated in all three measurement moments versus the patients who participated at 
Times 1 and 3.  
 
Considerations regarding the analyses  
Analyses with neuropsychological measures 
In this thesis, standardized scores of the neuropsychological assessments based on the 
mean and standard deviation of included control group (BBD patients), were used in the 
analyses. These standardized scores, instead of raw neuropsychological scores (with 
different ranges in the scoring), were chosen because these scores were summed up to 
constitute cognitive domain scores.  
In Chapter 5 the analyses concerning OCF were done on cognitive domains as well as 
on each neuropsychological test from the significant cognitive domains in order to present 
the findings as completely as possible. In the other studies, domain scores of 
neuropsychological functioning were used in order to limit the number of analyses (and 
reduce the chance of a Type 1 error and in order to keep the results interpretable.  
In the existing literature, the definitions of problems with OCD are inconsistent 
across studies. Impairment is defined as one, 1.5 and two standard deviation below the 
mean on one to four tests. Furthermore, a z-score more than one standard deviation 




 percentile are other definitions used 
[29]. These different definitions of cognitive impairment in combination with different 
comparison groups leads to different prevalence rates, as clearly demonstrated by 
Schilder et al. [50]. We have chosen for a definition of one standard deviation below the 
mean on a test and patients were classified according to the number of tests on which 
they significantly decreased (no decrease, decrease on one, two or ≥ three tests). Due to a 
lack of consensus about the definition in the literature, we have chosen for this sensitive 
definition to be able to generate indications which neuropsychological performance is 
affected in patients with BC. However, even with this sensitive definition, only the 
neuropsychological test of verbal fluency for professions turned out to be significant 
different in de BC group, compared to the BBD group. 
 
Considerations with regard to the sample size 
Efforts have been taken to increase the number of participants in this study by including 
more hospitals. The sample size of this study is comparable to Jim et al. [51], or even 
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larger than other studies in this field smaller (e.g., [9, 12, 44, 52-55]). The ambition was to 
include more patients in this study to preserve statistical power.  
A number of additional efforts have been taken to preserve statistical power. For 
instance, the factor analyses and the regression analyses were done on the sample of 
patients with a breast problem, instead of the BC patients only. In the regression analyses, 
diagnosis (BC or BBD) was always included to examine this influence on the dependent 
variable. Furthermore, preliminary (univariate) analyses were done to reduce the number 
of independent variables in the final regression analyses. A limitation of this procedure is 
that this may result in a sample-specific selection of variables in the multivariate 
regression analyses.  
 
The clinical relevance of significant findings 
Besides the statistically significant findings of the studies in this thesis, it is important to 
examine the clinically relevant effects. Concerning the significant decrease in satisfaction 
with SCF in BC patients, we were able to conclude that this decrease also was of clinical 
relevance, based on the defined minimal clinical important difference across time in 
satisfaction with SCF [56]. With regard to the significant results concerning OCF, the 
clinical relevance of these findings were not immediately obvious because values of the 
minimal clinical important differences are unknown.  
In addition, besides the comparisons between BC and BBD patients, the scores of the 
BC patients concerning SCF were also compared with a healthy control group, which 
provided more insight in the level of problems with SCF. It turned out that the scores of 
SCF stay within the normal range (based on the healthy control groups).  
 
 
Implications for further research  
 
Most patients who receive chemotherapy typically receive other treatment modalities as 
well. Besides the examination of the effects of chemotherapy on cognitive functioning, 
this thesis preliminary examined the effects of surgery (POCD) on cognitive functioning. 
Furthermore, it is known that other treatment modalities, such as radiation therapy 
and/or endocrine treatment can affect cognitive functioning as well. To unravel the 
separate effects of forms and dosages of (neo-) adjuvant chemotherapy, and other 
(adjuvant) treatment options for BC, larger prospective neuropsychological studies are 
needed in patients who are qualified to receive chemotherapy only (or a specific form and 
dosage of chemotherapy), and patients who are qualified to receive other therapies only 
(e.g., hormone therapy). However, this is not feasible in clinical practice, because most 
patients receive a combination of treatment modalities nowadays.  
Furthermore, a longer follow-up period would be interesting to examine the duration 
of the cognitive impairment following breast cancer treatment (verbal memory). Most 
longitudinal research is focusing on the acute phase after chemotherapy up to one or two 
years post-treatment. There are suggestions that the effects of chemotherapy on 
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cognitive functioning diminish over time. However, research has also provided evidence of 
long-term effects up to 20 years after treatment [57]. 
In addition, the exclusion criteria of the studies in this thesis were based on 
conditions that may increase the vulnerability to post-treatment cognitive decline, such as 
a neurological disorder or alcohol abuse. Therefore, patients who were probably at the 
highest risk for the most severe changes in cognitive performance may have been 
excluded from this study. As a consequence, the problems concerning cognitive 
functioning (OCF and/or SCF) may be an underestimation of the impact of chemotherapy 
on cognitive functioning. Additional research within samples of patients with BC in 
combination with other characteristics (e.g., alcohol abuse) is needed to address these 
questions [58].  
Additionally, it would be interesting to gather information about the influence of 
other side effects of chemotherapy and other treatment modalities (e.g., low hemoglobin 
levels [59, 60], pain in the arm because of the lymph node dissection, problems with for 
example the porth-o-cath, admission to the hospital because of side effects) on SCF and 
OCF. The impact of these side effects on cognitive functioning and QoL are understudied. 
In this thesis, the predictors of SCF are examined. The predictors of OCF also need to 
be examined. OCF is affected by an interplay of multiple factors. It is essential to 
establishing these factors in order to identify women with BC at higher risk for cognitive 
problems. Moreover, the potential relevance of psychological mechanisms, such as stress 
and coping style, in cancer patients’ experience of problems with OCF needs to be 
examined [61]. This can have significant implications for patient care, as changes in 
psychological factors, such as coping style may be achieved with a variety of interventions 
that psychologists and other behavioral health care providers can use for people living 
with cancer.  
Furthermore, different potential mechanisms for chemotherapy-induced cognitive 
dysfunction are described in the literature [62-64]: (i) the ability of certain cytotoxic 
agents of chemotherapy to cross the blood brain barrier, (ii) oxidative stress and DNA 
damage, (iii) the effects on cerebrovascular integrity due to cardio-toxicity, (iv) 
chemotherapy-induced brain alterations, (v) and an increased level of pro-inflammatory 
cytokines. The last years a number of important findings have been done (e.g., [65-68]), 
but more insight in these potential mechanisms is needed to better understand the 
chemobrain. 
In addition, it needs to be examined in a larger sample size if the patients with a higher 
age, lower educational level and the lack of having paid work (the latent class found in 
Chapter 6) are most vulnerable for the development of problems with OCF after 
chemotherapy for BC.  
Finally, it would be useful to have access to nationwide norms of the different 
neuropsychological tests based on the healthy population. Until now, studies used norm 
data based on their own generated control group or the reference data provided in the 
testing manual of the neuropsychological tests (in which a lot of different reference 
groups are used). Nationwide reference data will be very useful in the detection of 
problems with OCF in patients with BC.  
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Implications for clinical practice  
 
Although more research is warranted to unravel the chemobrain, several implications for 
clinical practice can be provided based on this thesis.  
 
Evidence-based information provision 
The information generated in this thesis about the existence, prevalence and course of 
problems with OCF and SCF facilitate health care professionals to provide evidence-based 
information to their patients. This information can be provided to all the patients with BC 
when they are informed about the other side-effects of chemotherapy as well (by their 
physician or their nurse practitioner). Patients can benefit from this knowledge in 
preparing themselves for the potential impact of BC treatment on cognitive impairment.  
More specifically, patients can be informed that with regard to side-effects of 
chemotherapy some patients experience problems with their cognitive functioning during 
and after treatment. The severity of problems with SCF can shortly increase after 
treatment and the satisfaction with SCF can decrease after ending chemotherapy. These 
changes are not disproportionate and for most patients the problems with SCF stay within 
the normal range. With regard to OCF patients can be informed about the possibility to 
experience problems concerning verbal memory after treatment. These problems are 
most severe three months after ending chemotherapy and will come almost at their 
baseline functioning one year after treatment. Furthermore, patients can be informed 
about the role of psychological factors (especially depressive symptoms and state anxiety) 
in the experience of SCF.  
 
Screening for cognitive dysfunction? 
As mentioned before, it needs to be considered if the standard neuropsychological 
assessments are sensitive enough to measure subtle dysfunctioning concerning OCF. This 
implicates that the implementation of neuropsychological assessments on a large scale 
does not add significant clarifications for the cause and nature of the problems with OCF 
in (ex-)BC patients and would be cost ineffective. This screening for OCF will not add 
significant value to the treatment plan of individual BC patients. Cognitive complaints 
alone do not justify neuropsychological assessments. It should only be used selectively in 
those patients in whom a suspicion exists about a decline in OCF based on the anamnestic 
and hetero-anamnestic details and other well known risk factors besides the BC (e.g., age, 
alcohol abuse).  
Earlier research and this thesis found weak associations between OCF and SCF. 
However, research has shown that SCF can predict OCF at a later stage [69]. However, this 
research was done in older adults instead of in a population with a disease, in which the 
mechanisms may be different. Therefore, the predictive value of SCF on future OCF 
functioning in BC patients needs to be further examined. Consequently, knowledge about 
the predictive value of SCF for OCF is too unstable to fully implement a screening tool for 
problems with SCF in BC patients in clinical practice in order to identify the patients who 
are at risk of developing problems with OCF. Nevertheless, on an individual basis it can be 
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worthwhile to measure the SCF of a BC patient, eventually combined with a proxy report, 
when there are indications that the BC patient suffers from the problems with SCF.  
Thus, screening for OCF and/or SCF on a large scale in clinical practice is not 
recommended based on the findings of this thesis and earlier research. 
 
Interventions in clinical practice 
A general intervention 
OCF and SCF can have an impact on aspects which are related to QoL and, therefore, 
attention to problems with OCF and SCF within the health care of BC patients is 
warranted. However, the impact of chemotherapy on OCF and SCF in patients with BC is 
limited and therefore, interventions should be time- and cost-efficiently. Therefore, 
participating in a revalidation program such as ‘Herstel en Balans’, which is already 
currently provided in a number of hospitals and revalidation centers in the Netherlands, is 
recommended. This revalidation program combined interventions for the psychosocial 
and physical problems after cancer(-treatment). Until more evidence is derived about the 
effectiveness of specific interventions for problems with OCF/SCF within patients with BC, 
interventions with broad neuropsychological, psychological, and physical elements (such 
as ‘Herstel en Balans’) offer the best option for BC patients with problems with OCF.  
  
Interventions for persisting problems with subjective and/or objective cognitive 
functioning 
When problems with SCF/OCF persist in patients after they have followed ‘Herstel en 
Balans’, interventions on an individual basis are recommended. Nowadays, research is 
focusing on specific, behavioral interventions, pharmacological interventions, and physical 
activity interventions for patients with cancer and problems with OCF/SCF.  
There is evidence for an association between problems with SCF and anxiety, 
depression, psychological distress, and fatigue. Interventions that have the potential to 
improve this emotional distress may be partially valuable since cognitive functioning and 
emotional distress seem to be related. Cognitive behavioral therapy can also be a useful 
intervention for problems with SCF, as demonstrated in patients with a chronic fatigue 
syndrome or multiple sclerosis. Their level of fatigue/depression and their problems with 
SCF decreased after treatment with cognitive behavioral therapy [70, 71].  
Interventions for individuals with persisting problems with SCF/OCF should rely on 
the basics, such as stress-management or psycho-education about possible problems with 
cognitive functioning (OCF and/or SCF) during and after BC treatment with chemotherapy 
[72]. Cognitive rehabilitation, in which psycho-education is an important element, aims to 
treat or to teach to manage the cognitive deficits. This can be a useful tool for BC patients. 
Strategy trainings are used to teach patients to apply strategies to cope with their 
cognitive problems (e.g., preventing or minimizing distractions, anticipating and planning, 
pacing of cognitive activities, basic cognitive compensation strategies, and/or use of 
mnemonics) [73]. Furthermore, retraining of specific cognitive skills can be attempted by 
means of having patients frequently perform exercises [73]. A number of studies have 
been done to examine the efficacy of neuropsychological training programs/rehabilitation 
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programs in cancer patients. Ferguson et al. found an intervention effect for verbal 
memory [74].  
Although pharmacological interventions are available for cognitive problems (see for 
overviews [73, 75, 76]), this treatment option is not recommended because the 
chemotherapy-induced cognitive problems are mild and only appear in a subgroup which 
is not yet clear enough to specify. This would lead to an over-treatment of a patient 
population that already receives a lot of pharmacological interventions.   
Thus, until more evidence is gathered about the effectiveness and the time- and cost 
efficiency of specific rehabilitation programs as well as cognitive behavioral therapy, 
patients are recommend to participate in the broad revalidation program ‘Herstel en 
Balans’. In individuals with persisting problems with SCF/OCF the presence of 
psychological distress, such as depressive symptoms or state anxiety, must be examined. 
Interventions aiming at treatment of psychological distress can have a beneficial effect on 
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Subjective cognitive functioning 
Een aanzienlijk deel van de patiënten ervaart subjectieve cognitieve klachten na de 
behandeling van borstkanker. Echter, slechts bij een klein deel van deze patiënten worden 
cognitieve stoornissen geobjectiveerd. Factoren zoals angst, depressie en vermoeidheid 
spelen een belangrijke rol in het subjectief cognitief functioneren. Meer longitudinaal 
onderzoek met een grote patiëntengroep, controlegroep, gevalideerd test-
instrumentarium en normering is nodig om de incidentie en aard van cognitieve 
achteruitgang, zowel objectief als subjectief na chemotherapie in beeld te brengen. 
Aandacht voor cognitieve klachten en stoornissen na behandeling van kanker is een 
belangrijk aandachtspunt tijdens de revalidatie. Psycho-educatie, dagstructurering, 










De casusbeschrijving “Cognitieve Problemen na radiotherapie en chemotherapie; niet 
altijd verwacht” van collegae A. Visser-Meily en C. van Heugten in het Tijdschrift voor 
Neuropsychologie 2009 nr. 3 [1], inspireerde tot het schrijven van een theoretisch artikel 
over het cognitief functioneren van borstkankerpatiënten na behandeling met chirurgie en 
adjuvante (aanvullende) therapie in de vorm van chemotherapie en radiotherapie.  
In de betreffende casusbeschrijving heeft patiënte behandeling van een 
cervixcarcinoom ondergaan met chemotherapie en lokale radiotherapie. Later krijgt zij 
naast lichamelijke problemen ook klachten van vermoeidheid en cognitie, vooral ten 
aanzien van het concentratievermogen, het denktempo en de woordvinding. Vanuit 
beeldvormend onderzoek blijkt er echter geen sprake te zijn van hersenmetastasen. In de 
theoretische discussie wordt vervolgens wel relatief veel aandacht besteed aan de 
gevolgen voor het cognitief functioneren van een hersentumor of hersenmetastasen en 
de behandeling daarvan, terwijl daar bij patiënte toch geen sprake van is. De collegae 
lijken verbaasd, maar bij patiënten met kanker, die zoals hier adjuvante chemotherapie 
hebben gehad, komen de genoemde cognitieve problemen veel voor. In de beschrijving 
van de gevolgen voor het cognitief functioneren van behandeling van kanker met 
chemotherapie missen wij een aantal relevante aspecten.  
Veranderingen in het cognitief functioneren zijn het meest onderzocht bij 
borstkankerpatiënten, maar zijn ook geconstateerd bij patiënten met andere vormen van 
kanker die zich niet in het centraal zenuwstelsel (CZS) bevinden, zoals longkanker en 
lymfeklierkanker [2]. Hieronder geven wij een overzicht van de huidige stand van zaken op 
dit onderzoeksgebied met betrekking tot borstkanker en doen wij enkele tentatieve 
uitspraken over de benadering van de cognitieve problematiek die borstkankerpatiënten 





Borstkanker is een steeds meer voorkomende ziekte in de Verenigde Staten en West-
Europa. De verwachting is dat over enkele jaren één op de zeven vrouwen in Nederland 
borstkanker zal ontwikkelen [3]. De overlevingskans na kanker is door vroege diagnostiek 
en verbetering van de behandeling sterk toegenomen. Steeds meer vrouwen leven met de 
lange termijneffecten van kanker, waardoor de kwaliteit van leven sterk in de 
belangstelling is komen te staan. In de afgelopen tien jaar is er dan ook in toenemende 
mate onderzoek verricht naar de effecten van chemotherapie op bijvoorbeeld angst, 
depressie, moeheid en haarverlies [4]. Naast deze lichamelijke en psychische gevolgen van 
chemotherapie geven meerdere vrouwen aan zich ook zorgen te maken over de 
consequenties voor het cognitief functioneren van de chemotherapie tijdens en na de 
behandeling, beter bekend als het ‘chemobrein’. Naar aanleiding van deze zorgen is er 
veel onderzoek verricht naar cognitieve stoornissen en klachten na behandeling voor 




september 2008 krijgt vrijwel iedere borstkankerpatiënt na chirurgie adjuvante 
chemotherapie [5]. De relevantie van deze onderzoeken naar de consequenties van 
chemotherapie is dus erg groot. 
 
 
Cognitieve stoornissen en subjectieve cognitieve klachten 
 
Allereerst is het belangrijk om onderscheid te maken tussen cognitieve stoornissen en 
subjectieve cognitieve klachten. Cognitieve stoornissen zijn te objectiveren door middel 
van neuropsychologisch onderzoek, terwijl subjectieve cognitieve klachten refereren naar 
de door de patiënt ervaren cognitieve problemen, en hun tevredenheid met hun cognitief 
functioneren in het dagelijks leven. Studies naar het cognitief functioneren bij 
borstkankerpatiënten die naast cognitieve stoornissen ook subjectieve klachten hebben 
onderzocht, vermelden dat er geen correlaties zijn tussen de objectieve afwijkingen in het 
neuropsychologisch onderzoek en de zelfrapportage van cognitieve klachten [6, 7]. Er zou 
wel een verband aanwezig zijn tussen subjectieve cognitieve klachten enerzijds en angst, 
depressie, vermoeidheid en slechtere gezondheidstoestand anderzijds [8, 9].  
 
 
Cognitieve stoornissen en subjectieve cognitieve klachten na behandeling 
voor borstkanker 
 
Bevindingen vanuit studies naar objectief cognitief functioneren 
In het verleden werden dikwijls cross-sectionele designs gebruikt om de cognitieve 
gevolgen van kanker en de behandeling hiervan te onderzoeken. Deze cross-sectionele 
onderzoeken laten inconsistente resultaten zien in relatie tot de vraag of chemotherapie 
het brein beïnvloedt. De studie van Wieneke en Dienst was de eerste studie waarbij 
neuropsychologische testen werden afgenomen bij borstkankerpatiënten (N = 28) met als 
doel het effect van chemotherapie op het cognitief functioneren te onderzoeken [10]. Uit 
hun resultaten bleek dat 75% van de patiënten een stoornis had op minimaal één van de 
testen. Ook andere onderzoekers bevestigden opnieuw dat chemotherapie een negatieve 
invloed heeft op cognitief functioneren [8, 11, 12]. Verder zou een hogere dosis 
chemotherapie tot meer cognitieve stoornissen leiden dan een lagere dosis 
chemotherapie [6, 11]. De aard van de cognitieve stoornissen kent een breed spectrum, 
inclusief aandacht, snelheid van informatieverwerking, mentale flexibiliteit, werk-
geheugen, korte en lange termijn geheugen, visueel geheugen, taal, visueel-ruimtelijke 
vaardigheden en motorische functies [10-13]. Er zijn echter ook recentere cross-sectionele 
onderzoeken die geen significante verschillen vinden in cognitief functioneren tussen 
patiënten die wel en niet behandeld zijn met chemotherapie [14, 15].  
Vanwege de uiteenlopende resultaten in de cross-sectionele onderzoeken zijn er in 
de afgelopen jaren verschillende prospectieve onderzoeken uitgevoerd om de relatie 
tussen chemotherapie en het brein te onderzoeken. De resultaten van deze onderzoeken 
lopen, net als bij de cross-sectionele onderzoeken, sterk uiteen. Er zijn studies die een 
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subtiele achteruitgang rapporteren in veel verschillende domeinen bij borstkanker 
patiënten na chemotherapie [16-19] maar er zijn ook prospectieve studies die geen 
achteruitgang vinden [20, 21]. De achteruitgang wordt bij deze studies op verschillende 
manieren berekend en gedefinieerd: er worden veranderingen op groepsniveau over de 
tijd bestudeerd [17, 19], er worden verschilscores tussen de twee meetmomenten 
berekend om vervolgens na te gaan of deze buiten het gecalculeerde reliable change 
interval vallen [16, 20, 21], of er wordt gebruik gemaakt van een op regressie gebaseerde 
benadering [18, 19]. Ook de periode waarover het cognitief functioneren wordt 
bestudeerd loopt uiteen van een moment tijdens de chemotherapie [21] tot een jaar na 
afronding van de chemotherapie [16-18, 20].  
Momenteel is het inzicht in de effecten van kanker en de behandeling hiervan op 
cognitief functioneren ontoereikend. Het is van belang om te onderzoeken welk profiel 
van cognitieve stoornissen naar voren komt en na te gaan wat de kenmerken zijn van de 
patiënten die cognitieve achteruitgang laten zien op neuropsychologische testen. 
 
Bevindingen vanuit studies naar subjectief cognitief functioneren 
Naast deze onderzoeken naar cognitieve stoornissen, zijn er ook studies verricht waarbij 
de effecten van behandeling op het subjectief cognitief functioneren zijn onderzocht. De 
prevalentie van subjectieve cognitieve klachten varieert sterk (21-90%), wat mogelijk een 
gevolg is van de verschillende gehanteerde definities, vragenlijsten en afkappunten [9]. 
Subjectieve cognitieve klachten komen voor bij borstkankerpatiënten, maar het is niet 
duidelijk of zij deze vaker ervaren vergeleken met de algemene populatie [22]. Er is geen 
effect van chemotherapie op de aanwezigheid van subjectieve cognitieve klachten; zowel 
vóór als na de behandeling worden deze klachten even vaak gerapporteerd. De ernst van 
de klachten neemt echter wel toe kort na de therapie [7, 23]. Naar het verdere verloop is 
tot nu toe te weinig gedegen onderzoek gedaan. Momenteel is het nog onduidelijk of de 
subjectieve cognitieve klachten vóór de behandeling gerelateerd kunnen zijn aan de stress 
die gepaard gaat met de diagnose borstkanker, of dat subjectieve cognitieve klachten een 
algemeen symptoom vormen dat in de gehele populatie voorkomt en dus niet specifiek is 
voor borstkankerpatiënten [9].  
 
Toekomstig onderzoek 
Methodologische beperkingen en heterogeniteit van de verschillende bestaande studies 
maken het moeilijk om definitieve conclusies te trekken. Een cross-sectioneel design 
maakt het onmogelijk om uitspraken te doen over de causaliteit van cognitieve 
stoornissen en subjectieve cognitieve klachten. Eveneens maakt het ontbreken van een 
baselinemeting het moeilijk om te beoordelen of de objectieve of subjectieve cognitieve 
klachten werkelijk toenemen na de behandeling van borstkanker. Dit is noodzakelijk om te 
weten omdat bekend is dat al voor de start van de adjuvante therapie cognitieve 
stoornissen aanwezig kunnen zijn [23, 24]. Andere veel voorkomende beperkingen in 
bestaande studies zijn de kleine patiëntenpopulaties, de vele verschillende soorten van 
adjuvante therapie en de gebruikte dosis, het gemis aan controlegroepen en de 




relatie. Er bestaat een grote diversiteit in de hantering van normen, de meetmomenten en 
de statistische analyse. Daarnaast kennen bestaande studies veel heterogeniteit in het 
testinstrumentarium dat gebruikt wordt om een bepaald domein van het cognitief 
functioneren in kaart te brengen. De inconsistente hantering van de definities die gebruikt 
worden om cognitief disfunctioneren te definiëren maakt het ook moeilijk om deze 
studies te evalueren. 
In 2006 is een internationale workshop gehouden over onderzoek naar cognitieve 
stoornissen na chemotherapie, waarbij onder andere werd gepleit voor het opzetten van 
prospectieve longitudinale studies om de incidentie van cognitieve achteruitgang na 
chemotherapie beter te kwantificeren [25]. Daarbij werd het belangrijk geacht dat het 
onderzoek een baselinemeting heeft, dat er grotere onderzoeksgroepen dan tot nu in 
onderzoek betrokken worden en dat er een controlegroep betrokken wordt. Noodzakelijk 
hierbij is dat er gevalideerde instrumenten en afkappunten gebruikt worden om 
objectieve en subjectieve cognitieve klachten te meten. Relevant is daarbij ook dat de 
gebruikte definitie voor cognitieve achteruitgang duidelijk vermeld wordt, omdat hier 
namelijk geen ‘gouden standaard’ voor is. In de beschrijving is het belangrijk om de 
volgende informatie te geven: het percentage van patiënten dat één of twee 
standaarddeviaties achteruit is gegaan tussen de baselinemeting en de vervolgmeting, het 
aantal testen waarin achteruitgang is opgetreden, het aantal cognitieve domeinen dat 
betrokken is bij de achteruitgang en het percentage van patiënten dat juist verbetert in de 
loop van de tijd [26]. Vanwege de relatie met subjectieve cognitieve klachten zijn angst, 
depressieve symptomen, vermoeidheid en kwaliteit van leven verder belangrijke factoren 
die meegenomen moeten worden in onderzoek.  
Momenteel wordt er verder onderzoek gedaan aan de Universiteit van Tilburg. Het 
primaire doel van dit onderzoek is om die vrouwen met borstkanker te identificeren die 
een jaar na chemotherapie nog uitgesproken subjectieve en/of objectieve cognitieve 
stoornissen ervaren, om vervolgens de factoren te vinden die tot het cognitieve 
disfunctioneren bijdragen en tenslotte te onderzoeken hoe groot de invloed van cognitief 
disfunctioneren is op de kwaliteit van leven van deze vrouwen. In samenwerking met het 
Center of Research on Psychology in Somatic Diseases van de Universiteit van Tilburg 
wordt in het TweeSteden ziekenhuis in Tilburg specifiek onderzocht of het niveau van 
subjectieve cognitieve klachten tot een jaar na de behandeling van borstkanker te 
voorspellen is vanuit een stress-kwetsbaarheidsmodel en of hiervoor andere 
risicofactoren te identificeren zijn. 
 
 
Mechanismen die een rol kunnen spelen in cognitief disfunctioneren na 
chemotherapie  
 
In een review van Vardy en Tannock wordt een overzicht gegeven van mogelijke 
mechanismen die een rol kunnen spelen in de ontwikkeling van cognitieve stoornissen bij 
chemotherapie [2]. Vardy en Tannock stellen dat de etiologie van cognitieve stoornissen 
nog onbekend is, maar waarschijnlijk multifactorieel bepaald is [2]. Mogelijke 
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mechanismen betreffen directe neurotoxische effecten zoals schade aan neuronen of 
omringende cellen en veranderingen in niveaus van neurotransmitters. Ondanks dat het 
brein een beschermingmechanisme heeft via de bloed-hersenbarrière, blijkt dat 
chemotherapeutica toch toegang krijgen tot de hersenen. Daarnaast zijn er indirecte 
effecten zoals hormonale veranderingen, ontregeling van het immuunsysteem, 
bloedstolsels in kleine vaten van het CZS en anemie.  
Beeldvormend onderzoek toont aan dat bij ex-kankerpatiënten die behandeld zijn 
met chemotherapie een afname van grijze en witte stof optreedt. Ook blijkt dat patiënten 
na behandeling met chemotherapie, bij de uitvoering van geheugentaken een verhoogde 
activering hebben in andere hersengebieden (bijvoorbeeld het cingulaire gebied, de gyrus 
frontalis inferior van de prefrontale cortex en cerebellum posterior) dan gezonde 
controleproefpersonen. Het brein werkt blijkbaar anders tijdens en na chemotherapie, 
maar de relatie met cognitieve stoornissen zoals geobjectiveerd in neuropsychologisch 
onderzoek is onduidelijk. Ook in neurofysiologische studies, waarin veranderingen in 
Event Related Potential en EEG’s zijn aangetoond, worden geen correlaties gevonden 
tussen resultaten in neuropsychologisch onderzoek en neurofysiologische maten. 
Veel kankerpatiënten krijgen een gecombineerde behandeling bestaande uit 
chirurgie (met variaties in uitgebreidheid en anesthesie), radiotherapie en 
hormoontherapie. Ook gebruiken de meeste kankerpatiënten pijnstillers en anti-emetica, 
middelen om misselijkheid en braken tijdens chemotherapie tegen te gaan. Van al deze 
middelen is nog onvoldoende bekend in hoeverre ze het cognitief functioneren nadelig 
beïnvloeden. Ook na behandeling met chirurgie en radiotherapie zonder adjuvante 
chemotherapie kunnen cognitieve stoornissen optreden [14]. Jim e.a. vonden geen 
verschillen tussen patiënten die na chirurgie behandeld werden met alleen chemo-
therapie, een combinatie van chemotherapie en radiotherapie of alleen radiotherapie 
[27]. De gevonden cognitieve stoornissen waren subtiel en lijken meer het resultaat van 
algemene effecten van kanker en de behandeling daarvan dan het resultaat van alleen 
chemotherapie [2].  
 
 
Implicaties voor interventies ten aanzien van subjectieve cognitieve 
klachten en cognitieve stoornissen 
 
Uit de voorafgaande beschouwing blijkt dat een meerderheid van de patiënten 
subjectieve cognitieve klachten rapporteert die niet objectiveerbaar zijn door middel van 
neuropsychologisch onderzoek. Hoewel het mogelijk is dat neuropsychologische testen 
niet sensitief genoeg zijn om subtiele cognitieve stoornissen in kaart te brengen valt het 
niet te ontkennen dat subjectieve cognitieve klachten in hoge mate samenhangen met 
vermoeidheid en psychologische factoren zoals angst en depressie. Dit impliceert dat het 
op grote schaal toepassen van neuropsychologische diagnostiek in de klinische praktijk 
vooralsnog weinig zou kunnen toevoegen aan het verhelderen van de oorzaak en de aard 
van het cognitief disfunctioneren bij (ex-)kankerpatiënten en zeer kostenineffectief zal 




waarde. Cognitieve klachten rechtvaardigen naar onze mening dus niet zonder meer 
neuropsychologische diagnostiek zoals Visser-Meily en van Heugten in hun casuïstiek 
stellen [1]. Uitgebreide neuropsychologische diagnostiek zou dan ook voorlopig selectief 
kunnen worden ingezet bij die patiënten bij wie op basis van de anamnestische en hetero-
anamnestische gegevens en bekende risicofactoren (zoals leeftijd, overmatig 
alcoholgebruik, familiaire belasting et cetera) een verdenking bestaat op een te 
objectiveren achteruitgang in het cognitief functioneren.  
Desondanks zijn cognitieve stoornissen en klachten zeer bepalend voor de kwaliteit 
van leven [28] en is het van belang dat er aandacht aan wordt besteed binnen het 
zorgaanbod voor de oncologische patiënt. Omdat moeheid en stemmingsproblemen vaak 
nog lange tijd na de behandeling voor kanker aanwezig zijn en een samenhang vertonen 
met subjectieve cognitieve klachten [9] zijn basisinterventies zoals psycho-educatie over 
mogelijke cognitieve problemen na behandeling voor kanker, dagstructurering, 
stressmanagement en eerste stap interventies zoals opgenomen in de recent gereviseerde 
richtlijn voor de behandeling van depressie het meest aangewezen. Hier zou het leren 
toepassen van een aantal basale cognitieve compensatiestrategieën aan toegevoegd 
kunnen worden. Dit is een vorm van zorgaanbod die prima kan plaatsvinden in de eerste 
en tweede lijn. Ook het programma Herstel en Balans zoals dat in diverse ziekenhuizen en 
revalidatiecentra wordt aangeboden, omvat een groot aantal van deze elementen [29].  
In de beschreven casus van Visser-Meily en van Heugten [1] lijken de hierboven 
beschreven aspecten van behandeling eveneens een belangrijke rol te hebben gespeeld. 
Door de aangeboden structuur ervaart patiënte minder druk en vermoeidheid en blijkbaar 
ook minder cognitieve klachten. Dit ligt in de lijn van de resultaten van een studie bij 
patiënten met het chronisch vermoeidheidssyndroom [30], waaruit bleek dat zowel het 
niveau van vermoeidheid als van subjectieve cognitieve klachten significant daalde na 
behandeling met cognitieve gedragstherapie. Het is dan ook in de casus van Visser-Meily 
en van Heugten [1] de vraag of vermoeidheid en stemming niet een prominentere rol 
hebben gespeeld in het cognitief functioneren dan aanvankelijk werd aangenomen.  
Omdat een aanzienlijk deel van deze patiënten last heeft van cognitieve klachten, 
welke een hoge correlatie hebben met angst en depressie, is het wel degelijk noodzakelijk 
dat “verwerkingsproblematiek” na een ernstige ziekte zoals kanker een centrale plek in de 
behandeling krijgt. De ziekte kanker grijpt diep in het persoonlijk leven in en raakt aan alle 
levensgebieden. Dit wil echter niet zeggen dat er aan cognitieve klachten en stoornissen 
voorbij kan worden gegaan. Het verdient dan ook zeker aanbeveling om psycho-educatie 
en het aanleren van compensatiestrategieën in een uitgebreider behandeltraject op te 
nemen. 




Een deel van de borstkankerpatiënten houdt cognitieve klachten na de behandeling van 
kanker. Het is van belang om onderscheid te maken tussen cognitieve stoornissen en 
subjectief cognitief functioneren in de praktijk. Deze klachten en/of stoornissen zijn over 
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het algemeen subtiel, maar kunnen langdurig aanwezig zijn en een negatieve invloed op 
de kwaliteit van leven uitoefenen. Verschillende mechanismen kunnen direct of indirect 
leiden tot cognitieve stoornissen door chemotherapie. De subjectieve klachten hebben 
een verband met angst, depressie en vermoeidheid. Grote longitudinale studies met een 
baselinemeting, een adequate controlegroep en een gevalideerd testinstrumentarium zijn 
noodzakelijk om de risicogroep en het profiel van cognitieve stoornissen preciezer in kaart 
te brengen. Wij onderschrijven het belang van aandacht voor de cognitieve problematiek 
in de revalidatie na behandeling voor kanker en pleiten voor het uitvoeren van 
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Chemotherapie is naast radiotherapie en chirurgie een veel gebruikte behandeling voor 
borstkanker. Het verbetert de levensverwachting van vrouwen met borstkanker 
aanzienlijk, maar het gaat ook gepaard met verschillende bijwerkingen. Onder deze 
bijwerkingen vallen onder andere de problemen met het cognitief functioneren. Aan deze 
bijwerking is de laatste jaren in toenemende mate aandacht besteed. Dit proefschrift 
beschrijft een prospectief onderzoek naar cognitief functioneren (zowel subjectief 
cognitief functioneren (SCF) als objectief cognitief functioneren (OCF)) en kwaliteit van 
leven bij vrouwen met borstkanker. Hiervoor hebben we bij vrouwen met borstkanker die 
daarvoor behandeld (gaan) worden met chemotherapie en bij vrouwen met een benigne 
afwijking aan de borst (controlegroep) op drie meetmomenten verschillende cognitieve 
functies bestudeerd en hebben we verschillende psychologische variabelen onderzocht.  
 
 
Subjectief cognitief functioneren 
 
In hoofdstuk 2 is een kritisch overzicht gegeven van de reeds gepubliceerde onderzoeken 
naar SCF bij vrouwen met borstkanker die daarvoor onder andere zijn behandeld met 
chemotherapie. Hieruit bleek dat de prevalentie van problemen met SCF aanzienlijk 
varieert. Mogelijke verklaringen hiervoor zijn de verschillende definities, vragenlijsten en 
afkappunten die gebruikt zijn om SCF te meten. Verder vonden we dat problemen met SCF 
inderdaad voorkomen bij vrouwen met borstkanker, maar het is onbekend of deze 
problemen bij hen vaker voorkomen dan in de algemene populatie. De literatuur liet geen 
verschillen zien in de prevalentie van problemen met SCF voor en na de behandeling voor 
borstkanker, wat indiceert dat er geen effect is van de behandeling op het voorkomen van 
de problemen met SCF. Ten opzichte van een baseline meting (voor de behandeling met 
systemische therapie) was er desondanks wel bewijs gevonden voor een toegenomen 
ernst van de problemen met SCF op korte termijn na de systemische behandeling. Verder 
is er in dit review een sterk bewijs voor het gebrek aan een relatie tussen SCF en OCF 
gevonden (beide globaal gemeten).  
Een andere bevinding uit hoofdstuk 2 was dat de manier waarop problemen met SCF 
gemeten is inconsistent is tussen de studies. Verschillende ad-hoc semigestructureerde 
interviews en meerdere zelfrapportage vragenlijsten zijn hiervoor gebruikt. Eén van de 
gebruikte vragenlijsten is de Cognitive Failures Questionnaire (CFQ). Omdat hiervoor 
meerdere factorstructuren bekend zijn in verschillende patiënten populaties was het doel 
van hoofdstuk 3 om de psychometrische eigenschappen van de vragenlijst bij vrouwen 
met een probleem aan de borst te onderzoeken. Geen van de bestaande modellen paste 
goed in onze sample zoals bleek uit confirmatieve factoranalyses. Uit een exploratieve 
factor analyse is gebleken dat een structuur met drie factoren (Vergeetachtigheid, 
Afwezigheid en Sociale roekeloosheid) goede psychometrische eigenschappen heeft. 
Hiermee zou de frequentie van problemen met SCF bij vrouwen met een probleem aan de 
borst goed gemeten kunnen worden.  
In hoofdstuk 2 zijn verder nog tekortkomingen van de gedane studies naar 
problemen met SCF beschreven: het cross-sectionele karakter van vele studies beperkt de 
166 Nederlandse samenvatting 
 
conclusies met betrekking tot causaliteit en de ontwikkeling van problemen met SCF over 
de tijd. Daar komt bij dat het gebrek aan een baseline meting het onmogelijk maakt om te 
beoordelen of er ook daadwerkelijk sprake is van een toename in de problemen met SCF 
na behandeling met systemische behandeling. Andere tekortkomingen omvatten onder 
andere de kleine groepen waarin het onderzoek is gedaan, het gebrek aan een controle 
groep en het gebrek aan controle voor variabelen die mogelijk ook een invloed hebben op 
de relatie (confounding variabelen). Daarom beschreef hoofdstuk 4 van dit proefschrift 
een prospectieve studie met een controle groep en een meting op baseline naar de 
problemen met SCF bij vrouwen met borstkanker die daarvoor behandeld (gaan) worden 
met chemotherapie. Hierbij was zowel de tevredenheid met het SCF als de frequentie van 
de problemen met SCF gemeten voor de start met de chemotherapie en drie maanden na 
de laatste kuur. Deze analyses zijn op twee manieren gedaan: de ene keer zonder rekening 
te houden met verstorende variabelen en vervolgens nog een keer met daarin 
verschillende variabelen als covariaten. Naast de geïncludeerde controlegroep hebben we 
de problemen met SCF ook nog kunnen vergelijken met een normpopulatie. Vrouwen met 
borstkanker verschilden niet in de frequentie van de problemen met SCF vergeleken met 
vrouwen met een benigne afwijking aan de borst, maar de tevredenheid met het SCF was 
wel afgenomen drie maanden na de laatste chemotherapie. Deze daling in de 
tevredenheid met SCF is ook klinisch relevant bevonden. Op beide meetmomenten bleven 
de gemiddelde scores van de tevredenheid met SCF echter wel binnen de normale range 
van scores (gebaseerd op de normpopulatie). Verder hebben we in dit onderzoek 
gevonden dat psychologische factoren (met name depressieve symptomen en situationele 
angst) voorspellers zijn voor de frequentie van problemen met SCF. Psychologische 
factoren, diagnose (maligne/benigne) en een eerdere behandeling door een 
psycholoog/psychiater bleken voorspellers te zijn voor de tevredenheid met SCF.  
Met betrekking tot SCF kan dus geconcludeerd worden dat de ernst van problemen 
met SCF op korte termijn toeneemt na de behandeling. De tevredenheid met SCF was 
afgenomen drie maanden na de laatste chemotherapie. Ondanks het feit dat de 
problemen binnen de range van de normpopulatie bleven, moet de statistische en klinisch 
relevante afname in tevredenheid met SCF serieus genomen worden.   
 
 
Objectief cognitief functioneren 
 
In hoofdstuk 5 was het effect van chemotherapie op OCF (de verschillende domeinen als 
ook op de verschillende neuropsychologische testen) in vrouwen met borstkanker 
onderzocht door vergelijkingen te maken met vrouwen met een benigne afwijking aan de 
borst voor en drie maanden na het beëindigen van de chemotherapie (en op vergelijkbare 
momenten gemeten bij de groep vrouwen met een benigne afwijking aan de borst). 
Vrouwen met borstkanker lieten een aangetast verbaal geheugen zien over de tijd 
vergeleken met vrouwen met een benigne afwijking aan de borst. Met betrekking tot het 
executief functioneren waren er wisselende resultaten gevonden: de verschillende 
neuropsychologische testen lieten geen significante verschillen zien met betrekking tot de 
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effecten van tijd of groep, maar de gecreëerde domeinscore liet een significant interactie 
effect zien (waarbij vrouwen met borstkanker drie maanden na de laatste chemotherapie 
verslechterd waren terwijl de vrouwen met een benigne afwijking aan de borst een kleine 
verbetering in het executief functioneren lieten zien). Verder vonden we alleen op de test 
voor de verbale vlotheid met betrekking tot beroepen een verschil tussen de vrouwen met 
borstkanker en vrouwen met een benigne afwijking aan de borst in het percentage van 
patiënten die een verbetering of een verslechtering lieten zien op de neuropsychologische 
testen. Vervolgens hebben we de resultaten met betrekking tot het OCF ook geanalyseerd 
met behulp van de ‘Reliable Change Index’ die gecorrigeerd was voor leereffecten. 
Hiermee kunnen individuen met een significante verandering over de tijd geïdentificeerd 
worden. We hebben geen verschillen gevonden in sociodemografische en psychologische 
variabelen tussen patiënten die een achteruitgang lieten zien op drie of meer 
neuropsychologische testen en patiënten met een achteruitgang op twee of minder 
neuropsychologische testen. In dit hoofdstuk hebben we verder nog kleine tot matige 
correlaties tussen specifieke neuropsychologische testen en de specifieke factor Sociale 
roekeloosheid van de CFQ gevonden. 
Het doel van hoofdstuk 6 was om het verloop van OCF tot één jaar na de afronding 
van de chemotherapie bij vrouwen met borstkanker te vergelijken met vrouwen met een 
benigne afwijking aan de borst. Het verbale geheugen van de vrouwen met borstkanker 
was afgenomen een jaar na de laatste chemotherapie, terwijl het verbale geheugen van 
de vrouwen met een benigne afwijking aan de borst stabiel bleef over de tijd. Daarnaast 
hebben we in hoofdstuk 6 het bestaan van verschillende longitudinale trajecten in de 
groep vrouwen met borstkanker onderzocht. Latente klasse analyses lieten drie klassen 
van vrouwen met borstkanker zien: ‘consistent hoog cognitief functioneren’, ‘consistent 
gemiddeld cognitief functioneren’ en ‘consistent laag cognitief functioneren’. Vrouwen 
met borstkanker in deze laatste groep waren significant ouder, minder goed opgeleid en 
hadden vaker geen betaald werk (of zijn met pensioen). De mogelijke kwetsbaarheid van 
deze groep met minder cognitieve reserve moet verder onderzocht worden. 
 
 
Invloed van cognitief functioneren op kwaliteit van leven 
 
Om beter inzicht te krijgen in de relatieve invloed van cognitief functioneren op de 
gesteldheid van vrouwen met borstkanker hebben we in hoofdstuk 7 de unieke bijdrage 
van cognitief functioneren (SCF en OCF) aan de kwaliteit van leven onderzocht. Vergeleken 
met vrouwen met een benigne probleem aan de borst bleek dat de totale kwaliteit van 
leven en algemene gezondheid en het domein van fysieke gezondheid aangedaan waren 
een jaar na de laatste chemotherapie bij vrouwen met borstkanker. Cognitief functioneren 
(SCF en OCF) bleek geen significante variantie toe te voegen aan het voorspellende model 
voor kwaliteit van leven (gecontroleerd voor sociodemografische, medische en 
psychologische variabelen). In de praktijk blijven vrouwen met borstkanker echter wel 
aangeven dat ze gehinderd worden door de cognitieve veranderingen tijdens en na de 
behandeling voor borstkanker. Meer onderzoek naar deze relatie is dus nodig.  
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Implicaties voor de praktijk 
 
De bevindingen van dit onderzoek over het bestaan, de prevalentie en de ontwikkeling 
van problemen met SCF en OCF kunnen clinici ondersteunen in het verschaffen van 
‘evidence-based’ informatie. Ze kunnen patiënten uitleggen dat sommige patiënten 
problemen ervaren met het cognitief functioneren tijdens en na de behandeling met 
chemotherapie. De ernst van de problemen met SCF kan tijdelijk toenemen na de 
behandeling en de tevredenheid met SCF kan afnemen nadat de chemotherapie afgerond 
is. Deze veranderingen zijn echter niet buiten proportioneel, bij de meeste patiënten 
blijven de problemen met SCF binnen de ´normale range´. Met betrekking tot het OCF 
kunnen patiënten geïnformeerd worden over de mogelijke problemen in het verbale 
geheugen na de behandeling. Deze problemen zijn het duidelijkst drie maanden na de 
laatste chemotherapie en het functioneren met betrekking tot het verbale geheugen is 
een jaar na de laatste chemotherapie weer bijna te vergelijken met het baseline niveau. 
Verder kunnen patiënten geïnformeerd worden over de rol van psychologische factoren 
(met name depressieve symptomen en situationele angst) in de ervaringen met 
betrekking tot SCF. Deze informatie kan patiënten helpen om zich voor te bereiden op de 
potentiele invloed van de behandeling voor borstkanker of het cognitief functioneren.  
Dit proefschrift vindt een beperkte invloed van chemotherapie op het cognitief 
functioneren bij vrouwen met borstkanker. Om deze reden moeten eventuele interventies 
tijd- en kosten effectief zijn. Totdat er meer bewijs is over de effectiviteit voor interventies 
die specifiek ontwikkeld zijn voor problemen met OCF/SCF bij vrouwen met borstkanker, 
bieden interventies met meerdere elementen (neuropsychologisch, psychosociaal, fysiek) 
een goede mogelijkheid om vrouwen met borstkanker te helpen met hun problemen met 
het cognitief functioneren. Het participeren aan het bestaande revalidatieprogramma 
zoals ‘Herstel en Balans’ is daarom aanbevolen. In dit revalidatieprogramma worden 
interventies voor psychosociale en fysieke problemen na (de behandeling van) kanker 
gecombineerd. Wanneer de problemen met het cognitief functioneren aan blijven houden 
ondanks dat vrouwen aan bijvoorbeeld ‘Herstel en Balans’ hebben geparticipeerd, is een 
interventie op individuele basis aanbevolen. Op dit moment worden er verschillende 
onderzoeken uitgevoerd naar het effect van specifieke gedragsinterventies, 
farmacologische interventies en interventies waarbij fysieke activiteit centraal staan op 
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Hester, ik mis je als kamergenootje! De afgelopen jaren hebben we veel met elkaar 
gedeeld. Jouw opgewektheid, ons gezamenlijk relativeringsvermogen met betrekking tot 
het werk en onze ongeordende bureaus maakten het een genot om elke dag naar mijn 
werk te komen. 
Mijn vrienden zoals die ook bijna allemaal bij mijn vrijgezellendag aanwezig waren 
wil ik bedanken voor de aangename afwisseling en de gezellige momenten. Ik geniet van 
de thee-avondjes met de hockey-meiden, de feestjes van ‘de middelbare school gang’ en 
´de mannenclub’ van Paul. Lieve Michelle, wat een geluk dat onze mannen vrienden van 
elkaar zijn en dat daar voor ons een hechte vriendschap uit voort is gekomen. We zijn zelfs 
nog elkaars huisgenoten geweest! Je niet aflatende interesse in mijn leventje en natuurlijk 
ons gedeelde vakgebied zorgen voor gezellige en boeiende thee-momenten. Mijn snoep-la 
zal altijd voor je gevuld blijven. Lieve Rinske en Steffi, bedankt voor de ontzettende lol die 
we als ‘drieling’ kunnen hebben. Rinske, bedankt voor je interesse in mij en mijn werk, 
soms ben je een beetje mijn personal coach. Steffi, wat heerlijk dat ik daarnaast met jou 
ook onbeschaamd uren lang over Meina en Maarten kan kletsen! Lieve Lieke, jou wil ik 
bedanken voor onze lange vriendschap waarin je altijd bent blijven investeren. Samen met 
de ‘middelbare school gang’ stonden we jaren lang in Brandpunt en we zijn samen aan de 
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studie Psychologie begonnen. Nu worden we in hetzelfde jaar dokter en doctor en daar 
ben ik trots op!  
Mijn (schoon)ouders, mijn zussen Maartje en Merel, Martijn, Emiel, Mark en ‘de 
kleintjes’ wil ik natuurlijk ook bedanken voor hun steun en afleiding. Franka en Jos, 
bedankt voor jullie interesse in mijn onderzoek en de goede zorgen voor Maarten. Wat is 
het fijn om twee zussen te hebben waar ik alles mee kan bespreken, waar de verse 
cappuccino altijd klaarstaat en waar in de zomer de barbecue wordt aangestoken. Ik 
geniet er ook van om te zien hoe Maarten met zijn neefjes en nichtje kan spelen. Lieve 
papa en mama, wat bof ik toch met jullie als ouders. Jullie hebben mij altijd positief 
gestimuleerd, zijn geïnteresseerd en hebben veel voor mij mogelijk gemaakt. Het is fijn om 
te weten dat jullie trots op mij zijn. Pap, ik weet zeker dat je nog een plekje zult vinden in 
de overvolle boekenkast voor dit boekje. Mama, de manier waarop jij voor Paul, Maarten 
en mij klaar staat zal ik nooit vergeten. 
Allerliefste Paul, wat wij samen hebben is zo kostbaar en dat maakt me gelukkig. 
Zoals ik bijna 9 jaar geleden al eens sms’te: ´Ik wil niet wennen aan jou´. De afgelopen 
jaren hebben we het samen voor elkaar gekregen dat ik niet alleen promovenda was, 
maar daarnaast ook nog echtgenote en moeder ben geworden. Het is een genot om 
samen met jou voor Maarten te zorgen. Hij is onze grote trots en wij weten echt zeker dat 
hij de allerliefste en allermooiste jongen van de hele wereld is. Dat vinden wij dan hè! De 
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